#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


#Text=Early Cannabis Use and Neurocognitive Risk: A Prospective Functional Neuroimaging Study
#Text=BACKGROUND:
#Text=Retrospective neuroimaging studies have suggested an association between early cannabis onset and later neurocognitive impairment.
1-1	0-5	Early	_	
1-2	6-14	Cannabis	_	
1-3	15-18	Use	_	
1-4	19-22	and	_	
1-5	23-37	Neurocognitive	_	
1-6	38-42	Risk	_	
1-7	42-43	:	_	
1-8	44-45	A	_	
1-9	46-57	Prospective	_	
1-10	58-68	Functional	_	
1-11	69-81	Neuroimaging	_	
1-12	82-87	Study	_	
1-13	88-98	BACKGROUND	_	
1-14	98-99	:	_	
1-15	100-113	Retrospective	_	
1-16	114-126	neuroimaging	_	
1-17	127-134	studies	_	
1-18	135-139	have	_	
1-19	140-149	suggested	_	
1-20	150-152	an	_	
1-21	153-164	association	_	
1-22	165-172	between	_	
1-23	173-178	early	_	
1-24	179-187	cannabis	_	
1-25	188-193	onset	_	
1-26	194-197	and	_	
1-27	198-203	later	_	
1-28	204-218	neurocognitive	_	
1-29	219-229	impairment	_	
1-30	229-230	.	_	

#Text=However, these studies have been limited in their ability to distinguish substance use risk factors from cannabis-induced effects on neurocognition.
2-1	231-238	However	_	
2-2	238-239	,	_	
2-3	240-245	these	_	
2-4	246-253	studies	_	
2-5	254-258	have	_	
2-6	259-263	been	_	
2-7	264-271	limited	_	
2-8	272-274	in	_	
2-9	275-280	their	_	
2-10	281-288	ability	_	
2-11	289-291	to	_	
2-12	292-303	distinguish	_	
2-13	304-313	substance	_	
2-14	314-317	use	_	
2-15	318-322	risk	_	
2-16	323-330	factors	_	
2-17	331-335	from	_	
2-18	336-352	cannabis-induced	_	
2-19	353-360	effects	_	
2-20	361-363	on	_	
2-21	364-378	neurocognition	_	
2-22	378-379	.	_	

#Text=We used a prospective cohort design to test whether neurocognitive differences preceded cannabis onset (substance use risk model) and if early cannabis use was associated with poorer neurocognitive development (cannabis exposure model).
3-1	380-382	We	_	
3-2	383-387	used	_	
3-3	388-389	a	_	
3-4	390-401	prospective	_	
3-5	402-408	cohort	_	
3-6	409-415	design	_	
3-7	416-418	to	_	
3-8	419-423	test	_	
3-9	424-431	whether	_	
3-10	432-446	neurocognitive	_	
3-11	447-458	differences	_	
3-12	459-467	preceded	_	
3-13	468-476	cannabis	_	
3-14	477-482	onset	_	
3-15	483-484	(	_	
3-16	484-493	substance	_	
3-17	494-497	use	_	
3-18	498-502	risk	_	
3-19	503-508	model	_	
3-20	508-509	)	_	
3-21	510-513	and	_	
3-22	514-516	if	_	
3-23	517-522	early	_	
3-24	523-531	cannabis	_	
3-25	532-535	use	_	
3-26	536-539	was	_	
3-27	540-550	associated	_	
3-28	551-555	with	_	
3-29	556-562	poorer	_	
3-30	563-577	neurocognitive	_	
3-31	578-589	development	_	
3-32	590-591	(	_	
3-33	591-599	cannabis	_	
3-34	600-608	exposure	_	
3-35	609-614	model	_	
3-36	614-615	)	_	
3-37	615-616	.	_	

#Text=METHODS:
#Text=Participants (N = 85) completed a visuospatial working memory task during functional magnetic resonance imaging and multiple cognitive assessments (Wechsler Intelligence Scale for Children-IV, Cambridge Neuropsychological Test Automated Battery) at 12 years of age, before any reported cannabis use (baseline), and at 15 years of age (follow-up: N = 85 cognitive assessments, n = 67 neuroimaging).
4-1	617-624	METHODS	_	
4-2	624-625	:	_	
4-3	626-638	Participants	_	
4-4	639-640	(	_	
4-5	640-641	N	_	
4-6	642-643	=	_	
4-7	644-646	85	_	
4-8	646-647	)	_	
4-9	648-657	completed	_	
4-10	658-659	a	_	
4-11	660-672	visuospatial	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[1]	
4-12	673-680	working	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[1]	
4-13	681-687	memory	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[1]	
4-14	688-692	task	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[1]	
4-15	693-699	during	_	
4-16	700-710	functional	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[2]	
4-17	711-719	magnetic	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[2]	
4-18	720-729	resonance	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[2]	
4-19	730-737	imaging	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[2]	
4-20	738-741	and	_	
4-21	742-750	multiple	_	
4-22	751-760	cognitive	_	
4-23	761-772	assessments	_	
4-24	773-774	(	_	
4-25	774-782	Wechsler	_	
4-26	783-795	Intelligence	_	
4-27	796-801	Scale	_	
4-28	802-805	for	_	
4-29	806-817	Children-IV	_	
4-30	817-818	,	_	
4-31	819-828	Cambridge	_	
4-32	829-847	Neuropsychological	_	
4-33	848-852	Test	_	
4-34	853-862	Automated	_	
4-35	863-870	Battery	_	
4-36	870-871	)	_	
4-37	872-874	at	_	
4-38	875-877	12	_	
4-39	878-883	years	_	
4-40	884-886	of	_	
4-41	887-890	age	_	
4-42	890-891	,	_	
4-43	892-898	before	_	
4-44	899-902	any	_	
4-45	903-911	reported	_	
4-46	912-920	cannabis	_	
4-47	921-924	use	_	
4-48	925-926	(	_	
4-49	926-934	baseline	_	
4-50	934-935	)	_	
4-51	935-936	,	_	
4-52	937-940	and	_	
4-53	941-943	at	_	
4-54	944-946	15	_	
4-55	947-952	years	_	
4-56	953-955	of	_	
4-57	956-959	age	_	
4-58	960-961	(	_	
4-59	961-970	follow-up	_	
4-60	970-971	:	_	
4-61	972-973	N	_	
4-62	974-975	=	_	
4-63	976-978	85	_	
4-64	979-988	cognitive	_	
4-65	989-1000	assessments	_	
4-66	1000-1001	,	_	
4-67	1002-1003	n	_	
4-68	1004-1005	=	_	
4-69	1006-1008	67	_	
4-70	1009-1021	neuroimaging	_	
4-71	1021-1022	)	_	
4-72	1022-1023	.	_	

#Text=By follow-up, 22 participants reported using cannabis and/or failed a Δ9-tetrahydrocannabinol urine screen (users).
5-1	1024-1026	By	_	
5-2	1027-1036	follow-up	_	
5-3	1036-1037	,	_	
5-4	1038-1040	22	_	
5-5	1041-1053	participants	_	
5-6	1054-1062	reported	_	
5-7	1063-1068	using	_	
5-8	1069-1077	cannabis	_	
5-9	1078-1081	and	_	
5-10	1081-1082	/	_	
5-11	1082-1084	or	_	
5-12	1085-1091	failed	_	
5-13	1092-1093	a	_	
5-14	1094-1096	Δ9	_	
5-15	1096-1097	-	_	
5-16	1097-1117	tetrahydrocannabinol	_	
5-17	1118-1123	urine	_	
5-18	1124-1130	screen	_	
5-19	1131-1132	(	_	
5-20	1132-1137	users	_	
5-21	1137-1138	)	_	
5-22	1138-1139	.	_	

#Text=RESULTS:
#Text=At baseline, group differences supported a risk model.
6-1	1140-1147	RESULTS	_	
6-2	1147-1148	:	_	
6-3	1149-1151	At	_	
6-4	1152-1160	baseline	_	
6-5	1160-1161	,	_	
6-6	1162-1167	group	_	
6-7	1168-1179	differences	_	
6-8	1180-1189	supported	_	
6-9	1190-1191	a	_	
6-10	1192-1196	risk	_	
6-11	1197-1202	model	_	
6-12	1202-1203	.	_	

#Text=Those who would initiate cannabis use by 15 years of age had activation differences in frontoparietal (increased) and visual association (decreased) regions and poorer executive planning scores (Stockings of Cambridge) compared with noninitiators.
7-1	1204-1209	Those	_	
7-2	1210-1213	who	_	
7-3	1214-1219	would	_	
7-4	1220-1228	initiate	_	
7-5	1229-1237	cannabis	_	
7-6	1238-1241	use	_	
7-7	1242-1244	by	_	
7-8	1245-1247	15	_	
7-9	1248-1253	years	_	
7-10	1254-1256	of	_	
7-11	1257-1260	age	_	
7-12	1261-1264	had	_	
7-13	1265-1275	activation	_	
7-14	1276-1287	differences	_	
7-15	1288-1290	in	_	
7-16	1291-1305	frontoparietal	_	
7-17	1306-1307	(	_	
7-18	1307-1316	increased	_	
7-19	1316-1317	)	_	
7-20	1318-1321	and	_	
7-21	1322-1328	visual	_	
7-22	1329-1340	association	_	
7-23	1341-1342	(	_	
7-24	1342-1351	decreased	_	
7-25	1351-1352	)	_	
7-26	1353-1360	regions	_	
7-27	1361-1364	and	_	
7-28	1365-1371	poorer	_	
7-29	1372-1381	executive	_	
7-30	1382-1390	planning	_	
7-31	1391-1397	scores	_	
7-32	1398-1399	(	_	
7-33	1399-1408	Stockings	_	
7-34	1409-1411	of	_	
7-35	1412-1421	Cambridge	_	
7-36	1421-1422	)	_	
7-37	1423-1431	compared	_	
7-38	1432-1436	with	_	
7-39	1437-1450	noninitiators	_	
7-40	1450-1451	.	_	

#Text=Limited support was found for a cannabis exposure model.
8-1	1452-1459	Limited	_	
8-2	1460-1467	support	_	
8-3	1468-1471	was	_	
8-4	1472-1477	found	_	
8-5	1478-1481	for	_	
8-6	1482-1483	a	_	
8-7	1484-1492	cannabis	_	
8-8	1493-1501	exposure	_	
8-9	1502-1507	model	_	
8-10	1507-1508	.	_	

#Text=At follow-up, activation in the cuneus displayed a significant cannabis dose-response relationship, although neither cannabis dose nor cuneus activation was associated with cognitive performance.
9-1	1509-1511	At	_	
9-2	1512-1521	follow-up	_	
9-3	1521-1522	,	_	
9-4	1523-1533	activation	_	
9-5	1534-1536	in	_	
9-6	1537-1540	the	_	
9-7	1541-1547	cuneus	_	
9-8	1548-1557	displayed	_	
9-9	1558-1559	a	_	
9-10	1560-1571	significant	_	
9-11	1572-1580	cannabis	_	
9-12	1581-1594	dose-response	_	
9-13	1595-1607	relationship	_	
9-14	1607-1608	,	_	
9-15	1609-1617	although	_	
9-16	1618-1625	neither	_	
9-17	1626-1634	cannabis	_	
9-18	1635-1639	dose	_	
9-19	1640-1643	nor	_	
9-20	1644-1650	cuneus	_	
9-21	1651-1661	activation	_	
9-22	1662-1665	was	_	
9-23	1666-1676	associated	_	
9-24	1677-1681	with	_	
9-25	1682-1691	cognitive	_	
9-26	1692-1703	performance	_	
9-27	1703-1704	.	_	

#Text=CONCLUSIONS:
#Text=The purported neurocognitive effects of early cannabis onset may not be due to cannabis initiation alone but also driven by limitations or late development of neurocognitive systems predictive of substance use.
10-1	1705-1716	CONCLUSIONS	_	
10-2	1716-1717	:	_	
10-3	1718-1721	The	_	
10-4	1722-1731	purported	_	
10-5	1732-1746	neurocognitive	_	
10-6	1747-1754	effects	_	
10-7	1755-1757	of	_	
10-8	1758-1763	early	_	
10-9	1764-1772	cannabis	_	
10-10	1773-1778	onset	_	
10-11	1779-1782	may	_	
10-12	1783-1786	not	_	
10-13	1787-1789	be	_	
10-14	1790-1793	due	_	
10-15	1794-1796	to	_	
10-16	1797-1805	cannabis	_	
10-17	1806-1816	initiation	_	
10-18	1817-1822	alone	_	
10-19	1823-1826	but	_	
10-20	1827-1831	also	_	
10-21	1832-1838	driven	_	
10-22	1839-1841	by	_	
10-23	1842-1853	limitations	_	
10-24	1854-1856	or	_	
10-25	1857-1861	late	_	
10-26	1862-1873	development	_	
10-27	1874-1876	of	_	
10-28	1877-1891	neurocognitive	_	
10-29	1892-1899	systems	_	
10-30	1900-1910	predictive	_	
10-31	1911-1913	of	_	
10-32	1914-1923	substance	_	
10-33	1924-1927	use	_	
10-34	1927-1928	.	_	

#Text=In addition, more prolonged cannabis exposure may be required to observe the cognitive effects of early cannabis onset.
11-1	1929-1931	In	_	
11-2	1932-1940	addition	_	
11-3	1940-1941	,	_	
11-4	1942-1946	more	_	
11-5	1947-1956	prolonged	_	
11-6	1957-1965	cannabis	_	
11-7	1966-1974	exposure	_	
11-8	1975-1978	may	_	
11-9	1979-1981	be	_	
11-10	1982-1990	required	_	
11-11	1991-1993	to	_	
11-12	1994-2001	observe	_	
11-13	2002-2005	the	_	
11-14	2006-2015	cognitive	_	
11-15	2016-2023	effects	_	
11-16	2024-2026	of	_	
11-17	2027-2032	early	_	
11-18	2033-2041	cannabis	_	
11-19	2042-2047	onset	_	
11-20	2047-2048	.	_	

#Text=The increasing legalization of marijuana has led to a growing interest in the potential effects of cannabis use early in development.
12-1	2049-2052	The	_	
12-2	2053-2063	increasing	_	
12-3	2064-2076	legalization	_	
12-4	2077-2079	of	_	
12-5	2080-2089	marijuana	_	
12-6	2090-2093	has	_	
12-7	2094-2097	led	_	
12-8	2098-2100	to	_	
12-9	2101-2102	a	_	
12-10	2103-2110	growing	_	
12-11	2111-2119	interest	_	
12-12	2120-2122	in	_	
12-13	2123-2126	the	_	
12-14	2127-2136	potential	_	
12-15	2137-2144	effects	_	
12-16	2145-2147	of	_	
12-17	2148-2156	cannabis	_	
12-18	2157-2160	use	_	
12-19	2161-2166	early	_	
12-20	2167-2169	in	_	
12-21	2170-2181	development	_	
12-22	2181-2182	.	_	

#Text=The primary psychoactive component of cannabis, Δ9-tetrahydrocannabinol (THC), is a partial agonist of CB1 receptors, which have a protracted developmental course in primate dorsolateral prefrontal cortex and are distributed in cortical association areas that are still maturing during adolescence.
13-1	2183-2186	The	_	
13-2	2187-2194	primary	_	
13-3	2195-2207	psychoactive	_	
13-4	2208-2217	component	_	
13-5	2218-2220	of	_	
13-6	2221-2229	cannabis	_	
13-7	2229-2230	,	_	
13-8	2231-2233	Δ9	_	
13-9	2233-2234	-	_	
13-10	2234-2254	tetrahydrocannabinol	_	
13-11	2255-2256	(	_	
13-12	2256-2259	THC	_	
13-13	2259-2260	)	_	
13-14	2260-2261	,	_	
13-15	2262-2264	is	_	
13-16	2265-2266	a	_	
13-17	2267-2274	partial	_	
13-18	2275-2282	agonist	_	
13-19	2283-2285	of	_	
13-20	2286-2289	CB1	_	
13-21	2290-2299	receptors	_	
13-22	2299-2300	,	_	
13-23	2301-2306	which	_	
13-24	2307-2311	have	_	
13-25	2312-2313	a	_	
13-26	2314-2324	protracted	_	
13-27	2325-2338	developmental	_	
13-28	2339-2345	course	_	
13-29	2346-2348	in	_	
13-30	2349-2356	primate	_	
13-31	2357-2369	dorsolateral	_	
13-32	2370-2380	prefrontal	_	
13-33	2381-2387	cortex	_	
13-34	2388-2391	and	_	
13-35	2392-2395	are	_	
13-36	2396-2407	distributed	_	
13-37	2408-2410	in	_	
13-38	2411-2419	cortical	_	
13-39	2420-2431	association	_	
13-40	2432-2437	areas	_	
13-41	2438-2442	that	_	
13-42	2443-2446	are	_	
13-43	2447-2452	still	_	
13-44	2453-2461	maturing	_	
13-45	2462-2468	during	_	
13-46	2469-2480	adolescence	_	
13-47	2480-2481	.	_	

#Text=Given the late maturation of the endocannabinoid system, it has been suggested that early cannabis exposure may impair neurocognitive development.
14-1	2482-2487	Given	_	
14-2	2488-2491	the	_	
14-3	2492-2496	late	_	
14-4	2497-2507	maturation	_	
14-5	2508-2510	of	_	
14-6	2511-2514	the	_	
14-7	2515-2530	endocannabinoid	_	
14-8	2531-2537	system	_	
14-9	2537-2538	,	_	
14-10	2539-2541	it	_	
14-11	2542-2545	has	_	
14-12	2546-2550	been	_	
14-13	2551-2560	suggested	_	
14-14	2561-2565	that	_	
14-15	2566-2571	early	_	
14-16	2572-2580	cannabis	_	
14-17	2581-2589	exposure	_	
14-18	2590-2593	may	_	
14-19	2594-2600	impair	_	
14-20	2601-2615	neurocognitive	_	
14-21	2616-2627	development	_	
14-22	2627-2628	.	_	

#Text=Retrospective studies in adults suggest that early cannabis initiation, independent of acute intoxication, is associated with poorer performance in working memory (WM) and visual attention tasks, verbal IQ, and more domain-general planning tasks [e.g., Stockings of Cambridge ] and executive function composites.
15-1	2629-2642	Retrospective	_	
15-2	2643-2650	studies	_	
15-3	2651-2653	in	_	
15-4	2654-2660	adults	_	
15-5	2661-2668	suggest	_	
15-6	2669-2673	that	_	
15-7	2674-2679	early	_	
15-8	2680-2688	cannabis	_	
15-9	2689-2699	initiation	_	
15-10	2699-2700	,	_	
15-11	2701-2712	independent	_	
15-12	2713-2715	of	_	
15-13	2716-2721	acute	_	
15-14	2722-2734	intoxication	_	
15-15	2734-2735	,	_	
15-16	2736-2738	is	_	
15-17	2739-2749	associated	_	
15-18	2750-2754	with	_	
15-19	2755-2761	poorer	_	
15-20	2762-2773	performance	_	
15-21	2774-2776	in	_	
15-22	2777-2784	working	_	
15-23	2785-2791	memory	_	
15-24	2792-2793	(	_	
15-25	2793-2795	WM	_	
15-26	2795-2796	)	_	
15-27	2797-2800	and	_	
15-28	2801-2807	visual	_	
15-29	2808-2817	attention	_	
15-30	2818-2823	tasks	_	
15-31	2823-2824	,	_	
15-32	2825-2831	verbal	_	
15-33	2832-2834	IQ	_	
15-34	2834-2835	,	_	
15-35	2836-2839	and	_	
15-36	2840-2844	more	_	
15-37	2845-2859	domain-general	_	
15-38	2860-2868	planning	_	
15-39	2869-2874	tasks	_	
15-40	2875-2876	[	_	
15-41	2876-2879	e.g	_	
15-42	2879-2880	.	_	
15-43	2880-2881	,	_	
15-44	2882-2891	Stockings	_	
15-45	2892-2894	of	_	
15-46	2895-2904	Cambridge	_	
15-47	2905-2906	]	_	
15-48	2907-2910	and	_	
15-49	2911-2920	executive	_	
15-50	2921-2929	function	_	
15-51	2930-2940	composites	_	
15-52	2940-2941	.	_	

#Text=Supporting this, neuroimaging finds that early onset users, compared to late onset users, have greater blood oxygen level–dependent (BOLD) activation in frontoparietal regions during WM in adulthood, with similar increased frontoparietal BOLD activation differences observed in adolescent cannabis users.
16-1	2942-2952	Supporting	_	
16-2	2953-2957	this	_	
16-3	2957-2958	,	_	
16-4	2959-2971	neuroimaging	_	
16-5	2972-2977	finds	_	
16-6	2978-2982	that	_	
16-7	2983-2988	early	_	
16-8	2989-2994	onset	_	
16-9	2995-3000	users	_	
16-10	3000-3001	,	_	
16-11	3002-3010	compared	_	
16-12	3011-3013	to	_	
16-13	3014-3018	late	_	
16-14	3019-3024	onset	_	
16-15	3025-3030	users	_	
16-16	3030-3031	,	_	
16-17	3032-3036	have	_	
16-18	3037-3044	greater	_	
16-19	3045-3050	blood	_	
16-20	3051-3057	oxygen	_	
16-21	3058-3073	level–dependent	_	
16-22	3074-3075	(	_	
16-23	3075-3079	BOLD	_	
16-24	3079-3080	)	_	
16-25	3081-3091	activation	_	
16-26	3092-3094	in	_	
16-27	3095-3109	frontoparietal	_	
16-28	3110-3117	regions	_	
16-29	3118-3124	during	_	
16-30	3125-3127	WM	_	
16-31	3128-3130	in	_	
16-32	3131-3140	adulthood	_	
16-33	3140-3141	,	_	
16-34	3142-3146	with	_	
16-35	3147-3154	similar	_	
16-36	3155-3164	increased	_	
16-37	3165-3179	frontoparietal	_	
16-38	3180-3184	BOLD	_	
16-39	3185-3195	activation	_	
16-40	3196-3207	differences	_	
16-41	3208-3216	observed	_	
16-42	3217-3219	in	_	
16-43	3220-3230	adolescent	_	
16-44	3231-3239	cannabis	_	
16-45	3240-3245	users	_	
16-46	3245-3246	.	_	

#Text=Retrospective studies are limited, however, as they do not account for neurocognitive function before cannabis onset, which may predict cannabis initiation and severity.
17-1	3247-3260	Retrospective	_	
17-2	3261-3268	studies	_	
17-3	3269-3272	are	_	
17-4	3273-3280	limited	_	
17-5	3280-3281	,	_	
17-6	3282-3289	however	_	
17-7	3289-3290	,	_	
17-8	3291-3293	as	_	
17-9	3294-3298	they	_	
17-10	3299-3301	do	_	
17-11	3302-3305	not	_	
17-12	3306-3313	account	_	
17-13	3314-3317	for	_	
17-14	3318-3332	neurocognitive	_	
17-15	3333-3341	function	_	
17-16	3342-3348	before	_	
17-17	3349-3357	cannabis	_	
17-18	3358-3363	onset	_	
17-19	3363-3364	,	_	
17-20	3365-3370	which	_	
17-21	3371-3374	may	_	
17-22	3375-3382	predict	_	
17-23	3383-3391	cannabis	_	
17-24	3392-3402	initiation	_	
17-25	3403-3406	and	_	
17-26	3407-3415	severity	_	
17-27	3415-3416	.	_	

#Text=Supporting this, substance use risk factors, including socioeconomic status and behavioral disinhibition phenotypes (e.g., externalizing psychopathology and impulsivity), are associated with frontoparietal activation differences and poorer cognitive performance.
18-1	3417-3427	Supporting	_	
18-2	3428-3432	this	_	
18-3	3432-3433	,	_	
18-4	3434-3443	substance	_	
18-5	3444-3447	use	_	
18-6	3448-3452	risk	_	
18-7	3453-3460	factors	_	
18-8	3460-3461	,	_	
18-9	3462-3471	including	_	
18-10	3472-3485	socioeconomic	_	
18-11	3486-3492	status	_	
18-12	3493-3496	and	_	
18-13	3497-3507	behavioral	_	
18-14	3508-3521	disinhibition	_	
18-15	3522-3532	phenotypes	_	
18-16	3533-3534	(	_	
18-17	3534-3537	e.g	_	
18-18	3537-3538	.	_	
18-19	3538-3539	,	_	
18-20	3540-3553	externalizing	_	
18-21	3554-3569	psychopathology	_	
18-22	3570-3573	and	_	
18-23	3574-3585	impulsivity	_	
18-24	3585-3586	)	_	
18-25	3586-3587	,	_	
18-26	3588-3591	are	_	
18-27	3592-3602	associated	_	
18-28	3603-3607	with	_	
18-29	3608-3622	frontoparietal	_	
18-30	3623-3633	activation	_	
18-31	3634-3645	differences	_	
18-32	3646-3649	and	_	
18-33	3650-3656	poorer	_	
18-34	3657-3666	cognitive	_	
18-35	3667-3678	performance	_	
18-36	3678-3679	.	_	

#Text=In addition, although a cannabis exposure effect predicts neurocognitive consequences to be largest for those who consume the most cannabis, few neuroimaging studies have examined the dose dependence of adolescent cannabis use results.
19-1	3680-3682	In	_	
19-2	3683-3691	addition	_	
19-3	3691-3692	,	_	
19-4	3693-3701	although	_	
19-5	3702-3703	a	_	
19-6	3704-3712	cannabis	_	
19-7	3713-3721	exposure	_	
19-8	3722-3728	effect	_	
19-9	3729-3737	predicts	_	
19-10	3738-3752	neurocognitive	_	
19-11	3753-3765	consequences	_	
19-12	3766-3768	to	_	
19-13	3769-3771	be	_	
19-14	3772-3779	largest	_	
19-15	3780-3783	for	_	
19-16	3784-3789	those	_	
19-17	3790-3793	who	_	
19-18	3794-3801	consume	_	
19-19	3802-3805	the	_	
19-20	3806-3810	most	_	
19-21	3811-3819	cannabis	_	
19-22	3819-3820	,	_	
19-23	3821-3824	few	_	
19-24	3825-3837	neuroimaging	_	
19-25	3838-3845	studies	_	
19-26	3846-3850	have	_	
19-27	3851-3859	examined	_	
19-28	3860-3863	the	_	
19-29	3864-3868	dose	_	
19-30	3869-3879	dependence	_	
19-31	3880-3882	of	_	
19-32	3883-3893	adolescent	_	
19-33	3894-3902	cannabis	_	
19-34	3903-3906	use	_	
19-35	3907-3914	results	_	
19-36	3914-3915	.	_	

#Text=Providing evidence against an exposure effect, recent work from our group suggested that cannabis age of onset associations with frontoparietal BOLD activation were not dose dependent in abstinent adults.
20-1	3916-3925	Providing	_	
20-2	3926-3934	evidence	_	
20-3	3935-3942	against	_	
20-4	3943-3945	an	_	
20-5	3946-3954	exposure	_	
20-6	3955-3961	effect	_	
20-7	3961-3962	,	_	
20-8	3963-3969	recent	_	
20-9	3970-3974	work	_	
20-10	3975-3979	from	_	
20-11	3980-3983	our	_	
20-12	3984-3989	group	_	
20-13	3990-3999	suggested	_	
20-14	4000-4004	that	_	
20-15	4005-4013	cannabis	_	
20-16	4014-4017	age	_	
20-17	4018-4020	of	_	
20-18	4021-4026	onset	_	
20-19	4027-4039	associations	_	
20-20	4040-4044	with	_	
20-21	4045-4059	frontoparietal	_	
20-22	4060-4064	BOLD	_	
20-23	4065-4075	activation	_	
20-24	4076-4080	were	_	
20-25	4081-4084	not	_	
20-26	4085-4089	dose	_	
20-27	4090-4099	dependent	_	
20-28	4100-4102	in	_	
20-29	4103-4112	abstinent	_	
20-30	4113-4119	adults	_	
20-31	4119-4120	.	_	

#Text=Combined, these results suggest that a portion of neurocognitive differences previously attributed to early cannabis onset may reflect individual differences that are present before cannabis initiation.
21-1	4121-4129	Combined	_	
21-2	4129-4130	,	_	
21-3	4131-4136	these	_	
21-4	4137-4144	results	_	
21-5	4145-4152	suggest	_	
21-6	4153-4157	that	_	
21-7	4158-4159	a	_	
21-8	4160-4167	portion	_	
21-9	4168-4170	of	_	
21-10	4171-4185	neurocognitive	_	
21-11	4186-4197	differences	_	
21-12	4198-4208	previously	_	
21-13	4209-4219	attributed	_	
21-14	4220-4222	to	_	
21-15	4223-4228	early	_	
21-16	4229-4237	cannabis	_	
21-17	4238-4243	onset	_	
21-18	4244-4247	may	_	
21-19	4248-4255	reflect	_	
21-20	4256-4266	individual	_	
21-21	4267-4278	differences	_	
21-22	4279-4283	that	_	
21-23	4284-4287	are	_	
21-24	4288-4295	present	_	
21-25	4296-4302	before	_	
21-26	4303-4311	cannabis	_	
21-27	4312-4322	initiation	_	
21-28	4322-4323	.	_	

#Text=In the current study, we used a prospective cohort design where task-based functional magnetic resonance imaging (fMRI) and cognitive performance were assessed before and after adolescents’ first cannabis use.
22-1	4324-4326	In	_	
22-2	4327-4330	the	_	
22-3	4331-4338	current	_	
22-4	4339-4344	study	_	
22-5	4344-4345	,	_	
22-6	4346-4348	we	_	
22-7	4349-4353	used	_	
22-8	4354-4355	a	_	
22-9	4356-4367	prospective	_	
22-10	4368-4374	cohort	_	
22-11	4375-4381	design	_	
22-12	4382-4387	where	_	
22-13	4388-4398	task-based	_	
22-14	4399-4409	functional	_	
22-15	4410-4418	magnetic	_	
22-16	4419-4428	resonance	_	
22-17	4429-4436	imaging	_	
22-18	4437-4438	(	_	
22-19	4438-4442	fMRI	_	
22-20	4442-4443	)	_	
22-21	4444-4447	and	_	
22-22	4448-4457	cognitive	_	
22-23	4458-4469	performance	_	
22-24	4470-4474	were	_	
22-25	4475-4483	assessed	_	
22-26	4484-4490	before	_	
22-27	4491-4494	and	_	
22-28	4495-4500	after	_	
22-29	4501-4512	adolescents	_	
22-30	4512-4513	’	_	
22-31	4514-4519	first	_	
22-32	4520-4528	cannabis	_	
22-33	4529-4532	use	_	
22-34	4532-4533	.	_	

#Text=We hypothesized that if reported cognitive effects of early cannabis use reflect pre- onset differences, those who would initiate cannabis use would have differential BOLD activation and poorer cognitive performance prior to cannabis initiation.
23-1	4534-4536	We	_	
23-2	4537-4549	hypothesized	_	
23-3	4550-4554	that	_	
23-4	4555-4557	if	_	
23-5	4558-4566	reported	_	
23-6	4567-4576	cognitive	_	
23-7	4577-4584	effects	_	
23-8	4585-4587	of	_	
23-9	4588-4593	early	_	
23-10	4594-4602	cannabis	_	
23-11	4603-4606	use	_	
23-12	4607-4614	reflect	_	
23-13	4615-4618	pre	_	
23-14	4618-4619	-	_	
23-15	4620-4625	onset	_	
23-16	4626-4637	differences	_	
23-17	4637-4638	,	_	
23-18	4639-4644	those	_	
23-19	4645-4648	who	_	
23-20	4649-4654	would	_	
23-21	4655-4663	initiate	_	
23-22	4664-4672	cannabis	_	
23-23	4673-4676	use	_	
23-24	4677-4682	would	_	
23-25	4683-4687	have	_	
23-26	4688-4700	differential	_	
23-27	4701-4705	BOLD	_	
23-28	4706-4716	activation	_	
23-29	4717-4720	and	_	
23-30	4721-4727	poorer	_	
23-31	4728-4737	cognitive	_	
23-32	4738-4749	performance	_	
23-33	4750-4755	prior	_	
23-34	4756-4758	to	_	
23-35	4759-4767	cannabis	_	
23-36	4768-4778	initiation	_	
23-37	4778-4779	.	_	

#Text=Within this substance use risk model, we hypothesized that neurocognitive differences would be driven by socioeconomic status and/or externalizing symptoms.
24-1	4780-4786	Within	_	
24-2	4787-4791	this	_	
24-3	4792-4801	substance	_	
24-4	4802-4805	use	_	
24-5	4806-4810	risk	_	
24-6	4811-4816	model	_	
24-7	4816-4817	,	_	
24-8	4818-4820	we	_	
24-9	4821-4833	hypothesized	_	
24-10	4834-4838	that	_	
24-11	4839-4853	neurocognitive	_	
24-12	4854-4865	differences	_	
24-13	4866-4871	would	_	
24-14	4872-4874	be	_	
24-15	4875-4881	driven	_	
24-16	4882-4884	by	_	
24-17	4885-4898	socioeconomic	_	
24-18	4899-4905	status	_	
24-19	4906-4909	and	_	
24-20	4909-4910	/	_	
24-21	4910-4912	or	_	
24-22	4913-4926	externalizing	_	
24-23	4927-4935	symptoms	_	
24-24	4935-4936	.	_	

#Text=Alternatively, if reported effects are the result of early cannabis exposure, we hypothesized that neurocognitive differences would emerge after cannabis initiation and would be dose dependent.
25-1	4937-4950	Alternatively	_	
25-2	4950-4951	,	_	
25-3	4952-4954	if	_	
25-4	4955-4963	reported	_	
25-5	4964-4971	effects	_	
25-6	4972-4975	are	_	
25-7	4976-4979	the	_	
25-8	4980-4986	result	_	
25-9	4987-4989	of	_	
25-10	4990-4995	early	_	
25-11	4996-5004	cannabis	_	
25-12	5005-5013	exposure	_	
25-13	5013-5014	,	_	
25-14	5015-5017	we	_	
25-15	5018-5030	hypothesized	_	
25-16	5031-5035	that	_	
25-17	5036-5050	neurocognitive	_	
25-18	5051-5062	differences	_	
25-19	5063-5068	would	_	
25-20	5069-5075	emerge	_	
25-21	5076-5081	after	_	
25-22	5082-5090	cannabis	_	
25-23	5091-5101	initiation	_	
25-24	5102-5105	and	_	
25-25	5106-5111	would	_	
25-26	5112-5114	be	_	
25-27	5115-5119	dose	_	
25-28	5120-5129	dependent	_	
25-29	5129-5130	.	_	

#Text=METHODS AND MATERIALS
#Text=Procedure
#Text=Participants were recruited at 12 years of age.
26-1	5131-5138	METHODS	http://www.case.edu/ProvCaRe/provcare#StudyMethod[3]	
26-2	5139-5142	AND	http://www.case.edu/ProvCaRe/provcare#StudyMethod[3]	
26-3	5143-5152	MATERIALS	http://www.case.edu/ProvCaRe/provcare#StudyMethod[3]	
26-4	5153-5162	Procedure	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
26-5	5163-5175	Participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
26-6	5176-5180	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
26-7	5181-5190	recruited	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
26-8	5191-5193	at	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
26-9	5194-5196	12	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
26-10	5197-5202	years	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
26-11	5203-5205	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
26-12	5206-5209	age	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
26-13	5209-5210	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	

#Text=Recruitment included an initial approach that enriched substance use risk characteristics (maternal substance use and low maternal socioeconomic status [SES] as well as participant delinquent behavior, poor academic performance, and peer substance use) followed by a more inclusive community sampling approach.
27-1	5211-5222	Recruitment	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
27-2	5223-5231	included	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
27-3	5232-5234	an	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
27-4	5235-5242	initial	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
27-5	5243-5251	approach	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
27-6	5252-5256	that	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
27-7	5257-5265	enriched	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
27-8	5266-5275	substance	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
27-9	5276-5279	use	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
27-10	5280-5284	risk	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
27-11	5285-5300	characteristics	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
27-12	5301-5302	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
27-13	5302-5310	maternal	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
27-14	5311-5320	substance	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
27-15	5321-5324	use	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
27-16	5325-5328	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
27-17	5329-5332	low	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
27-18	5333-5341	maternal	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
27-19	5342-5355	socioeconomic	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
27-20	5356-5362	status	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
27-21	5363-5364	[	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
27-22	5364-5367	SES	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
27-23	5367-5368	]	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
27-24	5369-5371	as	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
27-25	5372-5376	well	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
27-26	5377-5379	as	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
27-27	5380-5391	participant	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
27-28	5392-5402	delinquent	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
27-29	5403-5411	behavior	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
27-30	5411-5412	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
27-31	5413-5417	poor	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
27-32	5418-5426	academic	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
27-33	5427-5438	performance	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
27-34	5438-5439	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
27-35	5440-5443	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
27-36	5444-5448	peer	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
27-37	5449-5458	substance	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
27-38	5459-5462	use	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
27-39	5462-5463	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
27-40	5464-5472	followed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
27-41	5473-5475	by	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
27-42	5476-5477	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
27-43	5478-5482	more	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
27-44	5483-5492	inclusive	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
27-45	5493-5502	community	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
27-46	5503-5511	sampling	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
27-47	5512-5520	approach	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
27-48	5520-5521	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	

#Text=Participants’ substance use, externalizing symptoms, and demographic data were assessed at 12, 13, 14, and 15 years of age.
28-1	5522-5534	Participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
28-2	5534-5535	’	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
28-3	5536-5545	substance	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
28-4	5546-5549	use	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
28-5	5549-5550	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
28-6	5551-5564	externalizing	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
28-7	5565-5573	symptoms	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
28-8	5573-5574	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
28-9	5575-5578	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
28-10	5579-5590	demographic	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
28-11	5591-5595	data	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
28-12	5596-5600	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
28-13	5601-5609	assessed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
28-14	5610-5612	at	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
28-15	5613-5615	12	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
28-16	5615-5616	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
28-17	5617-5619	13	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
28-18	5619-5620	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
28-19	5621-5623	14	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
28-20	5623-5624	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
28-21	5625-5628	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
28-22	5629-5631	15	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
28-23	5632-5637	years	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
28-24	5638-5640	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
28-25	5641-5644	age	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
28-26	5644-5645	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	

#Text=Neuroimaging and cognitive testing were conducted at 12 and 15 years of age.
29-1	5646-5658	Neuroimaging	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
29-2	5659-5662	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
29-3	5663-5672	cognitive	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
29-4	5673-5680	testing	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
29-5	5681-5685	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
29-6	5686-5695	conducted	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
29-7	5696-5698	at	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
29-8	5699-5701	12	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
29-9	5702-5705	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
29-10	5706-5708	15	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
29-11	5709-5714	years	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
29-12	5715-5717	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
29-13	5718-5721	age	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
29-14	5721-5722	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	

#Text=The University of Pittsburgh’s Institutional Review Board approved the study procedures.
30-1	5723-5726	The	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
30-2	5727-5737	University	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
30-3	5738-5740	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
30-4	5741-5751	Pittsburgh	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
30-5	5751-5752	’	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
30-6	5752-5753	s	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
30-7	5754-5767	Institutional	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
30-8	5768-5774	Review	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
30-9	5775-5780	Board	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
30-10	5781-5789	approved	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
30-11	5790-5793	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
30-12	5794-5799	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
30-13	5800-5810	procedures	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
30-14	5810-5811	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	

#Text=Legal guardians provided informed consent, and all participants provided assent.
31-1	5812-5817	Legal	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
31-2	5818-5827	guardians	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
31-3	5828-5836	provided	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
31-4	5837-5845	informed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
31-5	5846-5853	consent	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
31-6	5853-5854	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
31-7	5855-5858	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
31-8	5859-5862	all	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
31-9	5863-5875	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
31-10	5876-5884	provided	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
31-11	5885-5891	assent	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
31-12	5891-5892	.	_	

#Text=Participants
#Text=Eighty-six participants completed all diagnostic and substance use assessments, the cognitive battery at 12 and 15 years of age, and fMRI at 12 years of age (baseline).
32-1	5893-5905	Participants	_	
32-2	5906-5916	Eighty-six	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
32-3	5917-5929	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
32-4	5930-5939	completed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
32-5	5940-5943	all	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
32-6	5944-5954	diagnostic	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
32-7	5955-5958	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
32-8	5959-5968	substance	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
32-9	5969-5972	use	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
32-10	5973-5984	assessments	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
32-11	5984-5985	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
32-12	5986-5989	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
32-13	5990-5999	cognitive	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
32-14	6000-6007	battery	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
32-15	6008-6010	at	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
32-16	6011-6013	12	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
32-17	6014-6017	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
32-18	6018-6020	15	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
32-19	6021-6026	years	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
32-20	6027-6029	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
32-21	6030-6033	age	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
32-22	6033-6034	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
32-23	6035-6038	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
32-24	6039-6043	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]|http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[7]	
32-25	6044-6046	at	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
32-26	6047-6049	12	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
32-27	6050-6055	years	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
32-28	6056-6058	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
32-29	6059-6062	age	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
32-30	6063-6064	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
32-31	6064-6072	baseline	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
32-32	6072-6073	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
32-33	6073-6074	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	

#Text=One participant was removed from all analyses based on reported cannabis use at baseline, resulting in a full sample of N = 85.
33-1	6075-6078	One	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
33-2	6079-6090	participant	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
33-3	6091-6094	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
33-4	6095-6102	removed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
33-5	6103-6107	from	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
33-6	6108-6111	all	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
33-7	6112-6120	analyses	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
33-8	6121-6126	based	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
33-9	6127-6129	on	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
33-10	6130-6138	reported	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
33-11	6139-6147	cannabis	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
33-12	6148-6151	use	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
33-13	6152-6154	at	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
33-14	6155-6163	baseline	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
33-15	6163-6164	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
33-16	6165-6174	resulting	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
33-17	6175-6177	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
33-18	6178-6179	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
33-19	6180-6184	full	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
33-20	6185-6191	sample	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
33-21	6192-6194	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
33-22	6195-6196	N	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
33-23	6197-6198	=	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
33-24	6199-6201	85	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
33-25	6201-6202	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	

#Text=Of these, 67 participants successfully completed fMRI acquisition at 15 years of age (follow-up).
34-1	6203-6205	Of	_	
34-2	6206-6211	these	_	
34-3	6211-6212	,	_	
34-4	6213-6215	67	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
34-5	6216-6228	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
34-6	6229-6241	successfully	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
34-7	6242-6251	completed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
34-8	6252-6256	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]|http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[10]	
34-9	6257-6268	acquisition	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
34-10	6269-6271	at	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
34-11	6272-6274	15	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
34-12	6275-6280	years	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
34-13	6281-6283	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
34-14	6284-6287	age	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
34-15	6288-6289	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
34-16	6289-6298	follow-up	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
34-17	6298-6299	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
34-18	6299-6300	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	

#Text=Reasons for unsuccessful neuroimaging follow-up were braces (n = 8), opting out (n = 5), unable to schedule (n = 4), and participant-elected early scan termination (n = 1).
35-1	6301-6308	Reasons	_	
35-2	6309-6312	for	_	
35-3	6313-6325	unsuccessful	_	
35-4	6326-6338	neuroimaging	_	
35-5	6339-6348	follow-up	_	
35-6	6349-6353	were	_	
35-7	6354-6360	braces	_	
35-8	6361-6362	(	_	
35-9	6362-6363	n	_	
35-10	6364-6365	=	_	
35-11	6366-6367	8	_	
35-12	6367-6368	)	_	
35-13	6368-6369	,	_	
35-14	6370-6376	opting	_	
35-15	6377-6380	out	_	
35-16	6381-6382	(	_	
35-17	6382-6383	n	_	
35-18	6384-6385	=	_	
35-19	6386-6387	5	_	
35-20	6387-6388	)	_	
35-21	6388-6389	,	_	
35-22	6390-6396	unable	_	
35-23	6397-6399	to	_	
35-24	6400-6408	schedule	_	
35-25	6409-6410	(	_	
35-26	6410-6411	n	_	
35-27	6412-6413	=	_	
35-28	6414-6415	4	_	
35-29	6415-6416	)	_	
35-30	6416-6417	,	_	
35-31	6418-6421	and	_	
35-32	6422-6441	participant-elected	_	
35-33	6442-6447	early	_	
35-34	6448-6452	scan	_	
35-35	6453-6464	termination	_	
35-36	6465-6466	(	_	
35-37	6466-6467	n	_	
35-38	6468-6469	=	_	
35-39	6470-6471	1	_	
35-40	6471-6472	)	_	
35-41	6472-6473	.	_	

#Text=At baseline, exclusion criteria included self-reported cannabis use, IQ scores below 80, current psychiatric disorder [Mini-International Neuropsychiatric Interview ] or psychiatric medication, previous head injury with loss of consciousness, and MRI contraindications.
36-1	6474-6476	At	_	
36-2	6477-6485	baseline	_	
36-3	6485-6486	,	_	
36-4	6487-6496	exclusion	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
36-5	6497-6505	criteria	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
36-6	6506-6514	included	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
36-7	6515-6528	self-reported	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
36-8	6529-6537	cannabis	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
36-9	6538-6541	use	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
36-10	6541-6542	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
36-11	6543-6545	IQ	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
36-12	6546-6552	scores	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
36-13	6553-6558	below	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
36-14	6559-6561	80	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
36-15	6561-6562	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
36-16	6563-6570	current	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
36-17	6571-6582	psychiatric	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
36-18	6583-6591	disorder	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
36-19	6592-6593	[	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
36-20	6593-6611	Mini-International	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
36-21	6612-6628	Neuropsychiatric	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
36-22	6629-6638	Interview	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
36-23	6639-6640	]	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
36-24	6641-6643	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
36-25	6644-6655	psychiatric	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
36-26	6656-6666	medication	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
36-27	6666-6667	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
36-28	6668-6676	previous	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
36-29	6677-6681	head	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
36-30	6682-6688	injury	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
36-31	6689-6693	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
36-32	6694-6698	loss	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
36-33	6699-6701	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
36-34	6702-6715	consciousness	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
36-35	6715-6716	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
36-36	6717-6720	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
36-37	6721-6724	MRI	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]|http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[12]	
36-38	6725-6742	contraindications	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
36-39	6742-6743	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	

#Text=On the day of neuroimaging visits, participants completed a multidrug urine screen (Uritox Medical, Toledo, OH; THC threshold 50 ng/mL).
37-1	6744-6746	On	_	
37-2	6747-6750	the	_	
37-3	6751-6754	day	_	
37-4	6755-6757	of	_	
37-5	6758-6770	neuroimaging	_	
37-6	6771-6777	visits	_	
37-7	6777-6778	,	_	
37-8	6779-6791	participants	_	
37-9	6792-6801	completed	_	
37-10	6802-6803	a	_	
37-11	6804-6813	multidrug	_	
37-12	6814-6819	urine	_	
37-13	6820-6826	screen	_	
37-14	6827-6828	(	_	
37-15	6828-6834	Uritox	_	
37-16	6835-6842	Medical	_	
37-17	6842-6843	,	_	
37-18	6844-6850	Toledo	_	
37-19	6850-6851	,	_	
37-20	6852-6854	OH	_	
37-21	6854-6855	;	_	
37-22	6856-6859	THC	_	
37-23	6860-6869	threshold	_	
37-24	6870-6872	50	_	
37-25	6873-6875	ng	_	
37-26	6875-6876	/	_	
37-27	6876-6878	mL	_	
37-28	6878-6879	)	_	
37-29	6879-6880	.	_	

#Text=All participants passed the drug screen at the baseline visit.
38-1	6881-6884	All	_	
38-2	6885-6897	participants	_	
38-3	6898-6904	passed	_	
38-4	6905-6908	the	_	
38-5	6909-6913	drug	_	
38-6	6914-6920	screen	_	
38-7	6921-6923	at	_	
38-8	6924-6927	the	_	
38-9	6928-6936	baseline	_	
38-10	6937-6942	visit	_	
38-11	6942-6943	.	_	

#Text=Two participants tested positive for THC at neuroimaging follow-up and were not scanned.
39-1	6944-6947	Two	_	
39-2	6948-6960	participants	_	
39-3	6961-6967	tested	_	
39-4	6968-6976	positive	_	
39-5	6977-6980	for	_	
39-6	6981-6984	THC	_	
39-7	6985-6987	at	_	
39-8	6988-7000	neuroimaging	_	
39-9	7001-7010	follow-up	_	
39-10	7011-7014	and	_	
39-11	7015-7019	were	_	
39-12	7020-7023	not	_	
39-13	7024-7031	scanned	_	
39-14	7031-7032	.	_	

#Text=One participant was scanned after passing a subsequent urine screen 5 weeks later.
40-1	7033-7036	One	_	
40-2	7037-7048	participant	_	
40-3	7049-7052	was	_	
40-4	7053-7060	scanned	_	
40-5	7061-7066	after	_	
40-6	7067-7074	passing	_	
40-7	7075-7076	a	_	
40-8	7077-7087	subsequent	_	
40-9	7088-7093	urine	_	
40-10	7094-7100	screen	_	
40-11	7101-7102	5	_	
40-12	7103-7108	weeks	_	
40-13	7109-7114	later	_	
40-14	7114-7115	.	_	

#Text=The other participant could not be reached again.
41-1	7116-7119	The	_	
41-2	7120-7125	other	_	
41-3	7126-7137	participant	_	
41-4	7138-7143	could	_	
41-5	7144-7147	not	_	
41-6	7148-7150	be	_	
41-7	7151-7158	reached	_	
41-8	7159-7164	again	_	
41-9	7164-7165	.	_	

#Text=One participant (user) was excluded from fMRI baseline analysis for completing less than three of the four imaging runs.
42-1	7166-7169	One	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
42-2	7170-7181	participant	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
42-3	7182-7183	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
42-4	7183-7187	user	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
42-5	7187-7188	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
42-6	7189-7192	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
42-7	7193-7201	excluded	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
42-8	7202-7206	from	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
42-9	7207-7211	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]|http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[14]	
42-10	7212-7220	baseline	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
42-11	7221-7229	analysis	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
42-12	7230-7233	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
42-13	7234-7244	completing	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
42-14	7245-7249	less	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
42-15	7250-7254	than	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
42-16	7255-7260	three	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
42-17	7261-7263	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
42-18	7264-7267	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
42-19	7268-7272	four	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
42-20	7273-7280	imaging	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
42-21	7281-7285	runs	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
42-22	7285-7286	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	

#Text=In addition, one participant’s (nonuser) neuroimaging follow-up was not included owing to a technical error.
43-1	7287-7289	In	_	
43-2	7290-7298	addition	_	
43-3	7298-7299	,	_	
43-4	7300-7303	one	_	
43-5	7304-7315	participant	_	
43-6	7315-7316	’	_	
43-7	7316-7317	s	_	
43-8	7318-7319	(	_	
43-9	7319-7326	nonuser	_	
43-10	7326-7327	)	_	
43-11	7328-7340	neuroimaging	_	
43-12	7341-7350	follow-up	_	
43-13	7351-7354	was	_	
43-14	7355-7358	not	_	
43-15	7359-7367	included	_	
43-16	7368-7373	owing	_	
43-17	7374-7376	to	_	
43-18	7377-7378	a	_	
43-19	7379-7388	technical	_	
43-20	7389-7394	error	_	
43-21	7394-7395	.	_	

#Text=The final neuroimaging sample consisted of 65 participants with neuroimaging data at both baseline and follow-up (Table 1).
44-1	7396-7399	The	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
44-2	7400-7405	final	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
44-3	7406-7418	neuroimaging	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
44-4	7419-7425	sample	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
44-5	7426-7435	consisted	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
44-6	7436-7438	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
44-7	7439-7441	65	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
44-8	7442-7454	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
44-9	7455-7459	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
44-10	7460-7472	neuroimaging	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
44-11	7473-7477	data	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
44-12	7478-7480	at	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
44-13	7481-7485	both	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
44-14	7486-7494	baseline	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
44-15	7495-7498	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
44-16	7499-7508	follow-up	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
44-17	7509-7510	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
44-18	7510-7515	Table	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
44-19	7516-7517	1	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
44-20	7517-7518	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
44-21	7518-7519	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	

#Text=Measures
#Text=Cannabis Use.
45-1	7520-7528	Measures	_	
45-2	7529-7537	Cannabis	_	
45-3	7538-7541	Use	_	
45-4	7541-7542	.	_	

#Text=Cannabis use was assessed at 12, 13, 14, and 15 years of age with validated self-report measures [; see Supplement] and kept confidential from the participants’ parents.
46-1	7543-7551	Cannabis	_	
46-2	7552-7555	use	_	
46-3	7556-7559	was	_	
46-4	7560-7568	assessed	_	
46-5	7569-7571	at	_	
46-6	7572-7574	12	_	
46-7	7574-7575	,	_	
46-8	7576-7578	13	_	
46-9	7578-7579	,	_	
46-10	7580-7582	14	_	
46-11	7582-7583	,	_	
46-12	7584-7587	and	_	
46-13	7588-7590	15	_	
46-14	7591-7596	years	_	
46-15	7597-7599	of	_	
46-16	7600-7603	age	_	
46-17	7604-7608	with	_	
46-18	7609-7618	validated	_	
46-19	7619-7630	self-report	_	
46-20	7631-7639	measures	_	
46-21	7640-7641	[	_	
46-22	7641-7642	;	_	
46-23	7643-7646	see	_	
46-24	7647-7657	Supplement	_	
46-25	7657-7658	]	_	
46-26	7659-7662	and	_	
46-27	7663-7667	kept	_	
46-28	7668-7680	confidential	_	
46-29	7681-7685	from	_	
46-30	7686-7689	the	_	
46-31	7690-7702	participants	_	
46-32	7702-7703	’	_	
46-33	7704-7711	parents	_	
46-34	7711-7712	.	_	

#Text=At baseline (12 years of age), no participant reported cannabis use.
47-1	7713-7715	At	_	
47-2	7716-7724	baseline	_	
47-3	7725-7726	(	_	
47-4	7726-7728	12	_	
47-5	7729-7734	years	_	
47-6	7735-7737	of	_	
47-7	7738-7741	age	_	
47-8	7741-7742	)	_	
47-9	7742-7743	,	_	
47-10	7744-7746	no	_	
47-11	7747-7758	participant	_	
47-12	7759-7767	reported	_	
47-13	7768-7776	cannabis	_	
47-14	7777-7780	use	_	
47-15	7780-7781	.	_	

#Text=By neuroimaging follow-up (15 years of age), 21 participants reported cannabis use during a previous assessment (13–15 years of age).
48-1	7782-7784	By	_	
48-2	7785-7797	neuroimaging	_	
48-3	7798-7807	follow-up	_	
48-4	7808-7809	(	_	
48-5	7809-7811	15	_	
48-6	7812-7817	years	_	
48-7	7818-7820	of	_	
48-8	7821-7824	age	_	
48-9	7824-7825	)	_	
48-10	7825-7826	,	_	
48-11	7827-7829	21	_	
48-12	7830-7842	participants	_	
48-13	7843-7851	reported	_	
48-14	7852-7860	cannabis	_	
48-15	7861-7864	use	_	
48-16	7865-7871	during	_	
48-17	7872-7873	a	_	
48-18	7874-7882	previous	_	
48-19	7883-7893	assessment	_	
48-20	7894-7895	(	_	
48-21	7895-7897	13	_	
48-22	7897-7898	–	_	
48-23	7898-7900	15	_	
48-24	7901-7906	years	_	
48-25	7907-7909	of	_	
48-26	7910-7913	age	_	
48-27	7913-7914	)	_	
48-28	7914-7915	.	_	

#Text=One participant did not report cannabis use but tested positive for THC at neuroimaging follow-up.
49-1	7916-7919	One	_	
49-2	7920-7931	participant	_	
49-3	7932-7935	did	_	
49-4	7936-7939	not	_	
49-5	7940-7946	report	_	
49-6	7947-7955	cannabis	_	
49-7	7956-7959	use	_	
49-8	7960-7963	but	_	
49-9	7964-7970	tested	_	
49-10	7971-7979	positive	_	
49-11	7980-7983	for	_	
49-12	7984-7987	THC	_	
49-13	7988-7990	at	_	
49-14	7991-8003	neuroimaging	_	
49-15	8004-8013	follow-up	_	
49-16	8013-8014	.	_	

#Text=For the current analyses, we classified these participants as cannabis users (n = 22).
50-1	8015-8018	For	_	
50-2	8019-8022	the	_	
50-3	8023-8030	current	_	
50-4	8031-8039	analyses	_	
50-5	8039-8040	,	_	
50-6	8041-8043	we	_	
50-7	8044-8054	classified	_	
50-8	8055-8060	these	_	
50-9	8061-8073	participants	_	
50-10	8074-8076	as	_	
50-11	8077-8085	cannabis	_	
50-12	8086-8091	users	_	
50-13	8092-8093	(	_	
50-14	8093-8094	n	_	
50-15	8095-8096	=	_	
50-16	8097-8099	22	_	
50-17	8099-8100	)	_	
50-18	8100-8101	.	_	

#Text=The remaining participants were classified as nonusers (n = 63).
51-1	8102-8105	The	_	
51-2	8106-8115	remaining	_	
51-3	8116-8128	participants	_	
51-4	8129-8133	were	_	
51-5	8134-8144	classified	_	
51-6	8145-8147	as	_	
51-7	8148-8156	nonusers	_	
51-8	8157-8158	(	_	
51-9	8158-8159	n	_	
51-10	8160-8161	=	_	
51-11	8162-8164	63	_	
51-12	8164-8165	)	_	
51-13	8165-8166	.	_	

#Text=Four participants did not report cannabis use during baseline, but at later assessments reported a cannabis age of onset that was during or before the baseline year.
52-1	8167-8171	Four	_	
52-2	8172-8184	participants	_	
52-3	8185-8188	did	_	
52-4	8189-8192	not	_	
52-5	8193-8199	report	_	
52-6	8200-8208	cannabis	_	
52-7	8209-8212	use	_	
52-8	8213-8219	during	_	
52-9	8220-8228	baseline	_	
52-10	8228-8229	,	_	
52-11	8230-8233	but	_	
52-12	8234-8236	at	_	
52-13	8237-8242	later	_	
52-14	8243-8254	assessments	_	
52-15	8255-8263	reported	_	
52-16	8264-8265	a	_	
52-17	8266-8274	cannabis	_	
52-18	8275-8278	age	_	
52-19	8279-8281	of	_	
52-20	8282-8287	onset	_	
52-21	8288-8292	that	_	
52-22	8293-8296	was	_	
52-23	8297-8303	during	_	
52-24	8304-8306	or	_	
52-25	8307-8313	before	_	
52-26	8314-8317	the	_	
52-27	8318-8326	baseline	_	
52-28	8327-8331	year	_	
52-29	8331-8332	.	_	

#Text=Accordingly, baseline analyses were rerun excluding these participants.
53-1	8333-8344	Accordingly	_	
53-2	8344-8345	,	_	
53-3	8346-8354	baseline	_	
53-4	8355-8363	analyses	_	
53-5	8364-8368	were	_	
53-6	8369-8374	rerun	_	
53-7	8375-8384	excluding	_	
53-8	8385-8390	these	_	
53-9	8391-8403	participants	_	
53-10	8403-8404	.	_	

#Text=Secondary analyses examined dose-response relationships in users with a total cannabis use measure (sum of joints per day from visits at 13–15 years of age).
54-1	8405-8414	Secondary	_	
54-2	8415-8423	analyses	_	
54-3	8424-8432	examined	_	
54-4	8433-8446	dose-response	_	
54-5	8447-8460	relationships	_	
54-6	8461-8463	in	_	
54-7	8464-8469	users	_	
54-8	8470-8474	with	_	
54-9	8475-8476	a	_	
54-10	8477-8482	total	_	
54-11	8483-8491	cannabis	_	
54-12	8492-8495	use	_	
54-13	8496-8503	measure	_	
54-14	8504-8505	(	_	
54-15	8505-8508	sum	_	
54-16	8509-8511	of	_	
54-17	8512-8518	joints	_	
54-18	8519-8522	per	_	
54-19	8523-8526	day	_	
54-20	8527-8531	from	_	
54-21	8532-8538	visits	_	
54-22	8539-8541	at	_	
54-23	8542-8544	13	_	
54-24	8544-8545	–	_	
54-25	8545-8547	15	_	
54-26	8548-8553	years	_	
54-27	8554-8556	of	_	
54-28	8557-8560	age	_	
54-29	8560-8561	)	_	
54-30	8561-8562	.	_	

#Text=To reduce the impact of a few participants with higher levels of use, this measure was log transformed (Supplemental Figure S1).
55-1	8563-8565	To	_	
55-2	8566-8572	reduce	_	
55-3	8573-8576	the	_	
55-4	8577-8583	impact	_	
55-5	8584-8586	of	_	
55-6	8587-8588	a	_	
55-7	8589-8592	few	_	
55-8	8593-8605	participants	_	
55-9	8606-8610	with	_	
55-10	8611-8617	higher	_	
55-11	8618-8624	levels	_	
55-12	8625-8627	of	_	
55-13	8628-8631	use	_	
55-14	8631-8632	,	_	
55-15	8633-8637	this	_	
55-16	8638-8645	measure	_	
55-17	8646-8649	was	_	
55-18	8650-8653	log	_	
55-19	8654-8665	transformed	_	
55-20	8666-8667	(	_	
55-21	8667-8679	Supplemental	_	
55-22	8680-8686	Figure	_	
55-23	8687-8689	S1	_	
55-24	8689-8690	)	_	
55-25	8690-8691	.	_	

#Text=Externalizing Symptoms.
56-1	8692-8705	Externalizing	_	
56-2	8706-8714	Symptoms	_	
56-3	8714-8715	.	_	

#Text=Primary caregivers reported participant behavior at 12, 13, 14, and 15 years of age using the Child Behavior Checklist.
57-1	8716-8723	Primary	_	
57-2	8724-8734	caregivers	_	
57-3	8735-8743	reported	_	
57-4	8744-8755	participant	_	
57-5	8756-8764	behavior	_	
57-6	8765-8767	at	_	
57-7	8768-8770	12	_	
57-8	8770-8771	,	_	
57-9	8772-8774	13	_	
57-10	8774-8775	,	_	
57-11	8776-8778	14	_	
57-12	8778-8779	,	_	
57-13	8780-8783	and	_	
57-14	8784-8786	15	_	
57-15	8787-8792	years	_	
57-16	8793-8795	of	_	
57-17	8796-8799	age	_	
57-18	8800-8805	using	_	
57-19	8806-8809	the	_	
57-20	8810-8815	Child	_	
57-21	8816-8824	Behavior	_	
57-22	8825-8834	Checklist	_	
57-23	8834-8835	.	_	

#Text=Covariate analyses used age- and gender-corrected externalizing scale t scores (EXT).
58-1	8836-8845	Covariate	_	
58-2	8846-8854	analyses	_	
58-3	8855-8859	used	_	
58-4	8860-8863	age	_	
58-5	8863-8864	-	_	
58-6	8865-8868	and	_	
58-7	8869-8885	gender-corrected	_	
58-8	8886-8899	externalizing	_	
58-9	8900-8905	scale	_	
58-10	8906-8907	t	_	
58-11	8908-8914	scores	_	
58-12	8915-8916	(	_	
58-13	8916-8919	EXT	_	
58-14	8919-8920	)	_	
58-15	8920-8921	.	_	

#Text=Socioeconomic Status.
59-1	8922-8935	Socioeconomic	_	
59-2	8936-8942	Status	_	
59-3	8942-8943	.	_	

#Text=As in other recent work examining adolescent cannabis use, we used a composite variable of family income and maternal education (family income–maternal education correlation: r = .496, t = 5.18, p < .001) to quantify SES for use as a covariate and mediator (Table 2).
60-1	8944-8946	As	_	
60-2	8947-8949	in	_	
60-3	8950-8955	other	_	
60-4	8956-8962	recent	_	
60-5	8963-8967	work	_	
60-6	8968-8977	examining	_	
60-7	8978-8988	adolescent	_	
60-8	8989-8997	cannabis	_	
60-9	8998-9001	use	_	
60-10	9001-9002	,	_	
60-11	9003-9005	we	_	
60-12	9006-9010	used	_	
60-13	9011-9012	a	_	
60-14	9013-9022	composite	_	
60-15	9023-9031	variable	_	
60-16	9032-9034	of	_	
60-17	9035-9041	family	_	
60-18	9042-9048	income	_	
60-19	9049-9052	and	_	
60-20	9053-9061	maternal	_	
60-21	9062-9071	education	_	
60-22	9072-9073	(	_	
60-23	9073-9079	family	_	
60-24	9080-9095	income–maternal	_	
60-25	9096-9105	education	_	
60-26	9106-9117	correlation	_	
60-27	9117-9118	:	_	
60-28	9119-9120	r	_	
60-29	9121-9122	=	_	
60-30	9123-9127	.496	_	
60-31	9127-9128	,	_	
60-32	9129-9130	t	_	
60-33	9131-9132	=	_	
60-34	9133-9137	5.18	_	
60-35	9137-9138	,	_	
60-36	9139-9140	p	_	
60-37	9141-9142	<	_	
60-38	9143-9147	.001	_	
60-39	9147-9148	)	_	
60-40	9149-9151	to	_	
60-41	9152-9160	quantify	_	
60-42	9161-9164	SES	_	
60-43	9165-9168	for	_	
60-44	9169-9172	use	_	
60-45	9173-9175	as	_	
60-46	9176-9177	a	_	
60-47	9178-9187	covariate	_	
60-48	9188-9191	and	_	
60-49	9192-9200	mediator	_	
60-50	9201-9202	(	_	
60-51	9202-9207	Table	_	
60-52	9208-9209	2	_	
60-53	9209-9210	)	_	
60-54	9210-9211	.	_	

#Text=One participant did not have family income data.
61-1	9212-9215	One	_	
61-2	9216-9227	participant	_	
61-3	9228-9231	did	_	
61-4	9232-9235	not	_	
61-5	9236-9240	have	_	
61-6	9241-9247	family	_	
61-7	9248-9254	income	_	
61-8	9255-9259	data	_	
61-9	9259-9260	.	_	

#Text=The SES composite represented only maternal education for this participant.
62-1	9261-9264	The	_	
62-2	9265-9268	SES	_	
62-3	9269-9278	composite	_	
62-4	9279-9290	represented	_	
62-5	9291-9295	only	_	
62-6	9296-9304	maternal	_	
62-7	9305-9314	education	_	
62-8	9315-9318	for	_	
62-9	9319-9323	this	_	
62-10	9324-9335	participant	_	
62-11	9335-9336	.	_	

#Text=Other Substance Use.
63-1	9337-9342	Other	_	
63-2	9343-9352	Substance	_	
63-3	9353-9356	Use	_	
63-4	9356-9357	.	_	

#Text=Participants were also asked about their use of alcohol and tobacco, with questions parallel to the marijuana questions.
64-1	9358-9370	Participants	_	
64-2	9371-9375	were	_	
64-3	9376-9380	also	_	
64-4	9381-9386	asked	_	
64-5	9387-9392	about	_	
64-6	9393-9398	their	_	
64-7	9399-9402	use	_	
64-8	9403-9405	of	_	
64-9	9406-9413	alcohol	_	
64-10	9414-9417	and	_	
64-11	9418-9425	tobacco	_	
64-12	9425-9426	,	_	
64-13	9427-9431	with	_	
64-14	9432-9441	questions	_	
64-15	9442-9450	parallel	_	
64-16	9451-9453	to	_	
64-17	9454-9457	the	_	
64-18	9458-9467	marijuana	_	
64-19	9468-9477	questions	_	
64-20	9477-9478	.	_	

#Text=At baseline, no participants reported alcohol use.
65-1	9479-9481	At	_	
65-2	9482-9490	baseline	_	
65-3	9490-9491	,	_	
65-4	9492-9494	no	_	
65-5	9495-9507	participants	_	
65-6	9508-9516	reported	_	
65-7	9517-9524	alcohol	_	
65-8	9525-9528	use	_	
65-9	9528-9529	.	_	

#Text=However, participants who initiated cannabis use by 15 years of age were also more likely to report alcohol use (Table 2).
66-1	9530-9537	However	_	
66-2	9537-9538	,	_	
66-3	9539-9551	participants	_	
66-4	9552-9555	who	_	
66-5	9556-9565	initiated	_	
66-6	9566-9574	cannabis	_	
66-7	9575-9578	use	_	
66-8	9579-9581	by	_	
66-9	9582-9584	15	_	
66-10	9585-9590	years	_	
66-11	9591-9593	of	_	
66-12	9594-9597	age	_	
66-13	9598-9602	were	_	
66-14	9603-9607	also	_	
66-15	9608-9612	more	_	
66-16	9613-9619	likely	_	
66-17	9620-9622	to	_	
66-18	9623-9629	report	_	
66-19	9630-9637	alcohol	_	
66-20	9638-9641	use	_	
66-21	9642-9643	(	_	
66-22	9643-9648	Table	_	
66-23	9649-9650	2	_	
66-24	9650-9651	)	_	
66-25	9651-9652	.	_	

#Text=Between baseline and follow-up, one cannabis initiator reported cigarette use and three reported use of other illicit drugs (dextromethorphan/“triple-c,” mushrooms, and Oxycontin).
#Text=fMRI WM Task.
67-1	9653-9660	Between	_	
67-2	9661-9669	baseline	_	
67-3	9670-9673	and	_	
67-4	9674-9683	follow-up	_	
67-5	9683-9684	,	_	
67-6	9685-9688	one	_	
67-7	9689-9697	cannabis	_	
67-8	9698-9707	initiator	_	
67-9	9708-9716	reported	_	
67-10	9717-9726	cigarette	_	
67-11	9727-9730	use	_	
67-12	9731-9734	and	_	
67-13	9735-9740	three	_	
67-14	9741-9749	reported	_	
67-15	9750-9753	use	_	
67-16	9754-9756	of	_	
67-17	9757-9762	other	_	
67-18	9763-9770	illicit	_	
67-19	9771-9776	drugs	_	
67-20	9777-9778	(	_	
67-21	9778-9794	dextromethorphan	_	
67-22	9794-9795	/	_	
67-23	9795-9796	“	_	
67-24	9796-9804	triple-c	_	
67-25	9804-9805	,	_	
67-26	9805-9806	”	_	
67-27	9807-9816	mushrooms	_	
67-28	9816-9817	,	_	
67-29	9818-9821	and	_	
67-30	9822-9831	Oxycontin	_	
67-31	9831-9832	)	_	
67-32	9832-9833	.	_	
67-33	9834-9838	fMRI	_	
67-34	9839-9841	WM	_	
67-35	9842-9846	Task	_	
67-36	9846-9847	.	_	

#Text=At both neuroimaging visits, participants performed the same task used in our work examining cannabis use history in adults (Figure 1): a spatial WM task with a 2 (load: one or three spatial locations) × 2 (delay length: 1500 or 6000 ms) × 2 (cue validity: match or nonmatch between cue and target) full factorial design.
68-1	9848-9850	At	_	
68-2	9851-9855	both	_	
68-3	9856-9868	neuroimaging	_	
68-4	9869-9875	visits	_	
68-5	9875-9876	,	_	
68-6	9877-9889	participants	_	
68-7	9890-9899	performed	_	
68-8	9900-9903	the	_	
68-9	9904-9908	same	_	
68-10	9909-9913	task	_	
68-11	9914-9918	used	_	
68-12	9919-9921	in	_	
68-13	9922-9925	our	_	
68-14	9926-9930	work	_	
68-15	9931-9940	examining	_	
68-16	9941-9949	cannabis	_	
68-17	9950-9953	use	_	
68-18	9954-9961	history	_	
68-19	9962-9964	in	_	
68-20	9965-9971	adults	_	
68-21	9972-9973	(	_	
68-22	9973-9979	Figure	_	
68-23	9980-9981	1	_	
68-24	9981-9982	)	_	
68-25	9982-9983	:	_	
68-26	9984-9985	a	_	
68-27	9986-9993	spatial	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[16]	
68-28	9994-9996	WM	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[16]	
68-29	9997-10001	task	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[16]	
68-30	10002-10006	with	_	
68-31	10007-10008	a	_	
68-32	10009-10010	2	_	
68-33	10011-10012	(	_	
68-34	10012-10016	load	_	
68-35	10016-10017	:	_	
68-36	10018-10021	one	_	
68-37	10022-10024	or	_	
68-38	10025-10030	three	_	
68-39	10031-10038	spatial	_	
68-40	10039-10048	locations	_	
68-41	10048-10049	)	_	
68-42	10050-10051	×	_	
68-43	10052-10053	2	_	
68-44	10054-10055	(	_	
68-45	10055-10060	delay	_	
68-46	10061-10067	length	_	
68-47	10067-10068	:	_	
68-48	10069-10073	1500	_	
68-49	10074-10076	or	_	
68-50	10077-10081	6000	_	
68-51	10082-10084	ms	_	
68-52	10084-10085	)	_	
68-53	10086-10087	×	_	
68-54	10088-10089	2	_	
68-55	10090-10091	(	_	
68-56	10091-10094	cue	_	
68-57	10095-10103	validity	_	
68-58	10103-10104	:	_	
68-59	10105-10110	match	_	
68-60	10111-10113	or	_	
68-61	10114-10122	nonmatch	_	
68-62	10123-10130	between	_	
68-63	10131-10134	cue	_	
68-64	10135-10138	and	_	
68-65	10139-10145	target	_	
68-66	10145-10146	)	_	
68-67	10147-10151	full	_	
68-68	10152-10161	factorial	_	
68-69	10162-10168	design	_	
68-70	10168-10169	.	_	

#Text=The protocol was designed with four neuroimaging runs of 24 trials each.
69-1	10170-10173	The	_	
69-2	10174-10182	protocol	_	
69-3	10183-10186	was	_	
69-4	10187-10195	designed	_	
69-5	10196-10200	with	_	
69-6	10201-10205	four	_	
69-7	10206-10218	neuroimaging	_	
69-8	10219-10223	runs	_	
69-9	10224-10226	of	_	
69-10	10227-10229	24	_	
69-11	10230-10236	trials	_	
69-12	10237-10241	each	_	
69-13	10241-10242	.	_	

#Text=An additional 48 partial trials (presenting only cue or cue and delay phases of the task) (Figure 1) were also included to estimate the hemodynamic response to individual task phases.
70-1	10243-10245	An	_	
70-2	10246-10256	additional	_	
70-3	10257-10259	48	_	
70-4	10260-10267	partial	_	
70-5	10268-10274	trials	_	
70-6	10275-10276	(	_	
70-7	10276-10286	presenting	_	
70-8	10287-10291	only	_	
70-9	10292-10295	cue	_	
70-10	10296-10298	or	_	
70-11	10299-10302	cue	_	
70-12	10303-10306	and	_	
70-13	10307-10312	delay	_	
70-14	10313-10319	phases	_	
70-15	10320-10322	of	_	
70-16	10323-10326	the	_	
70-17	10327-10331	task	_	
70-18	10331-10332	)	_	
70-19	10333-10334	(	_	
70-20	10334-10340	Figure	_	
70-21	10341-10342	1	_	
70-22	10342-10343	)	_	
70-23	10344-10348	were	_	
70-24	10349-10353	also	_	
70-25	10354-10362	included	_	
70-26	10363-10365	to	_	
70-27	10366-10374	estimate	_	
70-28	10375-10378	the	_	
70-29	10379-10390	hemodynamic	_	
70-30	10391-10399	response	_	
70-31	10400-10402	to	_	
70-32	10403-10413	individual	_	
70-33	10414-10418	task	_	
70-34	10419-10425	phases	_	
70-35	10425-10426	.	_	

#Text=In the current project, we collapsed across epochs and estimated trialwise hemodynamic responses to gain more power identifying effects of interest.
#Text=fMRI Data Acquisition and Preprocessing.
#Text=fMRI data were acquired and preprocessed using standardized approaches with the same parameters as our previous work (see Supplement).
71-1	10427-10429	In	_	
71-2	10430-10433	the	_	
71-3	10434-10441	current	_	
71-4	10442-10449	project	_	
71-5	10449-10450	,	_	
71-6	10451-10453	we	_	
71-7	10454-10463	collapsed	_	
71-8	10464-10470	across	_	
71-9	10471-10477	epochs	_	
71-10	10478-10481	and	_	
71-11	10482-10491	estimated	_	
71-12	10492-10501	trialwise	_	
71-13	10502-10513	hemodynamic	_	
71-14	10514-10523	responses	_	
71-15	10524-10526	to	_	
71-16	10527-10531	gain	_	
71-17	10532-10536	more	_	
71-18	10537-10542	power	_	
71-19	10543-10554	identifying	_	
71-20	10555-10562	effects	_	
71-21	10563-10565	of	_	
71-22	10566-10574	interest	_	
71-23	10574-10575	.	_	
71-24	10576-10580	fMRI	_	
71-25	10581-10585	Data	_	
71-26	10586-10597	Acquisition	_	
71-27	10598-10601	and	_	
71-28	10602-10615	Preprocessing	_	
71-29	10615-10616	.	_	
71-30	10617-10621	fMRI	_	
71-31	10622-10626	data	_	
71-32	10627-10631	were	_	
71-33	10632-10640	acquired	_	
71-34	10641-10644	and	_	
71-35	10645-10657	preprocessed	_	
71-36	10658-10663	using	_	
71-37	10664-10676	standardized	_	
71-38	10677-10687	approaches	_	
71-39	10688-10692	with	_	
71-40	10693-10696	the	_	
71-41	10697-10701	same	_	
71-42	10702-10712	parameters	_	
71-43	10713-10715	as	_	
71-44	10716-10719	our	_	
71-45	10720-10728	previous	_	
71-46	10729-10733	work	_	
71-47	10734-10735	(	_	
71-48	10735-10738	see	_	
71-49	10739-10749	Supplement	_	
71-50	10749-10750	)	_	
71-51	10750-10751	.	_	

#Text=Cognitive Battery.
72-1	10752-10761	Cognitive	_	
72-2	10762-10769	Battery	_	
72-3	10769-10770	.	_	

#Text=At a separate visit during baseline and follow-up years, participants completed multiple cognitive tests, including a Wechsler Intelligence Scale for Children-IV intelligence test with Perceptual Reasoning (WISC PER), Processing Speed, Verbal Comprehension, and WM subscales, and the following assessments from the Cambridge Neuropsychological Test Automated Battery (CANTAB): Intra-Extra Dimensional Set Shift, One Touch Stockings of Cambridge (OTS), Spatial Span, and Spatial WM (Supplement).
73-1	10771-10773	At	_	
73-2	10774-10775	a	_	
73-3	10776-10784	separate	_	
73-4	10785-10790	visit	_	
73-5	10791-10797	during	_	
73-6	10798-10806	baseline	_	
73-7	10807-10810	and	_	
73-8	10811-10820	follow-up	_	
73-9	10821-10826	years	_	
73-10	10826-10827	,	_	
73-11	10828-10840	participants	_	
73-12	10841-10850	completed	_	
73-13	10851-10859	multiple	_	
73-14	10860-10869	cognitive	_	
73-15	10870-10875	tests	_	
73-16	10875-10876	,	_	
73-17	10877-10886	including	_	
73-18	10887-10888	a	_	
73-19	10889-10897	Wechsler	_	
73-20	10898-10910	Intelligence	_	
73-21	10911-10916	Scale	_	
73-22	10917-10920	for	_	
73-23	10921-10932	Children-IV	_	
73-24	10933-10945	intelligence	_	
73-25	10946-10950	test	_	
73-26	10951-10955	with	_	
73-27	10956-10966	Perceptual	_	
73-28	10967-10976	Reasoning	_	
73-29	10977-10978	(	_	
73-30	10978-10982	WISC	_	
73-31	10983-10986	PER	_	
73-32	10986-10987	)	_	
73-33	10987-10988	,	_	
73-34	10989-10999	Processing	_	
73-35	11000-11005	Speed	_	
73-36	11005-11006	,	_	
73-37	11007-11013	Verbal	_	
73-38	11014-11027	Comprehension	_	
73-39	11027-11028	,	_	
73-40	11029-11032	and	_	
73-41	11033-11035	WM	_	
73-42	11036-11045	subscales	_	
73-43	11045-11046	,	_	
73-44	11047-11050	and	_	
73-45	11051-11054	the	_	
73-46	11055-11064	following	_	
73-47	11065-11076	assessments	_	
73-48	11077-11081	from	_	
73-49	11082-11085	the	_	
73-50	11086-11095	Cambridge	_	
73-51	11096-11114	Neuropsychological	_	
73-52	11115-11119	Test	_	
73-53	11120-11129	Automated	_	
73-54	11130-11137	Battery	_	
73-55	11138-11139	(	_	
73-56	11139-11145	CANTAB	_	
73-57	11145-11146	)	_	
73-58	11146-11147	:	_	
73-59	11148-11159	Intra-Extra	_	
73-60	11160-11171	Dimensional	_	
73-61	11172-11175	Set	_	
73-62	11176-11181	Shift	_	
73-63	11181-11182	,	_	
73-64	11183-11186	One	_	
73-65	11187-11192	Touch	_	
73-66	11193-11202	Stockings	_	
73-67	11203-11205	of	_	
73-68	11206-11215	Cambridge	_	
73-69	11216-11217	(	_	
73-70	11217-11220	OTS	_	
73-71	11220-11221	)	_	
73-72	11221-11222	,	_	
73-73	11223-11230	Spatial	_	
73-74	11231-11235	Span	_	
73-75	11235-11236	,	_	
73-76	11237-11240	and	_	
73-77	11241-11248	Spatial	_	
73-78	11249-11251	WM	_	
73-79	11252-11253	(	_	
73-80	11253-11263	Supplement	_	
73-81	11263-11264	)	_	
73-82	11264-11265	.	_	

#Text=Statistical Analysis
#Text=Covariate Selection and Analysis.
74-1	11266-11277	Statistical	_	
74-2	11278-11286	Analysis	_	
74-3	11287-11296	Covariate	_	
74-4	11297-11306	Selection	_	
74-5	11307-11310	and	_	
74-6	11311-11319	Analysis	_	
74-7	11319-11320	.	_	

#Text=Based on our hypothesis that neurocognitive differences associated with cannabis may be driven by SES and/or EXT, we examined their association with all neurocognitive outcomes.
75-1	11321-11326	Based	_	
75-2	11327-11329	on	_	
75-3	11330-11333	our	_	
75-4	11334-11344	hypothesis	_	
75-5	11345-11349	that	_	
75-6	11350-11364	neurocognitive	_	
75-7	11365-11376	differences	_	
75-8	11377-11387	associated	_	
75-9	11388-11392	with	_	
75-10	11393-11401	cannabis	_	
75-11	11402-11405	may	_	
75-12	11406-11408	be	_	
75-13	11409-11415	driven	_	
75-14	11416-11418	by	_	
75-15	11419-11422	SES	_	
75-16	11423-11426	and	_	
75-17	11426-11427	/	_	
75-18	11427-11429	or	_	
75-19	11430-11433	EXT	_	
75-20	11433-11434	,	_	
75-21	11435-11437	we	_	
75-22	11438-11446	examined	_	
75-23	11447-11452	their	_	
75-24	11453-11464	association	_	
75-25	11465-11469	with	_	
75-26	11470-11473	all	_	
75-27	11474-11488	neurocognitive	_	
75-28	11489-11497	outcomes	_	
75-29	11497-11498	.	_	

#Text=In cases where SES or EXT had a significant association with the same outcome as cannabis use, we used mediation analysis [bootstrap procedure with 5000 draws ] to dimensionally assess the extent to which SES and EXT contributed to cannabis group differences on neurocognitive outcomes.
76-1	11499-11501	In	_	
76-2	11502-11507	cases	_	
76-3	11508-11513	where	_	
76-4	11514-11517	SES	_	
76-5	11518-11520	or	_	
76-6	11521-11524	EXT	_	
76-7	11525-11528	had	_	
76-8	11529-11530	a	_	
76-9	11531-11542	significant	_	
76-10	11543-11554	association	_	
76-11	11555-11559	with	_	
76-12	11560-11563	the	_	
76-13	11564-11568	same	_	
76-14	11569-11576	outcome	_	
76-15	11577-11579	as	_	
76-16	11580-11588	cannabis	_	
76-17	11589-11592	use	_	
76-18	11592-11593	,	_	
76-19	11594-11596	we	_	
76-20	11597-11601	used	_	
76-21	11602-11611	mediation	_	
76-22	11612-11620	analysis	_	
76-23	11621-11622	[	_	
76-24	11622-11631	bootstrap	_	
76-25	11632-11641	procedure	_	
76-26	11642-11646	with	_	
76-27	11647-11651	5000	_	
76-28	11652-11657	draws	_	
76-29	11658-11659	]	_	
76-30	11660-11662	to	_	
76-31	11663-11676	dimensionally	_	
76-32	11677-11683	assess	_	
76-33	11684-11687	the	_	
76-34	11688-11694	extent	_	
76-35	11695-11697	to	_	
76-36	11698-11703	which	_	
76-37	11704-11707	SES	_	
76-38	11708-11711	and	_	
76-39	11712-11715	EXT	_	
76-40	11716-11727	contributed	_	
76-41	11728-11730	to	_	
76-42	11731-11739	cannabis	_	
76-43	11740-11745	group	_	
76-44	11746-11757	differences	_	
76-45	11758-11760	on	_	
76-46	11761-11775	neurocognitive	_	
76-47	11776-11784	outcomes	_	
76-48	11784-11785	.	_	

#Text=This analysis allowed us to statistically test the relative contribution of SES and EXT to observed cannabis neurocognitive differences, as opposed to solely relying on the interpretation of significance with and without these variables as covariates.
77-1	11786-11790	This	_	
77-2	11791-11799	analysis	_	
77-3	11800-11807	allowed	_	
77-4	11808-11810	us	_	
77-5	11811-11813	to	_	
77-6	11814-11827	statistically	_	
77-7	11828-11832	test	_	
77-8	11833-11836	the	_	
77-9	11837-11845	relative	_	
77-10	11846-11858	contribution	_	
77-11	11859-11861	of	_	
77-12	11862-11865	SES	_	
77-13	11866-11869	and	_	
77-14	11870-11873	EXT	_	
77-15	11874-11876	to	_	
77-16	11877-11885	observed	_	
77-17	11886-11894	cannabis	_	
77-18	11895-11909	neurocognitive	_	
77-19	11910-11921	differences	_	
77-20	11921-11922	,	_	
77-21	11923-11925	as	_	
77-22	11926-11933	opposed	_	
77-23	11934-11936	to	_	
77-24	11937-11943	solely	_	
77-25	11944-11951	relying	_	
77-26	11952-11954	on	_	
77-27	11955-11958	the	_	
77-28	11959-11973	interpretation	_	
77-29	11974-11976	of	_	
77-30	11977-11989	significance	_	
77-31	11990-11994	with	_	
77-32	11995-11998	and	_	
77-33	11999-12006	without	_	
77-34	12007-12012	these	_	
77-35	12013-12022	variables	_	
77-36	12023-12025	as	_	
77-37	12026-12036	covariates	_	
77-38	12036-12037	.	_	

#Text=Cannabis initiators were also more likely to initiate alcohol use (Table 1), and therefore we used alcohol usage group as a covariate and moderator to examine the specificity of results.
78-1	12038-12046	Cannabis	_	
78-2	12047-12057	initiators	_	
78-3	12058-12062	were	_	
78-4	12063-12067	also	_	
78-5	12068-12072	more	_	
78-6	12073-12079	likely	_	
78-7	12080-12082	to	_	
78-8	12083-12091	initiate	_	
78-9	12092-12099	alcohol	_	
78-10	12100-12103	use	_	
78-11	12104-12105	(	_	
78-12	12105-12110	Table	_	
78-13	12111-12112	1	_	
78-14	12112-12113	)	_	
78-15	12113-12114	,	_	
78-16	12115-12118	and	_	
78-17	12119-12128	therefore	_	
78-18	12129-12131	we	_	
78-19	12132-12136	used	_	
78-20	12137-12144	alcohol	_	
78-21	12145-12150	usage	_	
78-22	12151-12156	group	_	
78-23	12157-12159	as	_	
78-24	12160-12161	a	_	
78-25	12162-12171	covariate	_	
78-26	12172-12175	and	_	
78-27	12176-12185	moderator	_	
78-28	12186-12188	to	_	
78-29	12189-12196	examine	_	
78-30	12197-12200	the	_	
78-31	12201-12212	specificity	_	
78-32	12213-12215	of	_	
78-33	12216-12223	results	_	
78-34	12223-12224	.	_	

#Text=Scanner WM Performance.
79-1	12225-12232	Scanner	_	
79-2	12233-12235	WM	_	
79-3	12236-12247	Performance	_	
79-4	12247-12248	.	_	

#Text=WM accuracy and reaction time for correct trials were analyzed with linear mixed-effects models [lme4 package ].
80-1	12249-12251	WM	_	
80-2	12252-12260	accuracy	_	
80-3	12261-12264	and	_	
80-4	12265-12273	reaction	_	
80-5	12274-12278	time	_	
80-6	12279-12282	for	_	
80-7	12283-12290	correct	_	
80-8	12291-12297	trials	_	
80-9	12298-12302	were	_	
80-10	12303-12311	analyzed	_	
80-11	12312-12316	with	_	
80-12	12317-12323	linear	_	
80-13	12324-12337	mixed-effects	_	
80-14	12338-12344	models	_	
80-15	12345-12346	[	_	
80-16	12346-12350	lme4	_	
80-17	12351-12358	package	_	
80-18	12359-12360	]	_	
80-19	12360-12361	.	_	

#Text=Accuracy analysis excluded trials with omission errors (details on model specification can be found in the Supplement).
81-1	12362-12370	Accuracy	_	
81-2	12371-12379	analysis	_	
81-3	12380-12388	excluded	_	
81-4	12389-12395	trials	_	
81-5	12396-12400	with	_	
81-6	12401-12409	omission	_	
81-7	12410-12416	errors	_	
81-8	12417-12418	(	_	
81-9	12418-12425	details	_	
81-10	12426-12428	on	_	
81-11	12429-12434	model	_	
81-12	12435-12448	specification	_	
81-13	12449-12452	can	_	
81-14	12453-12455	be	_	
81-15	12456-12461	found	_	
81-16	12462-12464	in	_	
81-17	12465-12468	the	_	
81-18	12469-12479	Supplement	_	
81-19	12479-12480	)	_	
81-20	12480-12481	.	_	

#Text=Primary analyses focused on the main effects of usage group and interactions with visit (baseline/follow-up).
82-1	12482-12489	Primary	_	
82-2	12490-12498	analyses	_	
82-3	12499-12506	focused	_	
82-4	12507-12509	on	_	
82-5	12510-12513	the	_	
82-6	12514-12518	main	_	
82-7	12519-12526	effects	_	
82-8	12527-12529	of	_	
82-9	12530-12535	usage	_	
82-10	12536-12541	group	_	
82-11	12542-12545	and	_	
82-12	12546-12558	interactions	_	
82-13	12559-12563	with	_	
82-14	12564-12569	visit	_	
82-15	12570-12571	(	_	
82-16	12571-12579	baseline	_	
82-17	12579-12580	/	_	
82-18	12580-12589	follow-up	_	
82-19	12589-12590	)	_	
82-20	12590-12591	.	_	

#Text=Interactions between task factors and usage group were largely nonsignificant (Supplement).
#Text=fMRI.
83-1	12592-12604	Interactions	_	
83-2	12605-12612	between	_	
83-3	12613-12617	task	_	
83-4	12618-12625	factors	_	
83-5	12626-12629	and	_	
83-6	12630-12635	usage	_	
83-7	12636-12641	group	_	
83-8	12642-12646	were	_	
83-9	12647-12654	largely	_	
83-10	12655-12669	nonsignificant	_	
83-11	12670-12671	(	_	
83-12	12671-12681	Supplement	_	
83-13	12681-12682	)	_	
83-14	12682-12683	.	_	
83-15	12684-12688	fMRI	_	
83-16	12688-12689	.	_	

#Text=For each participant, at each visit, trialwise BOLD responses were estimated using AFNI’s 3dDeconvolve.
84-1	12690-12693	For	_	
84-2	12694-12698	each	_	
84-3	12699-12710	participant	_	
84-4	12710-12711	,	_	
84-5	12712-12714	at	_	
84-6	12715-12719	each	_	
84-7	12720-12725	visit	_	
84-8	12725-12726	,	_	
84-9	12727-12736	trialwise	_	
84-10	12737-12741	BOLD	_	
84-11	12742-12751	responses	_	
84-12	12752-12756	were	_	
84-13	12757-12766	estimated	_	
84-14	12767-12772	using	_	
84-15	12773-12777	AFNI	_	
84-16	12777-12778	’	_	
84-17	12778-12779	s	_	
84-18	12780-12792	3dDeconvolve	_	
84-19	12792-12793	.	_	

#Text=Trial time courses for correct, incorrect, and partial trials were modeled using TENT basis functions spanning 28 seconds with 15 time steps (TRs).
85-1	12794-12799	Trial	_	
85-2	12800-12804	time	_	
85-3	12805-12812	courses	_	
85-4	12813-12816	for	_	
85-5	12817-12824	correct	_	
85-6	12824-12825	,	_	
85-7	12826-12835	incorrect	_	
85-8	12835-12836	,	_	
85-9	12837-12840	and	_	
85-10	12841-12848	partial	_	
85-11	12849-12855	trials	_	
85-12	12856-12860	were	_	
85-13	12861-12868	modeled	_	
85-14	12869-12874	using	_	
85-15	12875-12879	TENT	_	
85-16	12880-12885	basis	_	
85-17	12886-12895	functions	_	
85-18	12896-12904	spanning	_	
85-19	12905-12907	28	_	
85-20	12908-12915	seconds	_	
85-21	12916-12920	with	_	
85-22	12921-12923	15	_	
85-23	12924-12928	time	_	
85-24	12929-12934	steps	_	
85-25	12935-12936	(	_	
85-26	12936-12939	TRs	_	
85-27	12939-12940	)	_	
85-28	12940-12941	.	_	

#Text=Owing to the temporal properties of hemodynamic responses, 1500- and 6000-ms delay trials were modeled separately.
86-1	12942-12947	Owing	_	
86-2	12948-12950	to	_	
86-3	12951-12954	the	_	
86-4	12955-12963	temporal	_	
86-5	12964-12974	properties	_	
86-6	12975-12977	of	_	
86-7	12978-12989	hemodynamic	_	
86-8	12990-12999	responses	_	
86-9	12999-13000	,	_	
86-10	13001-13005	1500	_	
86-11	13005-13006	-	_	
86-12	13007-13010	and	_	
86-13	13011-13015	6000	_	
86-14	13015-13016	-	_	
86-15	13016-13018	ms	_	
86-16	13019-13024	delay	_	
86-17	13025-13031	trials	_	
86-18	13032-13036	were	_	
86-19	13037-13044	modeled	_	
86-20	13045-13055	separately	_	
86-21	13055-13056	.	_	

#Text=Additional nuisance regressors included six rigid-body head motion parameters and their derivatives, and runwise zero through third order polynomials.
87-1	13057-13067	Additional	_	
87-2	13068-13076	nuisance	_	
87-3	13077-13087	regressors	_	
87-4	13088-13096	included	_	
87-5	13097-13100	six	_	
87-6	13101-13111	rigid-body	_	
87-7	13112-13116	head	_	
87-8	13117-13123	motion	_	
87-9	13124-13134	parameters	_	
87-10	13135-13138	and	_	
87-11	13139-13144	their	_	
87-12	13145-13156	derivatives	_	
87-13	13156-13157	,	_	
87-14	13158-13161	and	_	
87-15	13162-13169	runwise	_	
87-16	13170-13174	zero	_	
87-17	13175-13182	through	_	
87-18	13183-13188	third	_	
87-19	13189-13194	order	_	
87-20	13195-13206	polynomials	_	
87-21	13206-13207	.	_	

#Text=The current and preceding TRs were censored if the Euclidean norm head motion distance surpassed 0.9 mm (percentage of TRs censored: mean 6 SD,3.18% ± 6.29%).
#Text=fMRI: Voxelwise Testing.
88-1	13208-13211	The	_	
88-2	13212-13219	current	_	
88-3	13220-13223	and	_	
88-4	13224-13233	preceding	_	
88-5	13234-13237	TRs	_	
88-6	13238-13242	were	_	
88-7	13243-13251	censored	_	
88-8	13252-13254	if	_	
88-9	13255-13258	the	_	
88-10	13259-13268	Euclidean	_	
88-11	13269-13273	norm	_	
88-12	13274-13278	head	_	
88-13	13279-13285	motion	_	
88-14	13286-13294	distance	_	
88-15	13295-13304	surpassed	_	
88-16	13305-13308	0.9	_	
88-17	13309-13311	mm	_	
88-18	13312-13313	(	_	
88-19	13313-13323	percentage	_	
88-20	13324-13326	of	_	
88-21	13327-13330	TRs	_	
88-22	13331-13339	censored	_	
88-23	13339-13340	:	_	
88-24	13341-13345	mean	_	
88-25	13346-13347	6	_	
88-26	13348-13350	SD	_	
88-27	13350-13351	,	_	
88-28	13351-13356	3.18%	_	
88-29	13357-13358	±	_	
88-30	13359-13364	6.29%	_	
88-31	13364-13365	)	_	
88-32	13365-13366	.	_	
88-33	13367-13371	fMRI	_	
88-34	13371-13372	:	_	
88-35	13373-13382	Voxelwise	_	
88-36	13383-13390	Testing	_	
88-37	13390-13391	.	_	

#Text=Primary analysis consisted of three voxelwise analyses (baseline, follow-up, and the interaction between visits).
89-1	13392-13399	Primary	_	
89-2	13400-13408	analysis	_	
89-3	13409-13418	consisted	_	
89-4	13419-13421	of	_	
89-5	13422-13427	three	_	
89-6	13428-13437	voxelwise	_	
89-7	13438-13446	analyses	_	
89-8	13447-13448	(	_	
89-9	13448-13456	baseline	_	
89-10	13456-13457	,	_	
89-11	13458-13467	follow-up	_	
89-12	13467-13468	,	_	
89-13	13469-13472	and	_	
89-14	13473-13476	the	_	
89-15	13477-13488	interaction	_	
89-16	13489-13496	between	_	
89-17	13497-13503	visits	_	
89-18	13503-13504	)	_	
89-19	13504-13505	.	_	

#Text=Voxelwise group effects were examined on time courses from correct trials entered into a voxelwise multivariate model [3dMVM ].
90-1	13506-13515	Voxelwise	_	
90-2	13516-13521	group	_	
90-3	13522-13529	effects	_	
90-4	13530-13534	were	_	
90-5	13535-13543	examined	_	
90-6	13544-13546	on	_	
90-7	13547-13551	time	_	
90-8	13552-13559	courses	_	
90-9	13560-13564	from	_	
90-10	13565-13572	correct	_	
90-11	13573-13579	trials	_	
90-12	13580-13587	entered	_	
90-13	13588-13592	into	_	
90-14	13593-13594	a	_	
90-15	13595-13604	voxelwise	_	
90-16	13605-13617	multivariate	_	
90-17	13618-13623	model	_	
90-18	13624-13625	[	_	
90-19	13625-13630	3dMVM	_	
90-20	13631-13632	]	_	
90-21	13632-13633	.	_	

#Text=Interaction terms between TR and cannabis group or among TR, cannabis group, and visit were used to identify voxels whose hemodynamic response function differed between groups at one visit or between visits, respectively.
91-1	13634-13645	Interaction	_	
91-2	13646-13651	terms	_	
91-3	13652-13659	between	_	
91-4	13660-13662	TR	_	
91-5	13663-13666	and	_	
91-6	13667-13675	cannabis	_	
91-7	13676-13681	group	_	
91-8	13682-13684	or	_	
91-9	13685-13690	among	_	
91-10	13691-13693	TR	_	
91-11	13693-13694	,	_	
91-12	13695-13703	cannabis	_	
91-13	13704-13709	group	_	
91-14	13709-13710	,	_	
91-15	13711-13714	and	_	
91-16	13715-13720	visit	_	
91-17	13721-13725	were	_	
91-18	13726-13730	used	_	
91-19	13731-13733	to	_	
91-20	13734-13742	identify	_	
91-21	13743-13749	voxels	_	
91-22	13750-13755	whose	_	
91-23	13756-13767	hemodynamic	_	
91-24	13768-13776	response	_	
91-25	13777-13785	function	_	
91-26	13786-13794	differed	_	
91-27	13795-13802	between	_	
91-28	13803-13809	groups	_	
91-29	13810-13812	at	_	
91-30	13813-13816	one	_	
91-31	13817-13822	visit	_	
91-32	13823-13825	or	_	
91-33	13826-13833	between	_	
91-34	13834-13840	visits	_	
91-35	13840-13841	,	_	
91-36	13842-13854	respectively	_	
91-37	13854-13855	.	_	

#Text=Voxelwise differences were constrained to include voxels with 1) ≥50% probability of being gray matter in the Montreal Neurological Institute-152 template, 2) full echo-planar imaging coverage in all participants, and 3) a main effect of TR (F test) of p < .005 (uncorrected) (Supplemental Figure S3).
92-1	13856-13865	Voxelwise	_	
92-2	13866-13877	differences	_	
92-3	13878-13882	were	_	
92-4	13883-13894	constrained	_	
92-5	13895-13897	to	_	
92-6	13898-13905	include	_	
92-7	13906-13912	voxels	_	
92-8	13913-13917	with	_	
92-9	13918-13919	1	_	
92-10	13919-13920	)	_	
92-11	13921-13922	≥	_	
92-12	13922-13925	50%	_	
92-13	13926-13937	probability	_	
92-14	13938-13940	of	_	
92-15	13941-13946	being	_	
92-16	13947-13951	gray	_	
92-17	13952-13958	matter	_	
92-18	13959-13961	in	_	
92-19	13962-13965	the	_	
92-20	13966-13974	Montreal	_	
92-21	13975-13987	Neurological	_	
92-22	13988-13997	Institute	_	
92-23	13997-13998	-	_	
92-24	13998-14001	152	_	
92-25	14002-14010	template	_	
92-26	14010-14011	,	_	
92-27	14012-14013	2	_	
92-28	14013-14014	)	_	
92-29	14015-14019	full	_	
92-30	14020-14031	echo-planar	_	
92-31	14032-14039	imaging	_	
92-32	14040-14048	coverage	_	
92-33	14049-14051	in	_	
92-34	14052-14055	all	_	
92-35	14056-14068	participants	_	
92-36	14068-14069	,	_	
92-37	14070-14073	and	_	
92-38	14074-14075	3	_	
92-39	14075-14076	)	_	
92-40	14077-14078	a	_	
92-41	14079-14083	main	_	
92-42	14084-14090	effect	_	
92-43	14091-14093	of	_	
92-44	14094-14096	TR	_	
92-45	14097-14098	(	_	
92-46	14098-14099	F	_	
92-47	14100-14104	test	_	
92-48	14104-14105	)	_	
92-49	14106-14108	of	_	
92-50	14109-14110	p	_	
92-51	14111-14112	<	_	
92-52	14113-14117	.005	_	
92-53	14118-14119	(	_	
92-54	14119-14130	uncorrected	_	
92-55	14130-14131	)	_	
92-56	14132-14133	(	_	
92-57	14133-14145	Supplemental	_	
92-58	14146-14152	Figure	_	
92-59	14153-14155	S3	_	
92-60	14155-14156	)	_	
92-61	14156-14157	.	_	

#Text=Resulting clusters were deemed to have corrected significance if all voxels within a cluster had single voxelwise p values that were false discovery rate (FDR)-corrected significant (q < .05) and the cluster size exceeded the number of voxels required for a significant cluster size, according to AFNI’s 3dClustsim (acf option).
93-1	14158-14167	Resulting	_	
93-2	14168-14176	clusters	_	
93-3	14177-14181	were	_	
93-4	14182-14188	deemed	_	
93-5	14189-14191	to	_	
93-6	14192-14196	have	_	
93-7	14197-14206	corrected	_	
93-8	14207-14219	significance	_	
93-9	14220-14222	if	_	
93-10	14223-14226	all	_	
93-11	14227-14233	voxels	_	
93-12	14234-14240	within	_	
93-13	14241-14242	a	_	
93-14	14243-14250	cluster	_	
93-15	14251-14254	had	_	
93-16	14255-14261	single	_	
93-17	14262-14271	voxelwise	_	
93-18	14272-14273	p	_	
93-19	14274-14280	values	_	
93-20	14281-14285	that	_	
93-21	14286-14290	were	_	
93-22	14291-14296	false	_	
93-23	14297-14306	discovery	_	
93-24	14307-14311	rate	_	
93-25	14312-14313	(	_	
93-26	14313-14316	FDR	_	
93-27	14316-14317	)	_	
93-28	14317-14318	-	_	
93-29	14318-14327	corrected	_	
93-30	14328-14339	significant	_	
93-31	14340-14341	(	_	
93-32	14341-14342	q	_	
93-33	14343-14344	<	_	
93-34	14345-14348	.05	_	
93-35	14348-14349	)	_	
93-36	14350-14353	and	_	
93-37	14354-14357	the	_	
93-38	14358-14365	cluster	_	
93-39	14366-14370	size	_	
93-40	14371-14379	exceeded	_	
93-41	14380-14383	the	_	
93-42	14384-14390	number	_	
93-43	14391-14393	of	_	
93-44	14394-14400	voxels	_	
93-45	14401-14409	required	_	
93-46	14410-14413	for	_	
93-47	14414-14415	a	_	
93-48	14416-14427	significant	_	
93-49	14428-14435	cluster	_	
93-50	14436-14440	size	_	
93-51	14440-14441	,	_	
93-52	14442-14451	according	_	
93-53	14452-14454	to	_	
93-54	14455-14459	AFNI	_	
93-55	14459-14460	’	_	
93-56	14460-14461	s	_	
93-57	14462-14472	3dClustsim	_	
93-58	14473-14474	(	_	
93-59	14474-14477	acf	_	
93-60	14478-14484	option	_	
93-61	14484-14485	)	_	
93-62	14485-14486	.	_	

#Text=Based on this analysis, 11 or more contiguous (faces-touching; AFNI NN1) voxels with a single voxelwise threshold of q < .05 (baseline p = .0013, follow-up p = .0007, group by visit interaction p = .0002, main effect of usage group across visits p = .0015) were used to define significant clusters (Supplement).
#Text=fMRI: Covariate and Brain-Behavior Analysis.
94-1	14487-14492	Based	_	
94-2	14493-14495	on	_	
94-3	14496-14500	this	_	
94-4	14501-14509	analysis	_	
94-5	14509-14510	,	_	
94-6	14511-14513	11	_	
94-7	14514-14516	or	_	
94-8	14517-14521	more	_	
94-9	14522-14532	contiguous	_	
94-10	14533-14534	(	_	
94-11	14534-14548	faces-touching	_	
94-12	14548-14549	;	_	
94-13	14550-14554	AFNI	_	
94-14	14555-14558	NN1	_	
94-15	14558-14559	)	_	
94-16	14560-14566	voxels	_	
94-17	14567-14571	with	_	
94-18	14572-14573	a	_	
94-19	14574-14580	single	_	
94-20	14581-14590	voxelwise	_	
94-21	14591-14600	threshold	_	
94-22	14601-14603	of	_	
94-23	14604-14605	q	_	
94-24	14606-14607	<	_	
94-25	14608-14611	.05	_	
94-26	14612-14613	(	_	
94-27	14613-14621	baseline	_	
94-28	14622-14623	p	_	
94-29	14624-14625	=	_	
94-30	14626-14631	.0013	_	
94-31	14631-14632	,	_	
94-32	14633-14642	follow-up	_	
94-33	14643-14644	p	_	
94-34	14645-14646	=	_	
94-35	14647-14652	.0007	_	
94-36	14652-14653	,	_	
94-37	14654-14659	group	_	
94-38	14660-14662	by	_	
94-39	14663-14668	visit	_	
94-40	14669-14680	interaction	_	
94-41	14681-14682	p	_	
94-42	14683-14684	=	_	
94-43	14685-14690	.0002	_	
94-44	14690-14691	,	_	
94-45	14692-14696	main	_	
94-46	14697-14703	effect	_	
94-47	14704-14706	of	_	
94-48	14707-14712	usage	_	
94-49	14713-14718	group	_	
94-50	14719-14725	across	_	
94-51	14726-14732	visits	_	
94-52	14733-14734	p	_	
94-53	14735-14736	=	_	
94-54	14737-14742	.0015	_	
94-55	14742-14743	)	_	
94-56	14744-14748	were	_	
94-57	14749-14753	used	_	
94-58	14754-14756	to	_	
94-59	14757-14763	define	_	
94-60	14764-14775	significant	_	
94-61	14776-14784	clusters	_	
94-62	14785-14786	(	_	
94-63	14786-14796	Supplement	_	
94-64	14796-14797	)	_	
94-65	14797-14798	.	_	
94-66	14799-14803	fMRI	_	
94-67	14803-14804	:	_	
94-68	14805-14814	Covariate	_	
94-69	14815-14818	and	_	
94-70	14819-14833	Brain-Behavior	_	
94-71	14834-14842	Analysis	_	
94-72	14842-14843	.	_	

#Text=Covariate analysis used robust linear regression (m-estimation) performed on individual participant estimates of trialwise BOLD responses, measured as the dot product of the participant time course and the grand mean time course.
95-1	14844-14853	Covariate	_	
95-2	14854-14862	analysis	_	
95-3	14863-14867	used	_	
95-4	14868-14874	robust	_	
95-5	14875-14881	linear	_	
95-6	14882-14892	regression	_	
95-7	14893-14894	(	_	
95-8	14894-14906	m-estimation	_	
95-9	14906-14907	)	_	
95-10	14908-14917	performed	_	
95-11	14918-14920	on	_	
95-12	14921-14931	individual	_	
95-13	14932-14943	participant	_	
95-14	14944-14953	estimates	_	
95-15	14954-14956	of	_	
95-16	14957-14966	trialwise	_	
95-17	14967-14971	BOLD	_	
95-18	14972-14981	responses	_	
95-19	14981-14982	,	_	
95-20	14983-14991	measured	_	
95-21	14992-14994	as	_	
95-22	14995-14998	the	_	
95-23	14999-15002	dot	_	
95-24	15003-15010	product	_	
95-25	15011-15013	of	_	
95-26	15014-15017	the	_	
95-27	15018-15029	participant	_	
95-28	15030-15034	time	_	
95-29	15035-15041	course	_	
95-30	15042-15045	and	_	
95-31	15046-15049	the	_	
95-32	15050-15055	grand	_	
95-33	15056-15060	mean	_	
95-34	15061-15065	time	_	
95-35	15066-15072	course	_	
95-36	15072-15073	.	_	

#Text=This approach resulted in a single estimate of trialwise BOLD expression while also accommodating both long and short delay trials’ hemodynamic response function shape.
96-1	15074-15078	This	_	
96-2	15079-15087	approach	_	
96-3	15088-15096	resulted	_	
96-4	15097-15099	in	_	
96-5	15100-15101	a	_	
96-6	15102-15108	single	_	
96-7	15109-15117	estimate	_	
96-8	15118-15120	of	_	
96-9	15121-15130	trialwise	_	
96-10	15131-15135	BOLD	_	
96-11	15136-15146	expression	_	
96-12	15147-15152	while	_	
96-13	15153-15157	also	_	
96-14	15158-15171	accommodating	_	
96-15	15172-15176	both	_	
96-16	15177-15181	long	_	
96-17	15182-15185	and	_	
96-18	15186-15191	short	_	
96-19	15192-15197	delay	_	
96-20	15198-15204	trials	_	
96-21	15204-15205	’	_	
96-22	15206-15217	hemodynamic	_	
96-23	15218-15226	response	_	
96-24	15227-15235	function	_	
96-25	15236-15241	shape	_	
96-26	15241-15242	.	_	

#Text=Significance values were FDR corrected across clusters for each measure.
97-1	15243-15255	Significance	_	
97-2	15256-15262	values	_	
97-3	15263-15267	were	_	
97-4	15268-15271	FDR	_	
97-5	15272-15281	corrected	_	
97-6	15282-15288	across	_	
97-7	15289-15297	clusters	_	
97-8	15298-15301	for	_	
97-9	15302-15306	each	_	
97-10	15307-15314	measure	_	
97-11	15314-15315	.	_	

#Text=To assist in the interpretation of BOLD activation effects, we present the association of individual BOLD activation dot products and WM accuracy for all clusters.
98-1	15316-15318	To	_	
98-2	15319-15325	assist	_	
98-3	15326-15328	in	_	
98-4	15329-15332	the	_	
98-5	15333-15347	interpretation	_	
98-6	15348-15350	of	_	
98-7	15351-15355	BOLD	_	
98-8	15356-15366	activation	_	
98-9	15367-15374	effects	_	
98-10	15374-15375	,	_	
98-11	15376-15378	we	_	
98-12	15379-15386	present	_	
98-13	15387-15390	the	_	
98-14	15391-15402	association	_	
98-15	15403-15405	of	_	
98-16	15406-15416	individual	_	
98-17	15417-15421	BOLD	_	
98-18	15422-15432	activation	_	
98-19	15433-15436	dot	_	
98-20	15437-15445	products	_	
98-21	15446-15449	and	_	
98-22	15450-15452	WM	_	
98-23	15453-15461	accuracy	_	
98-24	15462-15465	for	_	
98-25	15466-15469	all	_	
98-26	15470-15478	clusters	_	
98-27	15478-15479	.	_	

#Text=In cases where there was a significant (FDR-corrected) association, mediation analysis was performed to examine whether participant BOLD response may account for group differences in WM performance.
99-1	15480-15482	In	_	
99-2	15483-15488	cases	_	
99-3	15489-15494	where	_	
99-4	15495-15500	there	_	
99-5	15501-15504	was	_	
99-6	15505-15506	a	_	
99-7	15507-15518	significant	_	
99-8	15519-15520	(	_	
99-9	15520-15533	FDR-corrected	_	
99-10	15533-15534	)	_	
99-11	15535-15546	association	_	
99-12	15546-15547	,	_	
99-13	15548-15557	mediation	_	
99-14	15558-15566	analysis	_	
99-15	15567-15570	was	_	
99-16	15571-15580	performed	_	
99-17	15581-15583	to	_	
99-18	15584-15591	examine	_	
99-19	15592-15599	whether	_	
99-20	15600-15611	participant	_	
99-21	15612-15616	BOLD	_	
99-22	15617-15625	response	_	
99-23	15626-15629	may	_	
99-24	15630-15637	account	_	
99-25	15638-15641	for	_	
99-26	15642-15647	group	_	
99-27	15648-15659	differences	_	
99-28	15660-15662	in	_	
99-29	15663-15665	WM	_	
99-30	15666-15677	performance	_	
99-31	15677-15678	.	_	

#Text=Significance values for indirect effects were obtained using 5000 draws in a bootstrap procedure [mediation package ].
100-1	15679-15691	Significance	_	
100-2	15692-15698	values	_	
100-3	15699-15702	for	_	
100-4	15703-15711	indirect	_	
100-5	15712-15719	effects	_	
100-6	15720-15724	were	_	
100-7	15725-15733	obtained	_	
100-8	15734-15739	using	_	
100-9	15740-15744	5000	_	
100-10	15745-15750	draws	_	
100-11	15751-15753	in	_	
100-12	15754-15755	a	_	
100-13	15756-15765	bootstrap	_	
100-14	15766-15775	procedure	_	
100-15	15776-15777	[	_	
100-16	15777-15786	mediation	_	
100-17	15787-15794	package	_	
100-18	15795-15796	]	_	
100-19	15796-15797	.	_	

#Text=Cognitive Battery.
101-1	15798-15807	Cognitive	_	
101-2	15808-15815	Battery	_	
101-3	15815-15816	.	_	

#Text=Group differences on the cognitive battery were analyzed using Welch’s unequal variance t tests.
102-1	15817-15822	Group	_	
102-2	15823-15834	differences	_	
102-3	15835-15837	on	_	
102-4	15838-15841	the	_	
102-5	15842-15851	cognitive	_	
102-6	15852-15859	battery	_	
102-7	15860-15864	were	_	
102-8	15865-15873	analyzed	_	
102-9	15874-15879	using	_	
102-10	15880-15885	Welch	_	
102-11	15885-15886	’	_	
102-12	15886-15887	s	_	
102-13	15888-15895	unequal	_	
102-14	15896-15904	variance	_	
102-15	15905-15906	t	_	
102-16	15907-15912	tests	_	
102-17	15912-15913	.	_	

#Text=Effect sizes (Cohen’s d) and their 95% confidence intervals (CIs) were estimated with the effsize package in R.
103-1	15914-15920	Effect	_	
103-2	15921-15926	sizes	_	
103-3	15927-15928	(	_	
103-4	15928-15933	Cohen	_	
103-5	15933-15934	’	_	
103-6	15934-15935	s	_	
103-7	15936-15937	d	_	
103-8	15937-15938	)	_	
103-9	15939-15942	and	_	
103-10	15943-15948	their	_	
103-11	15949-15952	95%	_	
103-12	15953-15963	confidence	_	
103-13	15964-15973	intervals	_	
103-14	15974-15975	(	_	
103-15	15975-15978	CIs	_	
103-16	15978-15979	)	_	
103-17	15980-15984	were	_	
103-18	15985-15994	estimated	_	
103-19	15995-15999	with	_	
103-20	16000-16003	the	_	
103-21	16004-16011	effsize	_	
103-22	16012-16019	package	_	
103-23	16020-16022	in	_	
103-24	16023-16024	R	_	
103-25	16024-16025	.	_	

#Text=Secondary models included SES, EXT, and alcohol usage as covariates and used robust linear regression (m-estimation) and Wald’s test for significance (FDR-corrected within each family of tests: baseline, follow-up, and difference scores).
104-1	16026-16035	Secondary	_	
104-2	16036-16042	models	_	
104-3	16043-16051	included	_	
104-4	16052-16055	SES	_	
104-5	16055-16056	,	_	
104-6	16057-16060	EXT	_	
104-7	16060-16061	,	_	
104-8	16062-16065	and	_	
104-9	16066-16073	alcohol	_	
104-10	16074-16079	usage	_	
104-11	16080-16082	as	_	
104-12	16083-16093	covariates	_	
104-13	16094-16097	and	_	
104-14	16098-16102	used	_	
104-15	16103-16109	robust	_	
104-16	16110-16116	linear	_	
104-17	16117-16127	regression	_	
104-18	16128-16129	(	_	
104-19	16129-16141	m-estimation	_	
104-20	16141-16142	)	_	
104-21	16143-16146	and	_	
104-22	16147-16151	Wald	_	
104-23	16151-16152	’	_	
104-24	16152-16153	s	_	
104-25	16154-16158	test	_	
104-26	16159-16162	for	_	
104-27	16163-16175	significance	_	
104-28	16176-16177	(	_	
104-29	16177-16190	FDR-corrected	_	
104-30	16191-16197	within	_	
104-31	16198-16202	each	_	
104-32	16203-16209	family	_	
104-33	16210-16212	of	_	
104-34	16213-16218	tests	_	
104-35	16218-16219	:	_	
104-36	16220-16228	baseline	_	
104-37	16228-16229	,	_	
104-38	16230-16239	follow-up	_	
104-39	16239-16240	,	_	
104-40	16241-16244	and	_	
104-41	16245-16255	difference	_	
104-42	16256-16262	scores	_	
104-43	16262-16263	)	_	
104-44	16263-16264	.	_	

#Text=RESULTS
#Text=Scanner WM Behavior
#Text=Accuracy.
105-1	16265-16272	RESULTS	_	
105-2	16273-16280	Scanner	_	
105-3	16281-16283	WM	_	
105-4	16284-16292	Behavior	_	
105-5	16293-16301	Accuracy	_	
105-6	16301-16302	.	_	

#Text=At baseline, in the full sample (N = 85), participants who would initiate cannabis use by follow-up (n = 22) had significantly lower WM accuracy (83.7% correct) than noninitiators (88.9% correct; χ21 = 4.66, t = −2.16, p = .031; Figure 1).
106-1	16303-16305	At	_	
106-2	16306-16314	baseline	_	
106-3	16314-16315	,	_	
106-4	16316-16318	in	_	
106-5	16319-16322	the	_	
106-6	16323-16327	full	_	
106-7	16328-16334	sample	_	
106-8	16335-16336	(	_	
106-9	16336-16337	N	_	
106-10	16338-16339	=	_	
106-11	16340-16342	85	_	
106-12	16342-16343	)	_	
106-13	16343-16344	,	_	
106-14	16345-16357	participants	_	
106-15	16358-16361	who	_	
106-16	16362-16367	would	_	
106-17	16368-16376	initiate	_	
106-18	16377-16385	cannabis	_	
106-19	16386-16389	use	_	
106-20	16390-16392	by	_	
106-21	16393-16402	follow-up	_	
106-22	16403-16404	(	_	
106-23	16404-16405	n	_	
106-24	16406-16407	=	_	
106-25	16408-16410	22	_	
106-26	16410-16411	)	_	
106-27	16412-16415	had	_	
106-28	16416-16429	significantly	_	
106-29	16430-16435	lower	_	
106-30	16436-16438	WM	_	
106-31	16439-16447	accuracy	_	
106-32	16448-16449	(	_	
106-33	16449-16454	83.7%	_	
106-34	16455-16462	correct	_	
106-35	16462-16463	)	_	
106-36	16464-16468	than	_	
106-37	16469-16482	noninitiators	_	
106-38	16483-16484	(	_	
106-39	16484-16489	88.9%	_	
106-40	16490-16497	correct	_	
106-41	16497-16498	;	_	
106-42	16499-16502	χ21	_	
106-43	16503-16504	=	_	
106-44	16505-16509	4.66	_	
106-45	16509-16510	,	_	
106-46	16511-16512	t	_	
106-47	16513-16514	=	_	
106-48	16515-16516	−	_	
106-49	16516-16520	2.16	_	
106-50	16520-16521	,	_	
106-51	16522-16523	p	_	
106-52	16524-16525	=	_	
106-53	16526-16530	.031	_	
106-54	16530-16531	;	_	
106-55	16532-16538	Figure	_	
106-56	16539-16540	1	_	
106-57	16540-16541	)	_	
106-58	16541-16542	.	_	

#Text=Lower WM accuracy at baseline was also observed in the longitudinal sample only (n = 66; t94.21 = −2.12, p = .037).
107-1	16543-16548	Lower	_	
107-2	16549-16551	WM	_	
107-3	16552-16560	accuracy	_	
107-4	16561-16563	at	_	
107-5	16564-16572	baseline	_	
107-6	16573-16576	was	_	
107-7	16577-16581	also	_	
107-8	16582-16590	observed	_	
107-9	16591-16593	in	_	
107-10	16594-16597	the	_	
107-11	16598-16610	longitudinal	_	
107-12	16611-16617	sample	_	
107-13	16618-16622	only	_	
107-14	16623-16624	(	_	
107-15	16624-16625	n	_	
107-16	16626-16627	=	_	
107-17	16628-16630	66	_	
107-18	16630-16631	;	_	
107-19	16632-16638	t94.21	_	
107-20	16639-16640	=	_	
107-21	16641-16642	−	_	
107-22	16642-16646	2.12	_	
107-23	16646-16647	,	_	
107-24	16648-16649	p	_	
107-25	16650-16651	=	_	
107-26	16652-16656	.037	_	
107-27	16656-16657	)	_	
107-28	16657-16658	.	_	

#Text=When removing the 4 participants with inconsistent cannabis onset report, baseline WM differences only reached trend levels (χ21 = 2.67, t = 21.66, p = .102).
108-1	16659-16663	When	_	
108-2	16664-16672	removing	_	
108-3	16673-16676	the	_	
108-4	16677-16678	4	_	
108-5	16679-16691	participants	_	
108-6	16692-16696	with	_	
108-7	16697-16709	inconsistent	_	
108-8	16710-16718	cannabis	_	
108-9	16719-16724	onset	_	
108-10	16725-16731	report	_	
108-11	16731-16732	,	_	
108-12	16733-16741	baseline	_	
108-13	16742-16744	WM	_	
108-14	16745-16756	differences	_	
108-15	16757-16761	only	_	
108-16	16762-16769	reached	_	
108-17	16770-16775	trend	_	
108-18	16776-16782	levels	_	
108-19	16783-16784	(	_	
108-20	16784-16787	χ21	_	
108-21	16788-16789	=	_	
108-22	16790-16794	2.67	_	
108-23	16794-16795	,	_	
108-24	16796-16797	t	_	
108-25	16798-16799	=	_	
108-26	16800-16805	21.66	_	
108-27	16805-16806	,	_	
108-28	16807-16808	p	_	
108-29	16809-16810	=	_	
108-30	16811-16815	.102	_	
108-31	16815-16816	)	_	
108-32	16816-16817	.	_	

#Text=Attrition did not predict WM accuracy (χ21 = 1.41, t = 0.73, p = .235) or moderate group differences at baseline (χ21 = 0.16, t = 0.40, p = .690).
109-1	16818-16827	Attrition	_	
109-2	16828-16831	did	_	
109-3	16832-16835	not	_	
109-4	16836-16843	predict	_	
109-5	16844-16846	WM	_	
109-6	16847-16855	accuracy	_	
109-7	16856-16857	(	_	
109-8	16857-16860	χ21	_	
109-9	16861-16862	=	_	
109-10	16863-16867	1.41	_	
109-11	16867-16868	,	_	
109-12	16869-16870	t	_	
109-13	16871-16872	=	_	
109-14	16873-16877	0.73	_	
109-15	16877-16878	,	_	
109-16	16879-16880	p	_	
109-17	16881-16882	=	_	
109-18	16883-16887	.235	_	
109-19	16887-16888	)	_	
109-20	16889-16891	or	_	
109-21	16892-16900	moderate	_	
109-22	16901-16906	group	_	
109-23	16907-16918	differences	_	
109-24	16919-16921	at	_	
109-25	16922-16930	baseline	_	
109-26	16931-16932	(	_	
109-27	16932-16935	χ21	_	
109-28	16936-16937	=	_	
109-29	16938-16942	0.16	_	
109-30	16942-16943	,	_	
109-31	16944-16945	t	_	
109-32	16946-16947	=	_	
109-33	16948-16952	0.40	_	
109-34	16952-16953	,	_	
109-35	16954-16955	p	_	
109-36	16956-16957	=	_	
109-37	16958-16962	.690	_	
109-38	16962-16963	)	_	
109-39	16963-16964	.	_	

#Text=At follow-up, users (90.5% correct) again had significantly lower WM accuracy (t94.21 = −2.27, p = .025) than nonusers (94.8% correct).
110-1	16965-16967	At	_	
110-2	16968-16977	follow-up	_	
110-3	16977-16978	,	_	
110-4	16979-16984	users	_	
110-5	16985-16986	(	_	
110-6	16986-16991	90.5%	_	
110-7	16992-16999	correct	_	
110-8	16999-17000	)	_	
110-9	17001-17006	again	_	
110-10	17007-17010	had	_	
110-11	17011-17024	significantly	_	
110-12	17025-17030	lower	_	
110-13	17031-17033	WM	_	
110-14	17034-17042	accuracy	_	
110-15	17043-17044	(	_	
110-16	17044-17050	t94.21	_	
110-17	17051-17052	=	_	
110-18	17053-17054	−	_	
110-19	17054-17058	2.27	_	
110-20	17058-17059	,	_	
110-21	17060-17061	p	_	
110-22	17062-17063	=	_	
110-23	17064-17068	.025	_	
110-24	17068-17069	)	_	
110-25	17070-17074	than	_	
110-26	17075-17083	nonusers	_	
110-27	17084-17085	(	_	
110-28	17085-17090	94.8%	_	
110-29	17091-17098	correct	_	
110-30	17098-17099	)	_	
110-31	17099-17100	.	_	

#Text=Longitudinally, the main effect of visit (follow-up vs. baseline) was significant (χ21 = 82.37, t = 9.08, p < .001), while the interaction term between usage group and visit was not (χ21 = .042, t= 0.21, p = .837), suggesting that there was equivalent developmental improvement and that the groups did not become increasingly different after cannabis initiation (Figure 1).
111-1	17101-17115	Longitudinally	_	
111-2	17115-17116	,	_	
111-3	17117-17120	the	_	
111-4	17121-17125	main	_	
111-5	17126-17132	effect	_	
111-6	17133-17135	of	_	
111-7	17136-17141	visit	_	
111-8	17142-17143	(	_	
111-9	17143-17152	follow-up	_	
111-10	17153-17155	vs	_	
111-11	17155-17156	.	_	
111-12	17157-17165	baseline	_	
111-13	17165-17166	)	_	
111-14	17167-17170	was	_	
111-15	17171-17182	significant	_	
111-16	17183-17184	(	_	
111-17	17184-17187	χ21	_	
111-18	17188-17189	=	_	
111-19	17190-17195	82.37	_	
111-20	17195-17196	,	_	
111-21	17197-17198	t	_	
111-22	17199-17200	=	_	
111-23	17201-17205	9.08	_	
111-24	17205-17206	,	_	
111-25	17207-17208	p	_	
111-26	17209-17210	<	_	
111-27	17211-17215	.001	_	
111-28	17215-17216	)	_	
111-29	17216-17217	,	_	
111-30	17218-17223	while	_	
111-31	17224-17227	the	_	
111-32	17228-17239	interaction	_	
111-33	17240-17244	term	_	
111-34	17245-17252	between	_	
111-35	17253-17258	usage	_	
111-36	17259-17264	group	_	
111-37	17265-17268	and	_	
111-38	17269-17274	visit	_	
111-39	17275-17278	was	_	
111-40	17279-17282	not	_	
111-41	17283-17284	(	_	
111-42	17284-17287	χ21	_	
111-43	17288-17289	=	_	
111-44	17290-17294	.042	_	
111-45	17294-17295	,	_	
111-46	17296-17297	t	_	
111-47	17297-17298	=	_	
111-48	17299-17303	0.21	_	
111-49	17303-17304	,	_	
111-50	17305-17306	p	_	
111-51	17307-17308	=	_	
111-52	17309-17313	.837	_	
111-53	17313-17314	)	_	
111-54	17314-17315	,	_	
111-55	17316-17326	suggesting	_	
111-56	17327-17331	that	_	
111-57	17332-17337	there	_	
111-58	17338-17341	was	_	
111-59	17342-17352	equivalent	_	
111-60	17353-17366	developmental	_	
111-61	17367-17378	improvement	_	
111-62	17379-17382	and	_	
111-63	17383-17387	that	_	
111-64	17388-17391	the	_	
111-65	17392-17398	groups	_	
111-66	17399-17402	did	_	
111-67	17403-17406	not	_	
111-68	17407-17413	become	_	
111-69	17414-17426	increasingly	_	
111-70	17427-17436	different	_	
111-71	17437-17442	after	_	
111-72	17443-17451	cannabis	_	
111-73	17452-17462	initiation	_	
111-74	17463-17464	(	_	
111-75	17464-17470	Figure	_	
111-76	17471-17472	1	_	
111-77	17472-17473	)	_	
111-78	17473-17474	.	_	

#Text=Accuracy: Covariate Relationships.
112-1	17475-17483	Accuracy	_	
112-2	17483-17484	:	_	
112-3	17485-17494	Covariate	_	
112-4	17495-17508	Relationships	_	
112-5	17508-17509	.	_	

#Text=Cannabis associations with WM accuracy remained significant or at a trend when covarying EXT (p values < .035), SES (p values < .073), or alcohol usage group (p values < .01), and these measures were not associated with WM accuracy (p values < .136), ruling out potential mediation (Supplement).
113-1	17510-17518	Cannabis	_	
113-2	17519-17531	associations	_	
113-3	17532-17536	with	_	
113-4	17537-17539	WM	_	
113-5	17540-17548	accuracy	_	
113-6	17549-17557	remained	_	
113-7	17558-17569	significant	_	
113-8	17570-17572	or	_	
113-9	17573-17575	at	_	
113-10	17576-17577	a	_	
113-11	17578-17583	trend	_	
113-12	17584-17588	when	_	
113-13	17589-17598	covarying	_	
113-14	17599-17602	EXT	_	
113-15	17603-17604	(	_	
113-16	17604-17605	p	_	
113-17	17606-17612	values	_	
113-18	17613-17614	<	_	
113-19	17615-17619	.035	_	
113-20	17619-17620	)	_	
113-21	17620-17621	,	_	
113-22	17622-17625	SES	_	
113-23	17626-17627	(	_	
113-24	17627-17628	p	_	
113-25	17629-17635	values	_	
113-26	17636-17637	<	_	
113-27	17638-17642	.073	_	
113-28	17642-17643	)	_	
113-29	17643-17644	,	_	
113-30	17645-17647	or	_	
113-31	17648-17655	alcohol	_	
113-32	17656-17661	usage	_	
113-33	17662-17667	group	_	
113-34	17668-17669	(	_	
113-35	17669-17670	p	_	
113-36	17671-17677	values	_	
113-37	17678-17679	<	_	
113-38	17680-17683	.01	_	
113-39	17683-17684	)	_	
113-40	17684-17685	,	_	
113-41	17686-17689	and	_	
113-42	17690-17695	these	_	
113-43	17696-17704	measures	_	
113-44	17705-17709	were	_	
113-45	17710-17713	not	_	
113-46	17714-17724	associated	_	
113-47	17725-17729	with	_	
113-48	17730-17732	WM	_	
113-49	17733-17741	accuracy	_	
113-50	17742-17743	(	_	
113-51	17743-17744	p	_	
113-52	17745-17751	values	_	
113-53	17752-17753	<	_	
113-54	17754-17758	.136	_	
113-55	17758-17759	)	_	
113-56	17759-17760	,	_	
113-57	17761-17767	ruling	_	
113-58	17768-17771	out	_	
113-59	17772-17781	potential	_	
113-60	17782-17791	mediation	_	
113-61	17792-17793	(	_	
113-62	17793-17803	Supplement	_	
113-63	17803-17804	)	_	
113-64	17804-17805	.	_	

#Text=Accuracy: Cannabis Dose-Response.
114-1	17806-17814	Accuracy	_	
114-2	17814-17815	:	_	
114-3	17816-17824	Cannabis	_	
114-4	17825-17838	Dose-Response	_	
114-5	17838-17839	.	_	

#Text=Cannabis dose was not associated with WM accuracy (cannabis use group only) at baseline (full sample: χ21 = 2.98, t = 21.73, p = .084; longitudinal sample: t19.4 = −1.81, p = .086) or follow-up(t19.4 = 2.677, p = .506).
115-1	17840-17848	Cannabis	_	
115-2	17849-17853	dose	_	
115-3	17854-17857	was	_	
115-4	17858-17861	not	_	
115-5	17862-17872	associated	_	
115-6	17873-17877	with	_	
115-7	17878-17880	WM	_	
115-8	17881-17889	accuracy	_	
115-9	17890-17891	(	_	
115-10	17891-17899	cannabis	_	
115-11	17900-17903	use	_	
115-12	17904-17909	group	_	
115-13	17910-17914	only	_	
115-14	17914-17915	)	_	
115-15	17916-17918	at	_	
115-16	17919-17927	baseline	_	
115-17	17928-17929	(	_	
115-18	17929-17933	full	_	
115-19	17934-17940	sample	_	
115-20	17940-17941	:	_	
115-21	17942-17945	χ21	_	
115-22	17946-17947	=	_	
115-23	17948-17952	2.98	_	
115-24	17952-17953	,	_	
115-25	17954-17955	t	_	
115-26	17956-17957	=	_	
115-27	17958-17963	21.73	_	
115-28	17963-17964	,	_	
115-29	17965-17966	p	_	
115-30	17967-17968	=	_	
115-31	17969-17973	.084	_	
115-32	17973-17974	;	_	
115-33	17975-17987	longitudinal	_	
115-34	17988-17994	sample	_	
115-35	17994-17995	:	_	
115-36	17996-18001	t19.4	_	
115-37	18002-18003	=	_	
115-38	18004-18005	−	_	
115-39	18005-18009	1.81	_	
115-40	18009-18010	,	_	
115-41	18011-18012	p	_	
115-42	18013-18014	=	_	
115-43	18015-18019	.086	_	
115-44	18019-18020	)	_	
115-45	18021-18023	or	_	
115-46	18024-18033	follow-up	_	
115-47	18033-18034	(	_	
115-48	18034-18039	t19.4	_	
115-49	18040-18041	=	_	
115-50	18042-18047	2.677	_	
115-51	18047-18048	,	_	
115-52	18049-18050	p	_	
115-53	18051-18052	=	_	
115-54	18053-18057	.506	_	
115-55	18057-18058	)	_	
115-56	18058-18059	.	_	

#Text=Reaction Time.
116-1	18060-18068	Reaction	_	
116-2	18069-18073	Time	_	
116-3	18073-18074	.	_	

#Text=Reaction time did not differ between usage groups at either baseline (full sample, cannabis initiators: 1130 ms, noninitiators: 1184 ms, χ21 = 1.84, t = 21.36, p = .175;longitudinal sample: t77.33 = 1.05, p = .299) or follow-up(cannabis users: 990 ms, nonusers: 984 ms; t77.33 = −.153,p = .879) (Figure 1).
117-1	18075-18083	Reaction	_	
117-2	18084-18088	time	_	
117-3	18089-18092	did	_	
117-4	18093-18096	not	_	
117-5	18097-18103	differ	_	
117-6	18104-18111	between	_	
117-7	18112-18117	usage	_	
117-8	18118-18124	groups	_	
117-9	18125-18127	at	_	
117-10	18128-18134	either	_	
117-11	18135-18143	baseline	_	
117-12	18144-18145	(	_	
117-13	18145-18149	full	_	
117-14	18150-18156	sample	_	
117-15	18156-18157	,	_	
117-16	18158-18166	cannabis	_	
117-17	18167-18177	initiators	_	
117-18	18177-18178	:	_	
117-19	18179-18183	1130	_	
117-20	18184-18186	ms	_	
117-21	18186-18187	,	_	
117-22	18188-18201	noninitiators	_	
117-23	18201-18202	:	_	
117-24	18203-18207	1184	_	
117-25	18208-18210	ms	_	
117-26	18210-18211	,	_	
117-27	18212-18215	χ21	_	
117-28	18216-18217	=	_	
117-29	18218-18222	1.84	_	
117-30	18222-18223	,	_	
117-31	18224-18225	t	_	
117-32	18226-18227	=	_	
117-33	18228-18233	21.36	_	
117-34	18233-18234	,	_	
117-35	18235-18236	p	_	
117-36	18237-18238	=	_	
117-37	18239-18243	.175	_	
117-38	18243-18244	;	_	
117-39	18244-18256	longitudinal	_	
117-40	18257-18263	sample	_	
117-41	18263-18264	:	_	
117-42	18265-18271	t77.33	_	
117-43	18272-18273	=	_	
117-44	18274-18278	1.05	_	
117-45	18278-18279	,	_	
117-46	18280-18281	p	_	
117-47	18282-18283	=	_	
117-48	18284-18288	.299	_	
117-49	18288-18289	)	_	
117-50	18290-18292	or	_	
117-51	18293-18302	follow-up	_	
117-52	18302-18303	(	_	
117-53	18303-18311	cannabis	_	
117-54	18312-18317	users	_	
117-55	18317-18318	:	_	
117-56	18319-18322	990	_	
117-57	18323-18325	ms	_	
117-58	18325-18326	,	_	
117-59	18327-18335	nonusers	_	
117-60	18335-18336	:	_	
117-61	18337-18340	984	_	
117-62	18341-18343	ms	_	
117-63	18343-18344	;	_	
117-64	18345-18351	t77.33	_	
117-65	18352-18353	=	_	
117-66	18354-18355	−	_	
117-67	18355-18359	.153	_	
117-68	18359-18360	,	_	
117-69	18360-18361	p	_	
117-70	18362-18363	=	_	
117-71	18364-18368	.879	_	
117-72	18368-18369	)	_	
117-73	18370-18371	(	_	
117-74	18371-18377	Figure	_	
117-75	18378-18379	1	_	
117-76	18379-18380	)	_	
117-77	18380-18381	.	_	

#Text=Functional Magnetic Resonance Imaging
#Text=Group Differences.
118-1	18382-18392	Functional	_	
118-2	18393-18401	Magnetic	_	
118-3	18402-18411	Resonance	_	
118-4	18412-18419	Imaging	_	
118-5	18420-18425	Group	_	
118-6	18426-18437	Differences	_	
118-7	18437-18438	.	_	

#Text=Head motion did not differ between groups at either baseline or follow-up (p values > .197) and was not associated with cannabis dose (p values > .568) (Supplement).
119-1	18439-18443	Head	_	
119-2	18444-18450	motion	_	
119-3	18451-18454	did	_	
119-4	18455-18458	not	_	
119-5	18459-18465	differ	_	
119-6	18466-18473	between	_	
119-7	18474-18480	groups	_	
119-8	18481-18483	at	_	
119-9	18484-18490	either	_	
119-10	18491-18499	baseline	_	
119-11	18500-18502	or	_	
119-12	18503-18512	follow-up	_	
119-13	18513-18514	(	_	
119-14	18514-18515	p	_	
119-15	18516-18522	values	_	
119-16	18523-18524	>	_	
119-17	18525-18529	.197	_	
119-18	18529-18530	)	_	
119-19	18531-18534	and	_	
119-20	18535-18538	was	_	
119-21	18539-18542	not	_	
119-22	18543-18553	associated	_	
119-23	18554-18558	with	_	
119-24	18559-18567	cannabis	_	
119-25	18568-18572	dose	_	
119-26	18573-18574	(	_	
119-27	18574-18575	p	_	
119-28	18576-18582	values	_	
119-29	18583-18584	>	_	
119-30	18585-18589	.568	_	
119-31	18589-18590	)	_	
119-32	18591-18592	(	_	
119-33	18592-18602	Supplement	_	
119-34	18602-18603	)	_	
119-35	18603-18604	.	_	

#Text=Activation of canonical WM regions was evident across groups, including posterior parietal and lateral prefrontal cortices (Supplemental Figure S4).
120-1	18605-18615	Activation	_	
120-2	18616-18618	of	_	
120-3	18619-18628	canonical	_	
120-4	18629-18631	WM	_	
120-5	18632-18639	regions	_	
120-6	18640-18643	was	_	
120-7	18644-18651	evident	_	
120-8	18652-18658	across	_	
120-9	18659-18665	groups	_	
120-10	18665-18666	,	_	
120-11	18667-18676	including	_	
120-12	18677-18686	posterior	_	
120-13	18687-18695	parietal	_	
120-14	18696-18699	and	_	
120-15	18700-18707	lateral	_	
120-16	18708-18718	prefrontal	_	
120-17	18719-18727	cortices	_	
120-18	18728-18729	(	_	
120-19	18729-18741	Supplemental	_	
120-20	18742-18748	Figure	_	
120-21	18749-18751	S4	_	
120-22	18751-18752	)	_	
120-23	18752-18753	.	_	

#Text=Group testing of correct trials’ hemodynamic response function time series revealed activation differences in visual association and frontoparietal regions (Table 3).
121-1	18754-18759	Group	_	
121-2	18760-18767	testing	_	
121-3	18768-18770	of	_	
121-4	18771-18778	correct	_	
121-5	18779-18785	trials	_	
121-6	18785-18786	’	_	
121-7	18787-18798	hemodynamic	_	
121-8	18799-18807	response	_	
121-9	18808-18816	function	_	
121-10	18817-18821	time	_	
121-11	18822-18828	series	_	
121-12	18829-18837	revealed	_	
121-13	18838-18848	activation	_	
121-14	18849-18860	differences	_	
121-15	18861-18863	in	_	
121-16	18864-18870	visual	_	
121-17	18871-18882	association	_	
121-18	18883-18886	and	_	
121-19	18887-18901	frontoparietal	_	
121-20	18902-18909	regions	_	
121-21	18910-18911	(	_	
121-22	18911-18916	Table	_	
121-23	18917-18918	3	_	
121-24	18918-18919	)	_	
121-25	18919-18920	.	_	

#Text=At baseline, users (n = 21) within the full neuroimaging sample (n = 84) displayed reduced activation in visual association regions (precuneus, lateral occipital gyrus/Brodmann area 19) and increased activation in frontoparietal regions (inferior parietal lobule, middle frontal gyrus [MFG], and the presupplementary motor area) relative to nonusers (Figure 2).
122-1	18921-18923	At	_	
122-2	18924-18932	baseline	_	
122-3	18932-18933	,	_	
122-4	18934-18939	users	_	
122-5	18940-18941	(	_	
122-6	18941-18942	n	_	
122-7	18943-18944	=	_	
122-8	18945-18947	21	_	
122-9	18947-18948	)	_	
122-10	18949-18955	within	_	
122-11	18956-18959	the	_	
122-12	18960-18964	full	_	
122-13	18965-18977	neuroimaging	_	
122-14	18978-18984	sample	_	
122-15	18985-18986	(	_	
122-16	18986-18987	n	_	
122-17	18988-18989	=	_	
122-18	18990-18992	84	_	
122-19	18992-18993	)	_	
122-20	18994-19003	displayed	_	
122-21	19004-19011	reduced	_	
122-22	19012-19022	activation	_	
122-23	19023-19025	in	_	
122-24	19026-19032	visual	_	
122-25	19033-19044	association	_	
122-26	19045-19052	regions	_	
122-27	19053-19054	(	_	
122-28	19054-19063	precuneus	_	
122-29	19063-19064	,	_	
122-30	19065-19072	lateral	_	
122-31	19073-19082	occipital	_	
122-32	19083-19088	gyrus	_	
122-33	19088-19089	/	_	
122-34	19089-19097	Brodmann	_	
122-35	19098-19102	area	_	
122-36	19103-19105	19	_	
122-37	19105-19106	)	_	
122-38	19107-19110	and	_	
122-39	19111-19120	increased	_	
122-40	19121-19131	activation	_	
122-41	19132-19134	in	_	
122-42	19135-19149	frontoparietal	_	
122-43	19150-19157	regions	_	
122-44	19158-19159	(	_	
122-45	19159-19167	inferior	_	
122-46	19168-19176	parietal	_	
122-47	19177-19183	lobule	_	
122-48	19183-19184	,	_	
122-49	19185-19191	middle	_	
122-50	19192-19199	frontal	_	
122-51	19200-19205	gyrus	_	
122-52	19206-19207	[	_	
122-53	19207-19210	MFG	_	
122-54	19210-19211	]	_	
122-55	19211-19212	,	_	
122-56	19213-19216	and	_	
122-57	19217-19220	the	_	
122-58	19221-19237	presupplementary	_	
122-59	19238-19243	motor	_	
122-60	19244-19248	area	_	
122-61	19248-19249	)	_	
122-62	19250-19258	relative	_	
122-63	19259-19261	to	_	
122-64	19262-19270	nonusers	_	
122-65	19271-19272	(	_	
122-66	19272-19278	Figure	_	
122-67	19279-19280	2	_	
122-68	19280-19281	)	_	
122-69	19281-19282	.	_	

#Text=Group differences at baseline were unchanged or became larger when examining just participants with longitudinal data or when excluding those with inconsistent cannabis onset report (Supplement).
123-1	19283-19288	Group	_	
123-2	19289-19300	differences	_	
123-3	19301-19303	at	_	
123-4	19304-19312	baseline	_	
123-5	19313-19317	were	_	
123-6	19318-19327	unchanged	_	
123-7	19328-19330	or	_	
123-8	19331-19337	became	_	
123-9	19338-19344	larger	_	
123-10	19345-19349	when	_	
123-11	19350-19359	examining	_	
123-12	19360-19364	just	_	
123-13	19365-19377	participants	_	
123-14	19378-19382	with	_	
123-15	19383-19395	longitudinal	_	
123-16	19396-19400	data	_	
123-17	19401-19403	or	_	
123-18	19404-19408	when	_	
123-19	19409-19418	excluding	_	
123-20	19419-19424	those	_	
123-21	19425-19429	with	_	
123-22	19430-19442	inconsistent	_	
123-23	19443-19451	cannabis	_	
123-24	19452-19457	onset	_	
123-25	19458-19464	report	_	
123-26	19465-19466	(	_	
123-27	19466-19476	Supplement	_	
123-28	19476-19477	)	_	
123-29	19477-19478	.	_	

#Text=At follow-up (n = 66), single time point group activation differences were limited to the cuneus, where the cannabis group displayed greater deactivation (Figure 3).
124-1	19479-19481	At	_	
124-2	19482-19491	follow-up	_	
124-3	19492-19493	(	_	
124-4	19493-19494	n	_	
124-5	19495-19496	=	_	
124-6	19497-19499	66	_	
124-7	19499-19500	)	_	
124-8	19500-19501	,	_	
124-9	19502-19508	single	_	
124-10	19509-19513	time	_	
124-11	19514-19519	point	_	
124-12	19520-19525	group	_	
124-13	19526-19536	activation	_	
124-14	19537-19548	differences	_	
124-15	19549-19553	were	_	
124-16	19554-19561	limited	_	
124-17	19562-19564	to	_	
124-18	19565-19568	the	_	
124-19	19569-19575	cuneus	_	
124-20	19575-19576	,	_	
124-21	19577-19582	where	_	
124-22	19583-19586	the	_	
124-23	19587-19595	cannabis	_	
124-24	19596-19601	group	_	
124-25	19602-19611	displayed	_	
124-26	19612-19619	greater	_	
124-27	19620-19632	deactivation	_	
124-28	19633-19634	(	_	
124-29	19634-19640	Figure	_	
124-30	19641-19642	3	_	
124-31	19642-19643	)	_	
124-32	19643-19644	.	_	

#Text=However, longitudinally, the main effects of user group were observed in inferior parietal lobule and visual association (Brodmann area 18/19) regions, and post hoc analysis revealed significant activation differences at follow-up in these regions (Supplemental Figure S7; Supplemental Table S3).
125-1	19645-19652	However	_	
125-2	19652-19653	,	_	
125-3	19654-19668	longitudinally	_	
125-4	19668-19669	,	_	
125-5	19670-19673	the	_	
125-6	19674-19678	main	_	
125-7	19679-19686	effects	_	
125-8	19687-19689	of	_	
125-9	19690-19694	user	_	
125-10	19695-19700	group	_	
125-11	19701-19705	were	_	
125-12	19706-19714	observed	_	
125-13	19715-19717	in	_	
125-14	19718-19726	inferior	_	
125-15	19727-19735	parietal	_	
125-16	19736-19742	lobule	_	
125-17	19743-19746	and	_	
125-18	19747-19753	visual	_	
125-19	19754-19765	association	_	
125-20	19766-19767	(	_	
125-21	19767-19775	Brodmann	_	
125-22	19776-19780	area	_	
125-23	19781-19783	18	_	
125-24	19783-19784	/	_	
125-25	19784-19786	19	_	
125-26	19786-19787	)	_	
125-27	19788-19795	regions	_	
125-28	19795-19796	,	_	
125-29	19797-19800	and	_	
125-30	19801-19805	post	_	
125-31	19806-19809	hoc	_	
125-32	19810-19818	analysis	_	
125-33	19819-19827	revealed	_	
125-34	19828-19839	significant	_	
125-35	19840-19850	activation	_	
125-36	19851-19862	differences	_	
125-37	19863-19865	at	_	
125-38	19866-19875	follow-up	_	
125-39	19876-19878	in	_	
125-40	19879-19884	these	_	
125-41	19885-19892	regions	_	
125-42	19893-19894	(	_	
125-43	19894-19906	Supplemental	_	
125-44	19907-19913	Figure	_	
125-45	19914-19916	S7	_	
125-46	19916-19917	;	_	
125-47	19918-19930	Supplemental	_	
125-48	19931-19936	Table	_	
125-49	19937-19939	S3	_	
125-50	19939-19940	)	_	
125-51	19940-19941	.	_	

#Text=Within the longitudinal model, only the posterior cingulate had a significant interaction term between usage group and visit, where stronger group differences were observed at baseline compared with follow-up (Figure 3).
126-1	19942-19948	Within	_	
126-2	19949-19952	the	_	
126-3	19953-19965	longitudinal	_	
126-4	19966-19971	model	_	
126-5	19971-19972	,	_	
126-6	19973-19977	only	_	
126-7	19978-19981	the	_	
126-8	19982-19991	posterior	_	
126-9	19992-20001	cingulate	_	
126-10	20002-20005	had	_	
126-11	20006-20007	a	_	
126-12	20008-20019	significant	_	
126-13	20020-20031	interaction	_	
126-14	20032-20036	term	_	
126-15	20037-20044	between	_	
126-16	20045-20050	usage	_	
126-17	20051-20056	group	_	
126-18	20057-20060	and	_	
126-19	20061-20066	visit	_	
126-20	20066-20067	,	_	
126-21	20068-20073	where	_	
126-22	20074-20082	stronger	_	
126-23	20083-20088	group	_	
126-24	20089-20100	differences	_	
126-25	20101-20105	were	_	
126-26	20106-20114	observed	_	
126-27	20115-20117	at	_	
126-28	20118-20126	baseline	_	
126-29	20127-20135	compared	_	
126-30	20136-20140	with	_	
126-31	20141-20150	follow-up	_	
126-32	20151-20152	(	_	
126-33	20152-20158	Figure	_	
126-34	20159-20160	3	_	
126-35	20160-20161	)	_	
126-36	20161-20162	.	_	

#Text=Covariate Analysis.
127-1	20163-20172	Covariate	_	
127-2	20173-20181	Analysis	_	
127-3	20181-20182	.	_	

#Text=No covariate had a significant corrected association with BOLD activation in clusters defined by cannabis use (Table 4).
128-1	20183-20185	No	_	
128-2	20186-20195	covariate	_	
128-3	20196-20199	had	_	
128-4	20200-20201	a	_	
128-5	20202-20213	significant	_	
128-6	20214-20223	corrected	_	
128-7	20224-20235	association	_	
128-8	20236-20240	with	_	
128-9	20241-20245	BOLD	_	
128-10	20246-20256	activation	_	
128-11	20257-20259	in	_	
128-12	20260-20268	clusters	_	
128-13	20269-20276	defined	_	
128-14	20277-20279	by	_	
128-15	20280-20288	cannabis	_	
128-16	20289-20292	use	_	
128-17	20293-20294	(	_	
128-18	20294-20299	Table	_	
128-19	20300-20301	4	_	
128-20	20301-20302	)	_	
128-21	20302-20303	.	_	

#Text=Furthermore, contrary to our hypothesis, post hoc analysis revealed that SES did not mediate group differences in BOLD activation in any cannabis-defined cluster (Supplemental Table S4).
129-1	20304-20315	Furthermore	_	
129-2	20315-20316	,	_	
129-3	20317-20325	contrary	_	
129-4	20326-20328	to	_	
129-5	20329-20332	our	_	
129-6	20333-20343	hypothesis	_	
129-7	20343-20344	,	_	
129-8	20345-20349	post	_	
129-9	20350-20353	hoc	_	
129-10	20354-20362	analysis	_	
129-11	20363-20371	revealed	_	
129-12	20372-20376	that	_	
129-13	20377-20380	SES	_	
129-14	20381-20384	did	_	
129-15	20385-20388	not	_	
129-16	20389-20396	mediate	_	
129-17	20397-20402	group	_	
129-18	20403-20414	differences	_	
129-19	20415-20417	in	_	
129-20	20418-20422	BOLD	_	
129-21	20423-20433	activation	_	
129-22	20434-20436	in	_	
129-23	20437-20440	any	_	
129-24	20441-20457	cannabis-defined	_	
129-25	20458-20465	cluster	_	
129-26	20466-20467	(	_	
129-27	20467-20479	Supplemental	_	
129-28	20480-20485	Table	_	
129-29	20486-20488	S4	_	
129-30	20488-20489	)	_	
129-31	20489-20490	.	_	

#Text=These results suggest that clusters defined by cannabis usage group were largely independent from SES, EXT, and alcohol usage group.
130-1	20491-20496	These	_	
130-2	20497-20504	results	_	
130-3	20505-20512	suggest	_	
130-4	20513-20517	that	_	
130-5	20518-20526	clusters	_	
130-6	20527-20534	defined	_	
130-7	20535-20537	by	_	
130-8	20538-20546	cannabis	_	
130-9	20547-20552	usage	_	
130-10	20553-20558	group	_	
130-11	20559-20563	were	_	
130-12	20564-20571	largely	_	
130-13	20572-20583	independent	_	
130-14	20584-20588	from	_	
130-15	20589-20592	SES	_	
130-16	20592-20593	,	_	
130-17	20594-20597	EXT	_	
130-18	20597-20598	,	_	
130-19	20599-20602	and	_	
130-20	20603-20610	alcohol	_	
130-21	20611-20616	usage	_	
130-22	20617-20622	group	_	
130-23	20622-20623	.	_	

#Text=Further-more, no significant interaction between alcohol and cannabis groups was observed in clusters distinguishing cannabis groups, suggesting that clusters were not biased by participants with combined cannabis and alcohol usage (Supplemental Table S5).
131-1	20624-20636	Further-more	_	
131-2	20636-20637	,	_	
131-3	20638-20640	no	_	
131-4	20641-20652	significant	_	
131-5	20653-20664	interaction	_	
131-6	20665-20672	between	_	
131-7	20673-20680	alcohol	_	
131-8	20681-20684	and	_	
131-9	20685-20693	cannabis	_	
131-10	20694-20700	groups	_	
131-11	20701-20704	was	_	
131-12	20705-20713	observed	_	
131-13	20714-20716	in	_	
131-14	20717-20725	clusters	_	
131-15	20726-20740	distinguishing	_	
131-16	20741-20749	cannabis	_	
131-17	20750-20756	groups	_	
131-18	20756-20757	,	_	
131-19	20758-20768	suggesting	_	
131-20	20769-20773	that	_	
131-21	20774-20782	clusters	_	
131-22	20783-20787	were	_	
131-23	20788-20791	not	_	
131-24	20792-20798	biased	_	
131-25	20799-20801	by	_	
131-26	20802-20814	participants	_	
131-27	20815-20819	with	_	
131-28	20820-20828	combined	_	
131-29	20829-20837	cannabis	_	
131-30	20838-20841	and	_	
131-31	20842-20849	alcohol	_	
131-32	20850-20855	usage	_	
131-33	20856-20857	(	_	
131-34	20857-20869	Supplemental	_	
131-35	20870-20875	Table	_	
131-36	20876-20878	S5	_	
131-37	20878-20879	)	_	
131-38	20879-20880	.	_	

#Text=Supporting the relative independence of the reported cannabis clusters from covariates, when we reran our voxelwise analysis using SES, EXT, and alcohol usage group as the primary variables, minimal overlap (23 total voxels) was observed between clusters defined by cannabis use and those defined by SES, EXT, and alcohol usage group (Supplement).
132-1	20881-20891	Supporting	_	
132-2	20892-20895	the	_	
132-3	20896-20904	relative	_	
132-4	20905-20917	independence	_	
132-5	20918-20920	of	_	
132-6	20921-20924	the	_	
132-7	20925-20933	reported	_	
132-8	20934-20942	cannabis	_	
132-9	20943-20951	clusters	_	
132-10	20952-20956	from	_	
132-11	20957-20967	covariates	_	
132-12	20967-20968	,	_	
132-13	20969-20973	when	_	
132-14	20974-20976	we	_	
132-15	20977-20982	reran	_	
132-16	20983-20986	our	_	
132-17	20987-20996	voxelwise	_	
132-18	20997-21005	analysis	_	
132-19	21006-21011	using	_	
132-20	21012-21015	SES	_	
132-21	21015-21016	,	_	
132-22	21017-21020	EXT	_	
132-23	21020-21021	,	_	
132-24	21022-21025	and	_	
132-25	21026-21033	alcohol	_	
132-26	21034-21039	usage	_	
132-27	21040-21045	group	_	
132-28	21046-21048	as	_	
132-29	21049-21052	the	_	
132-30	21053-21060	primary	_	
132-31	21061-21070	variables	_	
132-32	21070-21071	,	_	
132-33	21072-21079	minimal	_	
132-34	21080-21087	overlap	_	
132-35	21088-21089	(	_	
132-36	21089-21091	23	_	
132-37	21092-21097	total	_	
132-38	21098-21104	voxels	_	
132-39	21104-21105	)	_	
132-40	21106-21109	was	_	
132-41	21110-21118	observed	_	
132-42	21119-21126	between	_	
132-43	21127-21135	clusters	_	
132-44	21136-21143	defined	_	
132-45	21144-21146	by	_	
132-46	21147-21155	cannabis	_	
132-47	21156-21159	use	_	
132-48	21160-21163	and	_	
132-49	21164-21169	those	_	
132-50	21170-21177	defined	_	
132-51	21178-21180	by	_	
132-52	21181-21184	SES	_	
132-53	21184-21185	,	_	
132-54	21186-21189	EXT	_	
132-55	21189-21190	,	_	
132-56	21191-21194	and	_	
132-57	21195-21202	alcohol	_	
132-58	21203-21208	usage	_	
132-59	21209-21214	group	_	
132-60	21215-21216	(	_	
132-61	21216-21226	Supplement	_	
132-62	21226-21227	)	_	
132-63	21227-21228	.	_	

#Text=Brain-Behavior Analysis.
133-1	21229-21243	Brain-Behavior	_	
133-2	21244-21252	Analysis	_	
133-3	21252-21253	.	_	

#Text=At baseline, greater activation in the lateral occipital cortex was associated with higher WM accuracy (β = .340, tr = 3.39, p = .012 corrected) (Table 4).
134-1	21254-21256	At	_	
134-2	21257-21265	baseline	_	
134-3	21265-21266	,	_	
134-4	21267-21274	greater	_	
134-5	21275-21285	activation	_	
134-6	21286-21288	in	_	
134-7	21289-21292	the	_	
134-8	21293-21300	lateral	_	
134-9	21301-21310	occipital	_	
134-10	21311-21317	cortex	_	
134-11	21318-21321	was	_	
134-12	21322-21332	associated	_	
134-13	21333-21337	with	_	
134-14	21338-21344	higher	_	
134-15	21345-21347	WM	_	
134-16	21348-21356	accuracy	_	
134-17	21357-21358	(	_	
134-18	21358-21359	β	_	
134-19	21360-21361	=	_	
134-20	21362-21366	.340	_	
134-21	21366-21367	,	_	
134-22	21368-21370	tr	_	
134-23	21371-21372	=	_	
134-24	21373-21377	3.39	_	
134-25	21377-21378	,	_	
134-26	21379-21380	p	_	
134-27	21381-21382	=	_	
134-28	21383-21387	.012	_	
134-29	21388-21397	corrected	_	
134-30	21397-21398	)	_	
134-31	21399-21400	(	_	
134-32	21400-21405	Table	_	
134-33	21406-21407	4	_	
134-34	21407-21408	)	_	
134-35	21408-21409	.	_	

#Text=This association did not differ between groups (activation by group interaction, tr = 1.60, p = .108; user’s accuracy association: β =.405, nonuser’s accuracy association: β = .293).
135-1	21410-21414	This	_	
135-2	21415-21426	association	_	
135-3	21427-21430	did	_	
135-4	21431-21434	not	_	
135-5	21435-21441	differ	_	
135-6	21442-21449	between	_	
135-7	21450-21456	groups	_	
135-8	21457-21458	(	_	
135-9	21458-21468	activation	_	
135-10	21469-21471	by	_	
135-11	21472-21477	group	_	
135-12	21478-21489	interaction	_	
135-13	21489-21490	,	_	
135-14	21491-21493	tr	_	
135-15	21494-21495	=	_	
135-16	21496-21500	1.60	_	
135-17	21500-21501	,	_	
135-18	21502-21503	p	_	
135-19	21504-21505	=	_	
135-20	21506-21510	.108	_	
135-21	21510-21511	;	_	
135-22	21512-21516	user	_	
135-23	21516-21517	’	_	
135-24	21517-21518	s	_	
135-25	21519-21527	accuracy	_	
135-26	21528-21539	association	_	
135-27	21539-21540	:	_	
135-28	21541-21542	β	_	
135-29	21543-21544	=	_	
135-30	21544-21548	.405	_	
135-31	21548-21549	,	_	
135-32	21550-21557	nonuser	_	
135-33	21557-21558	’	_	
135-34	21558-21559	s	_	
135-35	21560-21568	accuracy	_	
135-36	21569-21580	association	_	
135-37	21580-21581	:	_	
135-38	21582-21583	β	_	
135-39	21584-21585	=	_	
135-40	21586-21590	.293	_	
135-41	21590-21591	)	_	
135-42	21591-21592	.	_	

#Text=Furthermore, lateral occipital cortex BOLD activation mediated the relationship between cannabis group and WM accuracy (average indirect pathway, β = 2.297 [95% CI, −.560 to −.097], p < .001) (Supplemental Figure S9).
136-1	21593-21604	Furthermore	_	
136-2	21604-21605	,	_	
136-3	21606-21613	lateral	_	
136-4	21614-21623	occipital	_	
136-5	21624-21630	cortex	_	
136-6	21631-21635	BOLD	_	
136-7	21636-21646	activation	_	
136-8	21647-21655	mediated	_	
136-9	21656-21659	the	_	
136-10	21660-21672	relationship	_	
136-11	21673-21680	between	_	
136-12	21681-21689	cannabis	_	
136-13	21690-21695	group	_	
136-14	21696-21699	and	_	
136-15	21700-21702	WM	_	
136-16	21703-21711	accuracy	_	
136-17	21712-21713	(	_	
136-18	21713-21720	average	_	
136-19	21721-21729	indirect	_	
136-20	21730-21737	pathway	_	
136-21	21737-21738	,	_	
136-22	21739-21740	β	_	
136-23	21741-21742	=	_	
136-24	21743-21748	2.297	_	
136-25	21749-21750	[	_	
136-26	21750-21753	95%	_	
136-27	21754-21756	CI	_	
136-28	21756-21757	,	_	
136-29	21758-21759	−	_	
136-30	21759-21763	.560	_	
136-31	21764-21766	to	_	
136-32	21767-21768	−	_	
136-33	21768-21772	.097	_	
136-34	21772-21773	]	_	
136-35	21773-21774	,	_	
136-36	21775-21776	p	_	
136-37	21777-21778	<	_	
136-38	21779-21783	.001	_	
136-39	21783-21784	)	_	
136-40	21785-21786	(	_	
136-41	21786-21798	Supplemental	_	
136-42	21799-21805	Figure	_	
136-43	21806-21808	S9	_	
136-44	21808-21809	)	_	
136-45	21809-21810	.	_	

#Text=Cannabis Dose-Response.
137-1	21811-21819	Cannabis	_	
137-2	21820-21833	Dose-Response	_	
137-3	21833-21834	.	_	

#Text=At follow-up, a significant dose-response relationship was observed for BOLD activation in the cuneus cluster B using robust linear regression with cannabis dose as the dependent variable (full user group, n = 14: β = .647, tr = 2.74, p = .0496 corrected, p = .0165 uncorrected; longitudinal sample, n = 13: β = .650, tr = 2.85, p = .042 corrected, p = .014, uncorrected) (Table 4; Figure 4).
138-1	21835-21837	At	_	
138-2	21838-21847	follow-up	_	
138-3	21847-21848	,	_	
138-4	21849-21850	a	_	
138-5	21851-21862	significant	_	
138-6	21863-21876	dose-response	_	
138-7	21877-21889	relationship	_	
138-8	21890-21893	was	_	
138-9	21894-21902	observed	_	
138-10	21903-21906	for	_	
138-11	21907-21911	BOLD	_	
138-12	21912-21922	activation	_	
138-13	21923-21925	in	_	
138-14	21926-21929	the	_	
138-15	21930-21936	cuneus	_	
138-16	21937-21944	cluster	_	
138-17	21945-21946	B	_	
138-18	21947-21952	using	_	
138-19	21953-21959	robust	_	
138-20	21960-21966	linear	_	
138-21	21967-21977	regression	_	
138-22	21978-21982	with	_	
138-23	21983-21991	cannabis	_	
138-24	21992-21996	dose	_	
138-25	21997-21999	as	_	
138-26	22000-22003	the	_	
138-27	22004-22013	dependent	_	
138-28	22014-22022	variable	_	
138-29	22023-22024	(	_	
138-30	22024-22028	full	_	
138-31	22029-22033	user	_	
138-32	22034-22039	group	_	
138-33	22039-22040	,	_	
138-34	22041-22042	n	_	
138-35	22043-22044	=	_	
138-36	22045-22047	14	_	
138-37	22047-22048	:	_	
138-38	22049-22050	β	_	
138-39	22051-22052	=	_	
138-40	22053-22057	.647	_	
138-41	22057-22058	,	_	
138-42	22059-22061	tr	_	
138-43	22062-22063	=	_	
138-44	22064-22068	2.74	_	
138-45	22068-22069	,	_	
138-46	22070-22071	p	_	
138-47	22072-22073	=	_	
138-48	22074-22079	.0496	_	
138-49	22080-22089	corrected	_	
138-50	22089-22090	,	_	
138-51	22091-22092	p	_	
138-52	22093-22094	=	_	
138-53	22095-22100	.0165	_	
138-54	22101-22112	uncorrected	_	
138-55	22112-22113	;	_	
138-56	22114-22126	longitudinal	_	
138-57	22127-22133	sample	_	
138-58	22133-22134	,	_	
138-59	22135-22136	n	_	
138-60	22137-22138	=	_	
138-61	22139-22141	13	_	
138-62	22141-22142	:	_	
138-63	22143-22144	β	_	
138-64	22145-22146	=	_	
138-65	22147-22151	.650	_	
138-66	22151-22152	,	_	
138-67	22153-22155	tr	_	
138-68	22156-22157	=	_	
138-69	22158-22162	2.85	_	
138-70	22162-22163	,	_	
138-71	22164-22165	p	_	
138-72	22166-22167	=	_	
138-73	22168-22172	.042	_	
138-74	22173-22182	corrected	_	
138-75	22182-22183	,	_	
138-76	22184-22185	p	_	
138-77	22186-22187	=	_	
138-78	22188-22192	.014	_	
138-79	22192-22193	,	_	
138-80	22194-22205	uncorrected	_	
138-81	22205-22206	)	_	
138-82	22207-22208	(	_	
138-83	22208-22213	Table	_	
138-84	22214-22215	4	_	
138-85	22215-22216	;	_	
138-86	22217-22223	Figure	_	
138-87	22224-22225	4	_	
138-88	22225-22226	)	_	
138-89	22226-22227	.	_	

#Text=This effect remained significant when covarying SES (full follow-up sample: β = .672, tr = 2.60, p = .023; longitudinal sample: β = .727, tr = 2.67, p = .021) and cannabis age of onset (full follow-up sample: β = .619, tr = 3.30, p = .007; longitudinal sample: β = .600, tr = 2.95, p = .014).
139-1	22228-22232	This	_	
139-2	22233-22239	effect	_	
139-3	22240-22248	remained	_	
139-4	22249-22260	significant	_	
139-5	22261-22265	when	_	
139-6	22266-22275	covarying	_	
139-7	22276-22279	SES	_	
139-8	22280-22281	(	_	
139-9	22281-22285	full	_	
139-10	22286-22295	follow-up	_	
139-11	22296-22302	sample	_	
139-12	22302-22303	:	_	
139-13	22304-22305	β	_	
139-14	22306-22307	=	_	
139-15	22308-22312	.672	_	
139-16	22312-22313	,	_	
139-17	22314-22316	tr	_	
139-18	22317-22318	=	_	
139-19	22319-22323	2.60	_	
139-20	22323-22324	,	_	
139-21	22325-22326	p	_	
139-22	22327-22328	=	_	
139-23	22329-22333	.023	_	
139-24	22333-22334	;	_	
139-25	22335-22347	longitudinal	_	
139-26	22348-22354	sample	_	
139-27	22354-22355	:	_	
139-28	22356-22357	β	_	
139-29	22358-22359	=	_	
139-30	22360-22364	.727	_	
139-31	22364-22365	,	_	
139-32	22366-22368	tr	_	
139-33	22369-22370	=	_	
139-34	22371-22375	2.67	_	
139-35	22375-22376	,	_	
139-36	22377-22378	p	_	
139-37	22379-22380	=	_	
139-38	22381-22385	.021	_	
139-39	22385-22386	)	_	
139-40	22387-22390	and	_	
139-41	22391-22399	cannabis	_	
139-42	22400-22403	age	_	
139-43	22404-22406	of	_	
139-44	22407-22412	onset	_	
139-45	22413-22414	(	_	
139-46	22414-22418	full	_	
139-47	22419-22428	follow-up	_	
139-48	22429-22435	sample	_	
139-49	22435-22436	:	_	
139-50	22437-22438	β	_	
139-51	22439-22440	=	_	
139-52	22441-22445	.619	_	
139-53	22445-22446	,	_	
139-54	22447-22449	tr	_	
139-55	22450-22451	=	_	
139-56	22452-22456	3.30	_	
139-57	22456-22457	,	_	
139-58	22458-22459	p	_	
139-59	22460-22461	=	_	
139-60	22462-22466	.007	_	
139-61	22466-22467	;	_	
139-62	22468-22480	longitudinal	_	
139-63	22481-22487	sample	_	
139-64	22487-22488	:	_	
139-65	22489-22490	β	_	
139-66	22491-22492	=	_	
139-67	22493-22497	.600	_	
139-68	22497-22498	,	_	
139-69	22499-22501	tr	_	
139-70	22502-22503	=	_	
139-71	22504-22508	2.95	_	
139-72	22508-22509	,	_	
139-73	22510-22511	p	_	
139-74	22512-22513	=	_	
139-75	22514-22518	.014	_	
139-76	22518-22519	)	_	
139-77	22519-22520	.	_	

#Text=BOLD activation in this cluster was not associated with cumulative alcohol use (β = .073, tr = 0.28, p = .788).
140-1	22521-22525	BOLD	_	
140-2	22526-22536	activation	_	
140-3	22537-22539	in	_	
140-4	22540-22544	this	_	
140-5	22545-22552	cluster	_	
140-6	22553-22556	was	_	
140-7	22557-22560	not	_	
140-8	22561-22571	associated	_	
140-9	22572-22576	with	_	
140-10	22577-22587	cumulative	_	
140-11	22588-22595	alcohol	_	
140-12	22596-22599	use	_	
140-13	22600-22601	(	_	
140-14	22601-22602	β	_	
140-15	22603-22604	=	_	
140-16	22605-22609	.073	_	
140-17	22609-22610	,	_	
140-18	22611-22613	tr	_	
140-19	22614-22615	=	_	
140-20	22616-22620	0.28	_	
140-21	22620-22621	,	_	
140-22	22622-22623	p	_	
140-23	22624-22625	=	_	
140-24	22626-22630	.788	_	
140-25	22630-22631	)	_	
140-26	22631-22632	.	_	

#Text=Consistent with an exposure effect, post hoc testing revealed there was not a prospective prediction from baseline BOLD activation to cannabis dose in this region (full user sample with dose, n = 20: β = .361, tr = 1.37, p = .188; longitudinal sample, n = 13; β = .108, tr = 0.30, p = .767) (Figure 4).
141-1	22633-22643	Consistent	_	
141-2	22644-22648	with	_	
141-3	22649-22651	an	_	
141-4	22652-22660	exposure	_	
141-5	22661-22667	effect	_	
141-6	22667-22668	,	_	
141-7	22669-22673	post	_	
141-8	22674-22677	hoc	_	
141-9	22678-22685	testing	_	
141-10	22686-22694	revealed	_	
141-11	22695-22700	there	_	
141-12	22701-22704	was	_	
141-13	22705-22708	not	_	
141-14	22709-22710	a	_	
141-15	22711-22722	prospective	_	
141-16	22723-22733	prediction	_	
141-17	22734-22738	from	_	
141-18	22739-22747	baseline	_	
141-19	22748-22752	BOLD	_	
141-20	22753-22763	activation	_	
141-21	22764-22766	to	_	
141-22	22767-22775	cannabis	_	
141-23	22776-22780	dose	_	
141-24	22781-22783	in	_	
141-25	22784-22788	this	_	
141-26	22789-22795	region	_	
141-27	22796-22797	(	_	
141-28	22797-22801	full	_	
141-29	22802-22806	user	_	
141-30	22807-22813	sample	_	
141-31	22814-22818	with	_	
141-32	22819-22823	dose	_	
141-33	22823-22824	,	_	
141-34	22825-22826	n	_	
141-35	22827-22828	=	_	
141-36	22829-22831	20	_	
141-37	22831-22832	:	_	
141-38	22833-22834	β	_	
141-39	22835-22836	=	_	
141-40	22837-22841	.361	_	
141-41	22841-22842	,	_	
141-42	22843-22845	tr	_	
141-43	22846-22847	=	_	
141-44	22848-22852	1.37	_	
141-45	22852-22853	,	_	
141-46	22854-22855	p	_	
141-47	22856-22857	=	_	
141-48	22858-22862	.188	_	
141-49	22862-22863	;	_	
141-50	22864-22876	longitudinal	_	
141-51	22877-22883	sample	_	
141-52	22883-22884	,	_	
141-53	22885-22886	n	_	
141-54	22887-22888	=	_	
141-55	22889-22891	13	_	
141-56	22891-22892	;	_	
141-57	22893-22894	β	_	
141-58	22895-22896	=	_	
141-59	22897-22901	.108	_	
141-60	22901-22902	,	_	
141-61	22903-22905	tr	_	
141-62	22906-22907	=	_	
141-63	22908-22912	0.30	_	
141-64	22912-22913	,	_	
141-65	22914-22915	p	_	
141-66	22916-22917	=	_	
141-67	22918-22922	.767	_	
141-68	22922-22923	)	_	
141-69	22924-22925	(	_	
141-70	22925-22931	Figure	_	
141-71	22932-22933	4	_	
141-72	22933-22934	)	_	
141-73	22934-22935	.	_	

#Text=Using linear mixed-effects models, the interaction between cannabis dose and visit did not reach significance in cuneus cluster B (χ21 = 2.03, t = 1.42, p = .154) but was significant when the three cuneus clusters were aggregated (A, B, and C;χ21 = 4.45, t = 2.11, p = .035).
142-1	22936-22941	Using	_	
142-2	22942-22948	linear	_	
142-3	22949-22962	mixed-effects	_	
142-4	22963-22969	models	_	
142-5	22969-22970	,	_	
142-6	22971-22974	the	_	
142-7	22975-22986	interaction	_	
142-8	22987-22994	between	_	
142-9	22995-23003	cannabis	_	
142-10	23004-23008	dose	_	
142-11	23009-23012	and	_	
142-12	23013-23018	visit	_	
142-13	23019-23022	did	_	
142-14	23023-23026	not	_	
142-15	23027-23032	reach	_	
142-16	23033-23045	significance	_	
142-17	23046-23048	in	_	
142-18	23049-23055	cuneus	_	
142-19	23056-23063	cluster	_	
142-20	23064-23065	B	_	
142-21	23066-23067	(	_	
142-22	23067-23070	χ21	_	
142-23	23071-23072	=	_	
142-24	23073-23077	2.03	_	
142-25	23077-23078	,	_	
142-26	23079-23080	t	_	
142-27	23081-23082	=	_	
142-28	23083-23087	1.42	_	
142-29	23087-23088	,	_	
142-30	23089-23090	p	_	
142-31	23091-23092	=	_	
142-32	23093-23097	.154	_	
142-33	23097-23098	)	_	
142-34	23099-23102	but	_	
142-35	23103-23106	was	_	
142-36	23107-23118	significant	_	
142-37	23119-23123	when	_	
142-38	23124-23127	the	_	
142-39	23128-23133	three	_	
142-40	23134-23140	cuneus	_	
142-41	23141-23149	clusters	_	
142-42	23150-23154	were	_	
142-43	23155-23165	aggregated	_	
142-44	23166-23167	(	_	
142-45	23167-23168	A	_	
142-46	23168-23169	,	_	
142-47	23170-23171	B	_	
142-48	23171-23172	,	_	
142-49	23173-23176	and	_	
142-50	23177-23178	C	_	
142-51	23178-23179	;	_	
142-52	23179-23182	χ21	_	
142-53	23183-23184	=	_	
142-54	23185-23189	4.45	_	
142-55	23189-23190	,	_	
142-56	23191-23192	t	_	
142-57	23193-23194	=	_	
142-58	23195-23199	2.11	_	
142-59	23199-23200	,	_	
142-60	23201-23202	p	_	
142-61	23203-23204	=	_	
142-62	23205-23209	.035	_	
142-63	23209-23210	)	_	
142-64	23210-23211	.	_	

#Text=This interaction remained significant when covarying SES (χ21 = 4.32, t = 2.08, p = .038) and cannabis age of onset (χ21 = 4.29, t = 2.07, p = .038) and the cuneus aggregate was not associated with cumulative alcohol use (β = .042, tr = 0.16, p = .875).
143-1	23212-23216	This	_	
143-2	23217-23228	interaction	_	
143-3	23229-23237	remained	_	
143-4	23238-23249	significant	_	
143-5	23250-23254	when	_	
143-6	23255-23264	covarying	_	
143-7	23265-23268	SES	_	
143-8	23269-23270	(	_	
143-9	23270-23273	χ21	_	
143-10	23274-23275	=	_	
143-11	23276-23280	4.32	_	
143-12	23280-23281	,	_	
143-13	23282-23283	t	_	
143-14	23284-23285	=	_	
143-15	23286-23290	2.08	_	
143-16	23290-23291	,	_	
143-17	23292-23293	p	_	
143-18	23294-23295	=	_	
143-19	23296-23300	.038	_	
143-20	23300-23301	)	_	
143-21	23302-23305	and	_	
143-22	23306-23314	cannabis	_	
143-23	23315-23318	age	_	
143-24	23319-23321	of	_	
143-25	23322-23327	onset	_	
143-26	23328-23329	(	_	
143-27	23329-23332	χ21	_	
143-28	23333-23334	=	_	
143-29	23335-23339	4.29	_	
143-30	23339-23340	,	_	
143-31	23341-23342	t	_	
143-32	23343-23344	=	_	
143-33	23345-23349	2.07	_	
143-34	23349-23350	,	_	
143-35	23351-23352	p	_	
143-36	23353-23354	=	_	
143-37	23355-23359	.038	_	
143-38	23359-23360	)	_	
143-39	23361-23364	and	_	
143-40	23365-23368	the	_	
143-41	23369-23375	cuneus	_	
143-42	23376-23385	aggregate	_	
143-43	23386-23389	was	_	
143-44	23390-23393	not	_	
143-45	23394-23404	associated	_	
143-46	23405-23409	with	_	
143-47	23410-23420	cumulative	_	
143-48	23421-23428	alcohol	_	
143-49	23429-23432	use	_	
143-50	23433-23434	(	_	
143-51	23434-23435	β	_	
143-52	23436-23437	=	_	
143-53	23438-23442	.042	_	
143-54	23442-23443	,	_	
143-55	23444-23446	tr	_	
143-56	23447-23448	=	_	
143-57	23449-23453	0.16	_	
143-58	23453-23454	,	_	
143-59	23455-23456	p	_	
143-60	23457-23458	=	_	
143-61	23459-23463	.875	_	
143-62	23463-23464	)	_	
143-63	23464-23465	.	_	

#Text=However, neither the cuneus aggregate nor the individual cuneus clusters were significant predictors of WM accuracy (Table 4) or performance on any tests in the cognitive battery (Supplemental Tables S6–S9).
144-1	23466-23473	However	_	
144-2	23473-23474	,	_	
144-3	23475-23482	neither	_	
144-4	23483-23486	the	_	
144-5	23487-23493	cuneus	_	
144-6	23494-23503	aggregate	_	
144-7	23504-23507	nor	_	
144-8	23508-23511	the	_	
144-9	23512-23522	individual	_	
144-10	23523-23529	cuneus	_	
144-11	23530-23538	clusters	_	
144-12	23539-23543	were	_	
144-13	23544-23555	significant	_	
144-14	23556-23566	predictors	_	
144-15	23567-23569	of	_	
144-16	23570-23572	WM	_	
144-17	23573-23581	accuracy	_	
144-18	23582-23583	(	_	
144-19	23583-23588	Table	_	
144-20	23589-23590	4	_	
144-21	23590-23591	)	_	
144-22	23592-23594	or	_	
144-23	23595-23606	performance	_	
144-24	23607-23609	on	_	
144-25	23610-23613	any	_	
144-26	23614-23619	tests	_	
144-27	23620-23622	in	_	
144-28	23623-23626	the	_	
144-29	23627-23636	cognitive	_	
144-30	23637-23644	battery	_	
144-31	23645-23646	(	_	
144-32	23646-23658	Supplemental	_	
144-33	23659-23665	Tables	_	
144-34	23666-23668	S6	_	
144-35	23668-23669	–	_	
144-36	23669-23671	S9	_	
144-37	23671-23672	)	_	
144-38	23672-23673	.	_	

#Text=Cognitive Battery
#Text=Figure 5 shows effect sizes of cognitive battery measures.
145-1	23674-23683	Cognitive	_	
145-2	23684-23691	Battery	_	
145-3	23692-23698	Figure	_	
145-4	23699-23700	5	_	
145-5	23701-23706	shows	_	
145-6	23707-23713	effect	_	
145-7	23714-23719	sizes	_	
145-8	23720-23722	of	_	
145-9	23723-23732	cognitive	_	
145-10	23733-23740	battery	_	
145-11	23741-23749	measures	_	
145-12	23749-23750	.	_	

#Text=Supplemental Table S10 shows complete group differences and covariate relationships.
146-1	23751-23763	Supplemental	_	
146-2	23764-23769	Table	_	
146-3	23770-23773	S10	_	
146-4	23774-23779	shows	_	
146-5	23780-23788	complete	_	
146-6	23789-23794	group	_	
146-7	23795-23806	differences	_	
146-8	23807-23810	and	_	
146-9	23811-23820	covariate	_	
146-10	23821-23834	relationships	_	
146-11	23834-23835	.	_	

#Text=Group Differences.
147-1	23836-23841	Group	_	
147-2	23842-23853	Differences	_	
147-3	23853-23854	.	_	

#Text=At baseline, within the full behavioral sample (N = 85), those who would go on to use cannabis by follow-up (users, n = 22) had significantly lower scores (FDR corrected, q < .05) on WISC PER (t35.062 = −2.91, p = .029 corrected, d = .741) and CANTAB OTS (t30.02 = −3.08, p = .029 corrected, d = .868) compared with nonusers (n = 63).
148-1	23855-23857	At	_	
148-2	23858-23866	baseline	_	
148-3	23866-23867	,	_	
148-4	23868-23874	within	_	
148-5	23875-23878	the	_	
148-6	23879-23883	full	_	
148-7	23884-23894	behavioral	_	
148-8	23895-23901	sample	_	
148-9	23902-23903	(	_	
148-10	23903-23904	N	_	
148-11	23905-23906	=	_	
148-12	23907-23909	85	_	
148-13	23909-23910	)	_	
148-14	23910-23911	,	_	
148-15	23912-23917	those	_	
148-16	23918-23921	who	_	
148-17	23922-23927	would	_	
148-18	23928-23930	go	_	
148-19	23931-23933	on	_	
148-20	23934-23936	to	_	
148-21	23937-23940	use	_	
148-22	23941-23949	cannabis	_	
148-23	23950-23952	by	_	
148-24	23953-23962	follow-up	_	
148-25	23963-23964	(	_	
148-26	23964-23969	users	_	
148-27	23969-23970	,	_	
148-28	23971-23972	n	_	
148-29	23973-23974	=	_	
148-30	23975-23977	22	_	
148-31	23977-23978	)	_	
148-32	23979-23982	had	_	
148-33	23983-23996	significantly	_	
148-34	23997-24002	lower	_	
148-35	24003-24009	scores	_	
148-36	24010-24011	(	_	
148-37	24011-24014	FDR	_	
148-38	24015-24024	corrected	_	
148-39	24024-24025	,	_	
148-40	24026-24027	q	_	
148-41	24028-24029	<	_	
148-42	24030-24033	.05	_	
148-43	24033-24034	)	_	
148-44	24035-24037	on	_	
148-45	24038-24042	WISC	_	
148-46	24043-24046	PER	_	
148-47	24047-24048	(	_	
148-48	24048-24055	t35.062	_	
148-49	24056-24057	=	_	
148-50	24058-24059	−	_	
148-51	24059-24063	2.91	_	
148-52	24063-24064	,	_	
148-53	24065-24066	p	_	
148-54	24067-24068	=	_	
148-55	24069-24073	.029	_	
148-56	24074-24083	corrected	_	
148-57	24083-24084	,	_	
148-58	24085-24086	d	_	
148-59	24087-24088	=	_	
148-60	24089-24093	.741	_	
148-61	24093-24094	)	_	
148-62	24095-24098	and	_	
148-63	24099-24105	CANTAB	_	
148-64	24106-24109	OTS	_	
148-65	24110-24111	(	_	
148-66	24111-24117	t30.02	_	
148-67	24118-24119	=	_	
148-68	24120-24121	−	_	
148-69	24121-24125	3.08	_	
148-70	24125-24126	,	_	
148-71	24127-24128	p	_	
148-72	24129-24130	=	_	
148-73	24131-24135	.029	_	
148-74	24136-24145	corrected	_	
148-75	24145-24146	,	_	
148-76	24147-24148	d	_	
148-77	24149-24150	=	_	
148-78	24151-24155	.868	_	
148-79	24155-24156	)	_	
148-80	24157-24165	compared	_	
148-81	24166-24170	with	_	
148-82	24171-24179	nonusers	_	
148-83	24180-24181	(	_	
148-84	24181-24182	n	_	
148-85	24183-24184	=	_	
148-86	24185-24187	63	_	
148-87	24187-24188	)	_	
148-88	24188-24189	.	_	

#Text=Both tests were significant when excluding the 4 participants with inconsistent cannabis onset report (WISC PER: t25.11 = −2.11,p = .045, d = .604; CANTAB OTS: t23.31 = −2.40, p = .025, d = .734).
149-1	24190-24194	Both	_	
149-2	24195-24200	tests	_	
149-3	24201-24205	were	_	
149-4	24206-24217	significant	_	
149-5	24218-24222	when	_	
149-6	24223-24232	excluding	_	
149-7	24233-24236	the	_	
149-8	24237-24238	4	_	
149-9	24239-24251	participants	_	
149-10	24252-24256	with	_	
149-11	24257-24269	inconsistent	_	
149-12	24270-24278	cannabis	_	
149-13	24279-24284	onset	_	
149-14	24285-24291	report	_	
149-15	24292-24293	(	_	
149-16	24293-24297	WISC	_	
149-17	24298-24301	PER	_	
149-18	24301-24302	:	_	
149-19	24303-24309	t25.11	_	
149-20	24310-24311	=	_	
149-21	24312-24313	−	_	
149-22	24313-24317	2.11	_	
149-23	24317-24318	,	_	
149-24	24318-24319	p	_	
149-25	24320-24321	=	_	
149-26	24322-24326	.045	_	
149-27	24326-24327	,	_	
149-28	24328-24329	d	_	
149-29	24330-24331	=	_	
149-30	24332-24336	.604	_	
149-31	24336-24337	;	_	
149-32	24338-24344	CANTAB	_	
149-33	24345-24348	OTS	_	
149-34	24348-24349	:	_	
149-35	24350-24356	t23.31	_	
149-36	24357-24358	=	_	
149-37	24359-24360	−	_	
149-38	24360-24364	2.40	_	
149-39	24364-24365	,	_	
149-40	24366-24367	p	_	
149-41	24368-24369	=	_	
149-42	24370-24374	.025	_	
149-43	24374-24375	,	_	
149-44	24376-24377	d	_	
149-45	24378-24379	=	_	
149-46	24380-24384	.734	_	
149-47	24384-24385	)	_	
149-48	24385-24386	.	_	

#Text=At follow-up, WISC PER remained significantly lower for the user group at the corrected level (t48.42 = −3.24,p = .019 corrected, d = .702), while CANTAB OTS was reduced to a corrected trend (t30.02 = −2.62, p = .061 corrected, d = .831).
150-1	24387-24389	At	_	
150-2	24390-24399	follow-up	_	
150-3	24399-24400	,	_	
150-4	24401-24405	WISC	_	
150-5	24406-24409	PER	_	
150-6	24410-24418	remained	_	
150-7	24419-24432	significantly	_	
150-8	24433-24438	lower	_	
150-9	24439-24442	for	_	
150-10	24443-24446	the	_	
150-11	24447-24451	user	_	
150-12	24452-24457	group	_	
150-13	24458-24460	at	_	
150-14	24461-24464	the	_	
150-15	24465-24474	corrected	_	
150-16	24475-24480	level	_	
150-17	24481-24482	(	_	
150-18	24482-24488	t48.42	_	
150-19	24489-24490	=	_	
150-20	24491-24492	−	_	
150-21	24492-24496	3.24	_	
150-22	24496-24497	,	_	
150-23	24497-24498	p	_	
150-24	24499-24500	=	_	
150-25	24501-24505	.019	_	
150-26	24506-24515	corrected	_	
150-27	24515-24516	,	_	
150-28	24517-24518	d	_	
150-29	24519-24520	=	_	
150-30	24521-24525	.702	_	
150-31	24525-24526	)	_	
150-32	24526-24527	,	_	
150-33	24528-24533	while	_	
150-34	24534-24540	CANTAB	_	
150-35	24541-24544	OTS	_	
150-36	24545-24548	was	_	
150-37	24549-24556	reduced	_	
150-38	24557-24559	to	_	
150-39	24560-24561	a	_	
150-40	24562-24571	corrected	_	
150-41	24572-24577	trend	_	
150-42	24578-24579	(	_	
150-43	24579-24585	t30.02	_	
150-44	24586-24587	=	_	
150-45	24588-24589	−	_	
150-46	24589-24593	2.62	_	
150-47	24593-24594	,	_	
150-48	24595-24596	p	_	
150-49	24597-24598	=	_	
150-50	24599-24603	.061	_	
150-51	24604-24613	corrected	_	
150-52	24613-24614	,	_	
150-53	24615-24616	d	_	
150-54	24617-24618	=	_	
150-55	24619-24623	.831	_	
150-56	24623-24624	)	_	
150-57	24624-24625	.	_	

#Text=No tests that were not significant at baseline became significant at follow-up.
151-1	24626-24628	No	_	
151-2	24629-24634	tests	_	
151-3	24635-24639	that	_	
151-4	24640-24644	were	_	
151-5	24645-24648	not	_	
151-6	24649-24660	significant	_	
151-7	24661-24663	at	_	
151-8	24664-24672	baseline	_	
151-9	24673-24679	became	_	
151-10	24680-24691	significant	_	
151-11	24692-24694	at	_	
151-12	24695-24704	follow-up	_	
151-13	24704-24705	.	_	

#Text=Further, longitudinal difference scores (follow-up − baseline) did not differ between groups for any test (p values > .126 uncorrected), suggesting that the groups were not increasingly different following cannabis initiation.
152-1	24706-24713	Further	_	
152-2	24713-24714	,	_	
152-3	24715-24727	longitudinal	_	
152-4	24728-24738	difference	_	
152-5	24739-24745	scores	_	
152-6	24746-24747	(	_	
152-7	24747-24756	follow-up	_	
152-8	24757-24758	−	_	
152-9	24759-24767	baseline	_	
152-10	24767-24768	)	_	
152-11	24769-24772	did	_	
152-12	24773-24776	not	_	
152-13	24777-24783	differ	_	
152-14	24784-24791	between	_	
152-15	24792-24798	groups	_	
152-16	24799-24802	for	_	
152-17	24803-24806	any	_	
152-18	24807-24811	test	_	
152-19	24812-24813	(	_	
152-20	24813-24814	p	_	
152-21	24815-24821	values	_	
152-22	24822-24823	>	_	
152-23	24824-24828	.126	_	
152-24	24829-24840	uncorrected	_	
152-25	24840-24841	)	_	
152-26	24841-24842	,	_	
152-27	24843-24853	suggesting	_	
152-28	24854-24858	that	_	
152-29	24859-24862	the	_	
152-30	24863-24869	groups	_	
152-31	24870-24874	were	_	
152-32	24875-24878	not	_	
152-33	24879-24891	increasingly	_	
152-34	24892-24901	different	_	
152-35	24902-24911	following	_	
152-36	24912-24920	cannabis	_	
152-37	24921-24931	initiation	_	
152-38	24931-24932	.	_	

#Text=Covariate Relationships.
153-1	24933-24942	Covariate	_	
153-2	24943-24956	Relationships	_	
153-3	24956-24957	.	_	

#Text=Both baseline WISC PER (β = .407, tr = 3.83, p = .001 corrected) and CANTAB OTS (β = .285, tr = 2.76, p = .010 corrected) were significantly associated with SES.
154-1	24958-24962	Both	_	
154-2	24963-24971	baseline	_	
154-3	24972-24976	WISC	_	
154-4	24977-24980	PER	_	
154-5	24981-24982	(	_	
154-6	24982-24983	β	_	
154-7	24984-24985	=	_	
154-8	24986-24990	.407	_	
154-9	24990-24991	,	_	
154-10	24992-24994	tr	_	
154-11	24995-24996	=	_	
154-12	24997-25001	3.83	_	
154-13	25001-25002	,	_	
154-14	25003-25004	p	_	
154-15	25005-25006	=	_	
154-16	25007-25011	.001	_	
154-17	25012-25021	corrected	_	
154-18	25021-25022	)	_	
154-19	25023-25026	and	_	
154-20	25027-25033	CANTAB	_	
154-21	25034-25037	OTS	_	
154-22	25038-25039	(	_	
154-23	25039-25040	β	_	
154-24	25041-25042	=	_	
154-25	25043-25047	.285	_	
154-26	25047-25048	,	_	
154-27	25049-25051	tr	_	
154-28	25052-25053	=	_	
154-29	25054-25058	2.76	_	
154-30	25058-25059	,	_	
154-31	25060-25061	p	_	
154-32	25062-25063	=	_	
154-33	25064-25068	.010	_	
154-34	25069-25078	corrected	_	
154-35	25078-25079	)	_	
154-36	25080-25084	were	_	
154-37	25085-25098	significantly	_	
154-38	25099-25109	associated	_	
154-39	25110-25114	with	_	
154-40	25115-25118	SES	_	
154-41	25118-25119	.	_	

#Text=When covarying SES, baseline cannabis group differences on WISC PER did not remain significant after correction but remained significant before correction (tr = −2.35, p = .102 corrected, p = .023 uncorrected), while group differences on CANTAB OTS retained corrected significance (tr = −3.00, p = .034 corrected).
155-1	25120-25124	When	_	
155-2	25125-25134	covarying	_	
155-3	25135-25138	SES	_	
155-4	25138-25139	,	_	
155-5	25140-25148	baseline	_	
155-6	25149-25157	cannabis	_	
155-7	25158-25163	group	_	
155-8	25164-25175	differences	_	
155-9	25176-25178	on	_	
155-10	25179-25183	WISC	_	
155-11	25184-25187	PER	_	
155-12	25188-25191	did	_	
155-13	25192-25195	not	_	
155-14	25196-25202	remain	_	
155-15	25203-25214	significant	_	
155-16	25215-25220	after	_	
155-17	25221-25231	correction	_	
155-18	25232-25235	but	_	
155-19	25236-25244	remained	_	
155-20	25245-25256	significant	_	
155-21	25257-25263	before	_	
155-22	25264-25274	correction	_	
155-23	25275-25276	(	_	
155-24	25276-25278	tr	_	
155-25	25279-25280	=	_	
155-26	25281-25282	−	_	
155-27	25282-25286	2.35	_	
155-28	25286-25287	,	_	
155-29	25288-25289	p	_	
155-30	25290-25291	=	_	
155-31	25292-25296	.102	_	
155-32	25297-25306	corrected	_	
155-33	25306-25307	,	_	
155-34	25308-25309	p	_	
155-35	25310-25311	=	_	
155-36	25312-25316	.023	_	
155-37	25317-25328	uncorrected	_	
155-38	25328-25329	)	_	
155-39	25329-25330	,	_	
155-40	25331-25336	while	_	
155-41	25337-25342	group	_	
155-42	25343-25354	differences	_	
155-43	25355-25357	on	_	
155-44	25358-25364	CANTAB	_	
155-45	25365-25368	OTS	_	
155-46	25369-25377	retained	_	
155-47	25378-25387	corrected	_	
155-48	25388-25400	significance	_	
155-49	25401-25402	(	_	
155-50	25402-25404	tr	_	
155-51	25405-25406	=	_	
155-52	25407-25408	−	_	
155-53	25408-25412	3.00	_	
155-54	25412-25413	,	_	
155-55	25414-25415	p	_	
155-56	25416-25417	=	_	
155-57	25418-25422	.034	_	
155-58	25423-25432	corrected	_	
155-59	25432-25433	)	_	
155-60	25433-25434	.	_	

#Text=Mediation analysis revealed small effect sizes for indirect pathways from usage group through SES to WISC PER (average indirect effect β = −.130 [95% CI −.294 to −.001], p = .048) and CANTABOTS (average indirect effect β = −.091 [95% CI −.203 to −.002], p = .046).
156-1	25435-25444	Mediation	_	
156-2	25445-25453	analysis	_	
156-3	25454-25462	revealed	_	
156-4	25463-25468	small	_	
156-5	25469-25475	effect	_	
156-6	25476-25481	sizes	_	
156-7	25482-25485	for	_	
156-8	25486-25494	indirect	_	
156-9	25495-25503	pathways	_	
156-10	25504-25508	from	_	
156-11	25509-25514	usage	_	
156-12	25515-25520	group	_	
156-13	25521-25528	through	_	
156-14	25529-25532	SES	_	
156-15	25533-25535	to	_	
156-16	25536-25540	WISC	_	
156-17	25541-25544	PER	_	
156-18	25545-25546	(	_	
156-19	25546-25553	average	_	
156-20	25554-25562	indirect	_	
156-21	25563-25569	effect	_	
156-22	25570-25571	β	_	
156-23	25572-25573	=	_	
156-24	25574-25575	−	_	
156-25	25575-25579	.130	_	
156-26	25580-25581	[	_	
156-27	25581-25584	95%	_	
156-28	25585-25587	CI	_	
156-29	25588-25589	−	_	
156-30	25589-25593	.294	_	
156-31	25594-25596	to	_	
156-32	25597-25598	−	_	
156-33	25598-25602	.001	_	
156-34	25602-25603	]	_	
156-35	25603-25604	,	_	
156-36	25605-25606	p	_	
156-37	25607-25608	=	_	
156-38	25609-25613	.048	_	
156-39	25613-25614	)	_	
156-40	25615-25618	and	_	
156-41	25619-25628	CANTABOTS	_	
156-42	25629-25630	(	_	
156-43	25630-25637	average	_	
156-44	25638-25646	indirect	_	
156-45	25647-25653	effect	_	
156-46	25654-25655	β	_	
156-47	25656-25657	=	_	
156-48	25658-25659	−	_	
156-49	25659-25663	.091	_	
156-50	25664-25665	[	_	
156-51	25665-25668	95%	_	
156-52	25669-25671	CI	_	
156-53	25672-25673	−	_	
156-54	25673-25677	.203	_	
156-55	25678-25680	to	_	
156-56	25681-25682	−	_	
156-57	25682-25686	.002	_	
156-58	25686-25687	]	_	
156-59	25687-25688	,	_	
156-60	25689-25690	p	_	
156-61	25691-25692	=	_	
156-62	25693-25697	.046	_	
156-63	25697-25698	)	_	
156-64	25698-25699	.	_	

#Text=Taken together, this suggests that small but significant portions of cannabis group differences on WISC PER and CANTAB OTS can be attributed to SES (partial mediation), but SES did not solely explain baseline cognitive differences (no full mediation).
157-1	25700-25705	Taken	_	
157-2	25706-25714	together	_	
157-3	25714-25715	,	_	
157-4	25716-25720	this	_	
157-5	25721-25729	suggests	_	
157-6	25730-25734	that	_	
157-7	25735-25740	small	_	
157-8	25741-25744	but	_	
157-9	25745-25756	significant	_	
157-10	25757-25765	portions	_	
157-11	25766-25768	of	_	
157-12	25769-25777	cannabis	_	
157-13	25778-25783	group	_	
157-14	25784-25795	differences	_	
157-15	25796-25798	on	_	
157-16	25799-25803	WISC	_	
157-17	25804-25807	PER	_	
157-18	25808-25811	and	_	
157-19	25812-25818	CANTAB	_	
157-20	25819-25822	OTS	_	
157-21	25823-25826	can	_	
157-22	25827-25829	be	_	
157-23	25830-25840	attributed	_	
157-24	25841-25843	to	_	
157-25	25844-25847	SES	_	
157-26	25848-25849	(	_	
157-27	25849-25856	partial	_	
157-28	25857-25866	mediation	_	
157-29	25866-25867	)	_	
157-30	25867-25868	,	_	
157-31	25869-25872	but	_	
157-32	25873-25876	SES	_	
157-33	25877-25880	did	_	
157-34	25881-25884	not	_	
157-35	25885-25891	solely	_	
157-36	25892-25899	explain	_	
157-37	25900-25908	baseline	_	
157-38	25909-25918	cognitive	_	
157-39	25919-25930	differences	_	
157-40	25931-25932	(	_	
157-41	25932-25934	no	_	
157-42	25935-25939	full	_	
157-43	25940-25949	mediation	_	
157-44	25949-25950	)	_	
157-45	25950-25951	.	_	

#Text=EXT was not associated with WISC PER or CANTAB OTS baseline performance (uncorrected p values > .415).
158-1	25952-25955	EXT	_	
158-2	25956-25959	was	_	
158-3	25960-25963	not	_	
158-4	25964-25974	associated	_	
158-5	25975-25979	with	_	
158-6	25980-25984	WISC	_	
158-7	25985-25988	PER	_	
158-8	25989-25991	or	_	
158-9	25992-25998	CANTAB	_	
158-10	25999-26002	OTS	_	
158-11	26003-26011	baseline	_	
158-12	26012-26023	performance	_	
158-13	26024-26025	(	_	
158-14	26025-26036	uncorrected	_	
158-15	26037-26038	p	_	
158-16	26039-26045	values	_	
158-17	26046-26047	>	_	
158-18	26048-26052	.415	_	
158-19	26052-26053	)	_	
158-20	26053-26054	.	_	

#Text=WISC PER did not differ between alcohol usage groups (t28.64 = −1.09, p = .283 uncorrected, p = .903 corrected).
159-1	26055-26059	WISC	_	
159-2	26060-26063	PER	_	
159-3	26064-26067	did	_	
159-4	26068-26071	not	_	
159-5	26072-26078	differ	_	
159-6	26079-26086	between	_	
159-7	26087-26094	alcohol	_	
159-8	26095-26100	usage	_	
159-9	26101-26107	groups	_	
159-10	26108-26109	(	_	
159-11	26109-26115	t28.64	_	
159-12	26116-26117	=	_	
159-13	26118-26119	−	_	
159-14	26119-26123	1.09	_	
159-15	26123-26124	,	_	
159-16	26125-26126	p	_	
159-17	26127-26128	=	_	
159-18	26129-26133	.283	_	
159-19	26134-26145	uncorrected	_	
159-20	26145-26146	,	_	
159-21	26147-26148	p	_	
159-22	26149-26150	=	_	
159-23	26151-26155	.903	_	
159-24	26156-26165	corrected	_	
159-25	26165-26166	)	_	
159-26	26166-26167	.	_	

#Text=Alcohol usage group was associated with CANTAB OTS at an uncorrected level (t36.82 = 2.38, p = .027 uncorrected, p = .470 corrected); however, when alcohol usage group was used as a covariate, cannabis usage remained significantly associated with CANTAB OTS (tr = −5.99, p < .001 corrected).
160-1	26168-26175	Alcohol	_	
160-2	26176-26181	usage	_	
160-3	26182-26187	group	_	
160-4	26188-26191	was	_	
160-5	26192-26202	associated	_	
160-6	26203-26207	with	_	
160-7	26208-26214	CANTAB	_	
160-8	26215-26218	OTS	_	
160-9	26219-26221	at	_	
160-10	26222-26224	an	_	
160-11	26225-26236	uncorrected	_	
160-12	26237-26242	level	_	
160-13	26243-26244	(	_	
160-14	26244-26250	t36.82	_	
160-15	26251-26252	=	_	
160-16	26253-26257	2.38	_	
160-17	26257-26258	,	_	
160-18	26259-26260	p	_	
160-19	26261-26262	=	_	
160-20	26263-26267	.027	_	
160-21	26268-26279	uncorrected	_	
160-22	26279-26280	,	_	
160-23	26281-26282	p	_	
160-24	26283-26284	=	_	
160-25	26285-26289	.470	_	
160-26	26290-26299	corrected	_	
160-27	26299-26300	)	_	
160-28	26300-26301	;	_	
160-29	26302-26309	however	_	
160-30	26309-26310	,	_	
160-31	26311-26315	when	_	
160-32	26316-26323	alcohol	_	
160-33	26324-26329	usage	_	
160-34	26330-26335	group	_	
160-35	26336-26339	was	_	
160-36	26340-26344	used	_	
160-37	26345-26347	as	_	
160-38	26348-26349	a	_	
160-39	26350-26359	covariate	_	
160-40	26359-26360	,	_	
160-41	26361-26369	cannabis	_	
160-42	26370-26375	usage	_	
160-43	26376-26384	remained	_	
160-44	26385-26398	significantly	_	
160-45	26399-26409	associated	_	
160-46	26410-26414	with	_	
160-47	26415-26421	CANTAB	_	
160-48	26422-26425	OTS	_	
160-49	26426-26427	(	_	
160-50	26427-26429	tr	_	
160-51	26430-26431	=	_	
160-52	26432-26433	−	_	
160-53	26433-26437	5.99	_	
160-54	26437-26438	,	_	
160-55	26439-26440	p	_	
160-56	26441-26442	<	_	
160-57	26443-26447	.001	_	
160-58	26448-26457	corrected	_	
160-59	26457-26458	)	_	
160-60	26458-26459	.	_	

#Text=The interaction between cannabis and alcohol usage groups was not significant (tr = 1.80, p = .076).
161-1	26460-26463	The	_	
161-2	26464-26475	interaction	_	
161-3	26476-26483	between	_	
161-4	26484-26492	cannabis	_	
161-5	26493-26496	and	_	
161-6	26497-26504	alcohol	_	
161-7	26505-26510	usage	_	
161-8	26511-26517	groups	_	
161-9	26518-26521	was	_	
161-10	26522-26525	not	_	
161-11	26526-26537	significant	_	
161-12	26538-26539	(	_	
161-13	26539-26541	tr	_	
161-14	26542-26543	=	_	
161-15	26544-26548	1.80	_	
161-16	26548-26549	,	_	
161-17	26550-26551	p	_	
161-18	26552-26553	=	_	
161-19	26554-26558	.076	_	
161-20	26558-26559	)	_	
161-21	26559-26560	.	_	

#Text=Cannabis Dose-Response.
162-1	26561-26569	Cannabis	_	
162-2	26570-26583	Dose-Response	_	
162-3	26583-26584	.	_	

#Text=No tests in the cognitive battery were associated with cannabis dose (baseline p values > .189; follow-up p values > .182; differences score p values > .310) (Supplemental Table S11).
163-1	26585-26587	No	_	
163-2	26588-26593	tests	_	
163-3	26594-26596	in	_	
163-4	26597-26600	the	_	
163-5	26601-26610	cognitive	_	
163-6	26611-26618	battery	_	
163-7	26619-26623	were	_	
163-8	26624-26634	associated	_	
163-9	26635-26639	with	_	
163-10	26640-26648	cannabis	_	
163-11	26649-26653	dose	_	
163-12	26654-26655	(	_	
163-13	26655-26663	baseline	_	
163-14	26664-26665	p	_	
163-15	26666-26672	values	_	
163-16	26673-26674	>	_	
163-17	26675-26679	.189	_	
163-18	26679-26680	;	_	
163-19	26681-26690	follow-up	_	
163-20	26691-26692	p	_	
163-21	26693-26699	values	_	
163-22	26700-26701	>	_	
163-23	26702-26706	.182	_	
163-24	26706-26707	;	_	
163-25	26708-26719	differences	_	
163-26	26720-26725	score	_	
163-27	26726-26727	p	_	
163-28	26728-26734	values	_	
163-29	26735-26736	>	_	
163-30	26737-26741	.310	_	
163-31	26741-26742	)	_	
163-32	26743-26744	(	_	
163-33	26744-26756	Supplemental	_	
163-34	26757-26762	Table	_	
163-35	26763-26766	S11	_	
163-36	26766-26767	)	_	
163-37	26767-26768	.	_	

#Text=DISCUSSION
#Text=Predictors of Early Cannabis Initiation
#Text=Consistent with previous work, our results show increased BOLD activation in the posterior parietal cortex in early cannabis users.
164-1	26769-26779	DISCUSSION	_	
164-2	26780-26790	Predictors	_	
164-3	26791-26793	of	_	
164-4	26794-26799	Early	_	
164-5	26800-26808	Cannabis	_	
164-6	26809-26819	Initiation	_	
164-7	26820-26830	Consistent	_	
164-8	26831-26835	with	_	
164-9	26836-26844	previous	_	
164-10	26845-26849	work	_	
164-11	26849-26850	,	_	
164-12	26851-26854	our	_	
164-13	26855-26862	results	_	
164-14	26863-26867	show	_	
164-15	26868-26877	increased	_	
164-16	26878-26882	BOLD	_	
164-17	26883-26893	activation	_	
164-18	26894-26896	in	_	
164-19	26897-26900	the	_	
164-20	26901-26910	posterior	_	
164-21	26911-26919	parietal	_	
164-22	26920-26926	cortex	_	
164-23	26927-26929	in	_	
164-24	26930-26935	early	_	
164-25	26936-26944	cannabis	_	
164-26	26945-26950	users	_	
164-27	26950-26951	.	_	

#Text=However, for the first time, we show that these differences can be observed before reported cannabis onset.
165-1	26952-26959	However	_	
165-2	26959-26960	,	_	
165-3	26961-26964	for	_	
165-4	26965-26968	the	_	
165-5	26969-26974	first	_	
165-6	26975-26979	time	_	
165-7	26979-26980	,	_	
165-8	26981-26983	we	_	
165-9	26984-26988	show	_	
165-10	26989-26993	that	_	
165-11	26994-26999	these	_	
165-12	27000-27011	differences	_	
165-13	27012-27015	can	_	
165-14	27016-27018	be	_	
165-15	27019-27027	observed	_	
165-16	27028-27034	before	_	
165-17	27035-27043	reported	_	
165-18	27044-27052	cannabis	_	
165-19	27053-27058	onset	_	
165-20	27058-27059	.	_	

#Text=Similarly, we demonstrate activation differences before use in the MFG, which has previously been implicated in cannabis age of onset and cannabis frequency.
166-1	27060-27069	Similarly	_	
166-2	27069-27070	,	_	
166-3	27071-27073	we	_	
166-4	27074-27085	demonstrate	_	
166-5	27086-27096	activation	_	
166-6	27097-27108	differences	_	
166-7	27109-27115	before	_	
166-8	27116-27119	use	_	
166-9	27120-27122	in	_	
166-10	27123-27126	the	_	
166-11	27127-27130	MFG	_	
166-12	27130-27131	,	_	
166-13	27132-27137	which	_	
166-14	27138-27141	has	_	
166-15	27142-27152	previously	_	
166-16	27153-27157	been	_	
166-17	27158-27168	implicated	_	
166-18	27169-27171	in	_	
166-19	27172-27180	cannabis	_	
166-20	27181-27184	age	_	
166-21	27185-27187	of	_	
166-22	27188-27193	onset	_	
166-23	27194-27197	and	_	
166-24	27198-27206	cannabis	_	
166-25	27207-27216	frequency	_	
166-26	27216-27217	.	_	

#Text=The largest effect sizes for cognitive differences were observed in visuospatial executive function tasks (e.g., WISC PER and CANTAB OTS).
167-1	27218-27221	The	_	
167-2	27222-27229	largest	_	
167-3	27230-27236	effect	_	
167-4	27237-27242	sizes	_	
167-5	27243-27246	for	_	
167-6	27247-27256	cognitive	_	
167-7	27257-27268	differences	_	
167-8	27269-27273	were	_	
167-9	27274-27282	observed	_	
167-10	27283-27285	in	_	
167-11	27286-27298	visuospatial	_	
167-12	27299-27308	executive	_	
167-13	27309-27317	function	_	
167-14	27318-27323	tasks	_	
167-15	27324-27325	(	_	
167-16	27325-27328	e.g	_	
167-17	27328-27329	.	_	
167-18	27329-27330	,	_	
167-19	27331-27335	WISC	_	
167-20	27336-27339	PER	_	
167-21	27340-27343	and	_	
167-22	27344-27350	CANTAB	_	
167-23	27351-27354	OTS	_	
167-24	27354-27355	)	_	
167-25	27355-27356	.	_	

#Text=Consistent with this, reduced BOLD activation was observed in visual association regions while increased BOLD activation was observed in frontoparietal regions associated with executive function (MFG, presupplementary motor area, and posterior parietal cortex).
168-1	27357-27367	Consistent	_	
168-2	27368-27372	with	_	
168-3	27373-27377	this	_	
168-4	27377-27378	,	_	
168-5	27379-27386	reduced	_	
168-6	27387-27391	BOLD	_	
168-7	27392-27402	activation	_	
168-8	27403-27406	was	_	
168-9	27407-27415	observed	_	
168-10	27416-27418	in	_	
168-11	27419-27425	visual	_	
168-12	27426-27437	association	_	
168-13	27438-27445	regions	_	
168-14	27446-27451	while	_	
168-15	27452-27461	increased	_	
168-16	27462-27466	BOLD	_	
168-17	27467-27477	activation	_	
168-18	27478-27481	was	_	
168-19	27482-27490	observed	_	
168-20	27491-27493	in	_	
168-21	27494-27508	frontoparietal	_	
168-22	27509-27516	regions	_	
168-23	27517-27527	associated	_	
168-24	27528-27532	with	_	
168-25	27533-27542	executive	_	
168-26	27543-27551	function	_	
168-27	27552-27553	(	_	
168-28	27553-27556	MFG	_	
168-29	27556-27557	,	_	
168-30	27558-27574	presupplementary	_	
168-31	27575-27580	motor	_	
168-32	27581-27585	area	_	
168-33	27585-27586	,	_	
168-34	27587-27590	and	_	
168-35	27591-27600	posterior	_	
168-36	27601-27609	parietal	_	
168-37	27610-27616	cortex	_	
168-38	27616-27617	)	_	
168-39	27617-27618	.	_	

#Text=Furthermore, scanner WM performance differences at baseline were significantly mediated by reduced activation in the visual association cortex (Brodmann area 19).
169-1	27619-27630	Furthermore	_	
169-2	27630-27631	,	_	
169-3	27632-27639	scanner	_	
169-4	27640-27642	WM	_	
169-5	27643-27654	performance	_	
169-6	27655-27666	differences	_	
169-7	27667-27669	at	_	
169-8	27670-27678	baseline	_	
169-9	27679-27683	were	_	
169-10	27684-27697	significantly	_	
169-11	27698-27706	mediated	_	
169-12	27707-27709	by	_	
169-13	27710-27717	reduced	_	
169-14	27718-27728	activation	_	
169-15	27729-27731	in	_	
169-16	27732-27735	the	_	
169-17	27736-27742	visual	_	
169-18	27743-27754	association	_	
169-19	27755-27761	cortex	_	
169-20	27762-27763	(	_	
169-21	27763-27771	Brodmann	_	
169-22	27772-27776	area	_	
169-23	27777-27779	19	_	
169-24	27779-27780	)	_	
169-25	27780-27781	.	_	

#Text=Accordingly, our data suggest a possible specific association between cannabis use risk and limitations in visuospatial cognition.
170-1	27782-27793	Accordingly	_	
170-2	27793-27794	,	_	
170-3	27795-27798	our	_	
170-4	27799-27803	data	_	
170-5	27804-27811	suggest	_	
170-6	27812-27813	a	_	
170-7	27814-27822	possible	_	
170-8	27823-27831	specific	_	
170-9	27832-27843	association	_	
170-10	27844-27851	between	_	
170-11	27852-27860	cannabis	_	
170-12	27861-27864	use	_	
170-13	27865-27869	risk	_	
170-14	27870-27873	and	_	
170-15	27874-27885	limitations	_	
170-16	27886-27888	in	_	
170-17	27889-27901	visuospatial	_	
170-18	27902-27911	cognition	_	
170-19	27911-27912	.	_	

#Text=However, in light of the diversity of cognitive tests that displayed moderate to large effect sizes at baseline, our data could alternatively be viewed as implicating a more domain general, cognitive control deficit.
171-1	27913-27920	However	_	
171-2	27920-27921	,	_	
171-3	27922-27924	in	_	
171-4	27925-27930	light	_	
171-5	27931-27933	of	_	
171-6	27934-27937	the	_	
171-7	27938-27947	diversity	_	
171-8	27948-27950	of	_	
171-9	27951-27960	cognitive	_	
171-10	27961-27966	tests	_	
171-11	27967-27971	that	_	
171-12	27972-27981	displayed	_	
171-13	27982-27990	moderate	_	
171-14	27991-27993	to	_	
171-15	27994-27999	large	_	
171-16	28000-28006	effect	_	
171-17	28007-28012	sizes	_	
171-18	28013-28015	at	_	
171-19	28016-28024	baseline	_	
171-20	28024-28025	,	_	
171-21	28026-28029	our	_	
171-22	28030-28034	data	_	
171-23	28035-28040	could	_	
171-24	28041-28054	alternatively	_	
171-25	28055-28057	be	_	
171-26	28058-28064	viewed	_	
171-27	28065-28067	as	_	
171-28	28068-28079	implicating	_	
171-29	28080-28081	a	_	
171-30	28082-28086	more	_	
171-31	28087-28093	domain	_	
171-32	28094-28101	general	_	
171-33	28101-28102	,	_	
171-34	28103-28112	cognitive	_	
171-35	28113-28120	control	_	
171-36	28121-28128	deficit	_	
171-37	28128-28129	.	_	

#Text=This is consistent with a recent large twin study demonstrating that lower IQ scores precede cannabis use and with work showing that poor cognitive control (characterized as neurobehavioral disinhibition) predicts alcohol initiation and substance use disorder onset.
172-1	28130-28134	This	_	
172-2	28135-28137	is	_	
172-3	28138-28148	consistent	_	
172-4	28149-28153	with	_	
172-5	28154-28155	a	_	
172-6	28156-28162	recent	_	
172-7	28163-28168	large	_	
172-8	28169-28173	twin	_	
172-9	28174-28179	study	_	
172-10	28180-28193	demonstrating	_	
172-11	28194-28198	that	_	
172-12	28199-28204	lower	_	
172-13	28205-28207	IQ	_	
172-14	28208-28214	scores	_	
172-15	28215-28222	precede	_	
172-16	28223-28231	cannabis	_	
172-17	28232-28235	use	_	
172-18	28236-28239	and	_	
172-19	28240-28244	with	_	
172-20	28245-28249	work	_	
172-21	28250-28257	showing	_	
172-22	28258-28262	that	_	
172-23	28263-28267	poor	_	
172-24	28268-28277	cognitive	_	
172-25	28278-28285	control	_	
172-26	28286-28287	(	_	
172-27	28287-28300	characterized	_	
172-28	28301-28303	as	_	
172-29	28304-28319	neurobehavioral	_	
172-30	28320-28333	disinhibition	_	
172-31	28333-28334	)	_	
172-32	28335-28343	predicts	_	
172-33	28344-28351	alcohol	_	
172-34	28352-28362	initiation	_	
172-35	28363-28366	and	_	
172-36	28367-28376	substance	_	
172-37	28377-28380	use	_	
172-38	28381-28389	disorder	_	
172-39	28390-28395	onset	_	
172-40	28395-28396	.	_	

#Text=Contrary to our hypotheses, baseline neurocognitive differences were not fully explained by SES or EXT.
173-1	28397-28405	Contrary	_	
173-2	28406-28408	to	_	
173-3	28409-28412	our	_	
173-4	28413-28423	hypotheses	_	
173-5	28423-28424	,	_	
173-6	28425-28433	baseline	_	
173-7	28434-28448	neurocognitive	_	
173-8	28449-28460	differences	_	
173-9	28461-28465	were	_	
173-10	28466-28469	not	_	
173-11	28470-28475	fully	_	
173-12	28476-28485	explained	_	
173-13	28486-28488	by	_	
173-14	28489-28492	SES	_	
173-15	28493-28495	or	_	
173-16	28496-28499	EXT	_	
173-17	28499-28500	.	_	

#Text=Moreover, while some frontoparietal differences were observed at follow-up when considering main effects across visits (posterior parietal cortex), others (MFG and presupplementary motor area) were not.
174-1	28501-28509	Moreover	_	
174-2	28509-28510	,	_	
174-3	28511-28516	while	_	
174-4	28517-28521	some	_	
174-5	28522-28536	frontoparietal	_	
174-6	28537-28548	differences	_	
174-7	28549-28553	were	_	
174-8	28554-28562	observed	_	
174-9	28563-28565	at	_	
174-10	28566-28575	follow-up	_	
174-11	28576-28580	when	_	
174-12	28581-28592	considering	_	
174-13	28593-28597	main	_	
174-14	28598-28605	effects	_	
174-15	28606-28612	across	_	
174-16	28613-28619	visits	_	
174-17	28620-28621	(	_	
174-18	28621-28630	posterior	_	
174-19	28631-28639	parietal	_	
174-20	28640-28646	cortex	_	
174-21	28646-28647	)	_	
174-22	28647-28648	,	_	
174-23	28649-28655	others	_	
174-24	28656-28657	(	_	
174-25	28657-28660	MFG	_	
174-26	28661-28664	and	_	
174-27	28665-28681	presupplementary	_	
174-28	28682-28687	motor	_	
174-29	28688-28692	area	_	
174-30	28692-28693	)	_	
174-31	28694-28698	were	_	
174-32	28699-28702	not	_	
174-33	28702-28703	.	_	

#Text=This suggests that BOLD predictors of cannabis may reflect alternative processes than those solely represented by sociodemographic risk factors or cognitive function indexed by frontoparietal regions.
175-1	28704-28708	This	_	
175-2	28709-28717	suggests	_	
175-3	28718-28722	that	_	
175-4	28723-28727	BOLD	_	
175-5	28728-28738	predictors	_	
175-6	28739-28741	of	_	
175-7	28742-28750	cannabis	_	
175-8	28751-28754	may	_	
175-9	28755-28762	reflect	_	
175-10	28763-28774	alternative	_	
175-11	28775-28784	processes	_	
175-12	28785-28789	than	_	
175-13	28790-28795	those	_	
175-14	28796-28802	solely	_	
175-15	28803-28814	represented	_	
175-16	28815-28817	by	_	
175-17	28818-28834	sociodemographic	_	
175-18	28835-28839	risk	_	
175-19	28840-28847	factors	_	
175-20	28848-28850	or	_	
175-21	28851-28860	cognitive	_	
175-22	28861-28869	function	_	
175-23	28870-28877	indexed	_	
175-24	28878-28880	by	_	
175-25	28881-28895	frontoparietal	_	
175-26	28896-28903	regions	_	
175-27	28903-28904	.	_	

#Text=Recent work from our group indicates that WM development is supported by normative increases in the engagement of visual association regions and normative decreases in frontoparietal regions.
176-1	28905-28911	Recent	_	
176-2	28912-28916	work	_	
176-3	28917-28921	from	_	
176-4	28922-28925	our	_	
176-5	28926-28931	group	_	
176-6	28932-28941	indicates	_	
176-7	28942-28946	that	_	
176-8	28947-28949	WM	_	
176-9	28950-28961	development	_	
176-10	28962-28964	is	_	
176-11	28965-28974	supported	_	
176-12	28975-28977	by	_	
176-13	28978-28987	normative	_	
176-14	28988-28997	increases	_	
176-15	28998-29000	in	_	
176-16	29001-29004	the	_	
176-17	29005-29015	engagement	_	
176-18	29016-29018	of	_	
176-19	29019-29025	visual	_	
176-20	29026-29037	association	_	
176-21	29038-29045	regions	_	
176-22	29046-29049	and	_	
176-23	29050-29059	normative	_	
176-24	29060-29069	decreases	_	
176-25	29070-29072	in	_	
176-26	29073-29087	frontoparietal	_	
176-27	29088-29095	regions	_	
176-28	29095-29096	.	_	

#Text=Thus, reduced engagement of visual association regions and increased engagement of frontoparietal regions in those who go on to initiate cannabis use may reflect late neurodevelopment.
177-1	29097-29101	Thus	_	
177-2	29101-29102	,	_	
177-3	29103-29110	reduced	_	
177-4	29111-29121	engagement	_	
177-5	29122-29124	of	_	
177-6	29125-29131	visual	_	
177-7	29132-29143	association	_	
177-8	29144-29151	regions	_	
177-9	29152-29155	and	_	
177-10	29156-29165	increased	_	
177-11	29166-29176	engagement	_	
177-12	29177-29179	of	_	
177-13	29180-29194	frontoparietal	_	
177-14	29195-29202	regions	_	
177-15	29203-29205	in	_	
177-16	29206-29211	those	_	
177-17	29212-29215	who	_	
177-18	29216-29218	go	_	
177-19	29219-29221	on	_	
177-20	29222-29224	to	_	
177-21	29225-29233	initiate	_	
177-22	29234-29242	cannabis	_	
177-23	29243-29246	use	_	
177-24	29247-29250	may	_	
177-25	29251-29258	reflect	_	
177-26	29259-29263	late	_	
177-27	29264-29280	neurodevelopment	_	
177-28	29280-29281	.	_	

#Text=To this end, our results showing increased activation in frontoparietal regions before cannabis use in adolescence are inconsistent with our previous research showing that early cannabis onset is associated with decreased frontoparietal activation in adulthood.
178-1	29282-29284	To	_	
178-2	29285-29289	this	_	
178-3	29290-29293	end	_	
178-4	29293-29294	,	_	
178-5	29295-29298	our	_	
178-6	29299-29306	results	_	
178-7	29307-29314	showing	_	
178-8	29315-29324	increased	_	
178-9	29325-29335	activation	_	
178-10	29336-29338	in	_	
178-11	29339-29353	frontoparietal	_	
178-12	29354-29361	regions	_	
178-13	29362-29368	before	_	
178-14	29369-29377	cannabis	_	
178-15	29378-29381	use	_	
178-16	29382-29384	in	_	
178-17	29385-29396	adolescence	_	
178-18	29397-29400	are	_	
178-19	29401-29413	inconsistent	_	
178-20	29414-29418	with	_	
178-21	29419-29422	our	_	
178-22	29423-29431	previous	_	
178-23	29432-29440	research	_	
178-24	29441-29448	showing	_	
178-25	29449-29453	that	_	
178-26	29454-29459	early	_	
178-27	29460-29468	cannabis	_	
178-28	29469-29474	onset	_	
178-29	29475-29477	is	_	
178-30	29478-29488	associated	_	
178-31	29489-29493	with	_	
178-32	29494-29503	decreased	_	
178-33	29504-29518	frontoparietal	_	
178-34	29519-29529	activation	_	
178-35	29530-29532	in	_	
178-36	29533-29542	adulthood	_	
178-37	29542-29543	.	_	

#Text=In light of normative neurodevelopmental decreases in frontoparietal engagement [; see for review], differences in frontoparietal regions associated with substance use risk may involve an interaction between stable trait-level differences and developmental processes.
179-1	29544-29546	In	_	
179-2	29547-29552	light	_	
179-3	29553-29555	of	_	
179-4	29556-29565	normative	_	
179-5	29566-29584	neurodevelopmental	_	
179-6	29585-29594	decreases	_	
179-7	29595-29597	in	_	
179-8	29598-29612	frontoparietal	_	
179-9	29613-29623	engagement	_	
179-10	29624-29625	[	_	
179-11	29625-29626	;	_	
179-12	29627-29630	see	_	
179-13	29631-29634	for	_	
179-14	29635-29641	review	_	
179-15	29641-29642	]	_	
179-16	29642-29643	,	_	
179-17	29644-29655	differences	_	
179-18	29656-29658	in	_	
179-19	29659-29673	frontoparietal	_	
179-20	29674-29681	regions	_	
179-21	29682-29692	associated	_	
179-22	29693-29697	with	_	
179-23	29698-29707	substance	_	
179-24	29708-29711	use	_	
179-25	29712-29716	risk	_	
179-26	29717-29720	may	_	
179-27	29721-29728	involve	_	
179-28	29729-29731	an	_	
179-29	29732-29743	interaction	_	
179-30	29744-29751	between	_	
179-31	29752-29758	stable	_	
179-32	29759-29770	trait-level	_	
179-33	29771-29782	differences	_	
179-34	29783-29786	and	_	
179-35	29787-29800	developmental	_	
179-36	29801-29810	processes	_	
179-37	29810-29811	.	_	

#Text=Given that the groups were significantly different on many neurocognitive measures while covarying SES and externalizing symptoms, this neurodevelopmental risk may be relatively distinct from demographic factors.
180-1	29812-29817	Given	_	
180-2	29818-29822	that	_	
180-3	29823-29826	the	_	
180-4	29827-29833	groups	_	
180-5	29834-29838	were	_	
180-6	29839-29852	significantly	_	
180-7	29853-29862	different	_	
180-8	29863-29865	on	_	
180-9	29866-29870	many	_	
180-10	29871-29885	neurocognitive	_	
180-11	29886-29894	measures	_	
180-12	29895-29900	while	_	
180-13	29901-29910	covarying	_	
180-14	29911-29914	SES	_	
180-15	29915-29918	and	_	
180-16	29919-29932	externalizing	_	
180-17	29933-29941	symptoms	_	
180-18	29941-29942	,	_	
180-19	29943-29947	this	_	
180-20	29948-29966	neurodevelopmental	_	
180-21	29967-29971	risk	_	
180-22	29972-29975	may	_	
180-23	29976-29978	be	_	
180-24	29979-29989	relatively	_	
180-25	29990-29998	distinct	_	
180-26	29999-30003	from	_	
180-27	30004-30015	demographic	_	
180-28	30016-30023	factors	_	
180-29	30023-30024	.	_	

#Text=However, further prospective longitudinal neuroimaging research with deep phenotyping and larger samples is needed to examine whether neurodevelopment of frontoparietal BOLD serves as a further risk and/or protective factor in the pathway from demographic factors to substance use initiation.
181-1	30025-30032	However	_	
181-2	30032-30033	,	_	
181-3	30034-30041	further	_	
181-4	30042-30053	prospective	_	
181-5	30054-30066	longitudinal	_	
181-6	30067-30079	neuroimaging	_	
181-7	30080-30088	research	_	
181-8	30089-30093	with	_	
181-9	30094-30098	deep	_	
181-10	30099-30110	phenotyping	_	
181-11	30111-30114	and	_	
181-12	30115-30121	larger	_	
181-13	30122-30129	samples	_	
181-14	30130-30132	is	_	
181-15	30133-30139	needed	_	
181-16	30140-30142	to	_	
181-17	30143-30150	examine	_	
181-18	30151-30158	whether	_	
181-19	30159-30175	neurodevelopment	_	
181-20	30176-30178	of	_	
181-21	30179-30193	frontoparietal	_	
181-22	30194-30198	BOLD	_	
181-23	30199-30205	serves	_	
181-24	30206-30208	as	_	
181-25	30209-30210	a	_	
181-26	30211-30218	further	_	
181-27	30219-30223	risk	_	
181-28	30224-30227	and	_	
181-29	30227-30228	/	_	
181-30	30228-30230	or	_	
181-31	30231-30241	protective	_	
181-32	30242-30248	factor	_	
181-33	30249-30251	in	_	
181-34	30252-30255	the	_	
181-35	30256-30263	pathway	_	
181-36	30264-30268	from	_	
181-37	30269-30280	demographic	_	
181-38	30281-30288	factors	_	
181-39	30289-30291	to	_	
181-40	30292-30301	substance	_	
181-41	30302-30305	use	_	
181-42	30306-30316	initiation	_	
181-43	30316-30317	.	_	

#Text=Finally, in the current sample, BOLD activation and cognitive performance differences were more strongly associated with risk for cannabis initiation rather than alcohol initiation.
182-1	30318-30325	Finally	_	
182-2	30325-30326	,	_	
182-3	30327-30329	in	_	
182-4	30330-30333	the	_	
182-5	30334-30341	current	_	
182-6	30342-30348	sample	_	
182-7	30348-30349	,	_	
182-8	30350-30354	BOLD	_	
182-9	30355-30365	activation	_	
182-10	30366-30369	and	_	
182-11	30370-30379	cognitive	_	
182-12	30380-30391	performance	_	
182-13	30392-30403	differences	_	
182-14	30404-30408	were	_	
182-15	30409-30413	more	_	
182-16	30414-30422	strongly	_	
182-17	30423-30433	associated	_	
182-18	30434-30438	with	_	
182-19	30439-30443	risk	_	
182-20	30444-30447	for	_	
182-21	30448-30456	cannabis	_	
182-22	30457-30467	initiation	_	
182-23	30468-30474	rather	_	
182-24	30475-30479	than	_	
182-25	30480-30487	alcohol	_	
182-26	30488-30498	initiation	_	
182-27	30498-30499	.	_	

#Text=This is unexpected because cannabis and alcohol initiation typically share cognitive risk factors.
183-1	30500-30504	This	_	
183-2	30505-30507	is	_	
183-3	30508-30518	unexpected	_	
183-4	30519-30526	because	_	
183-5	30527-30535	cannabis	_	
183-6	30536-30539	and	_	
183-7	30540-30547	alcohol	_	
183-8	30548-30558	initiation	_	
183-9	30559-30568	typically	_	
183-10	30569-30574	share	_	
183-11	30575-30584	cognitive	_	
183-12	30585-30589	risk	_	
183-13	30590-30597	factors	_	
183-14	30597-30598	.	_	

#Text=However, it is worth noting that access to alcohol is generally greater than access to cannabis during adolescence.
184-1	30599-30606	However	_	
184-2	30606-30607	,	_	
184-3	30608-30610	it	_	
184-4	30611-30613	is	_	
184-5	30614-30619	worth	_	
184-6	30620-30626	noting	_	
184-7	30627-30631	that	_	
184-8	30632-30638	access	_	
184-9	30639-30641	to	_	
184-10	30642-30649	alcohol	_	
184-11	30650-30652	is	_	
184-12	30653-30662	generally	_	
184-13	30663-30670	greater	_	
184-14	30671-30675	than	_	
184-15	30676-30682	access	_	
184-16	30683-30685	to	_	
184-17	30686-30694	cannabis	_	
184-18	30695-30701	during	_	
184-19	30702-30713	adolescence	_	
184-20	30713-30714	.	_	

#Text=Accordingly, cannabis use during early adolescence may be a stronger indicator of substance use severity.
185-1	30715-30726	Accordingly	_	
185-2	30726-30727	,	_	
185-3	30728-30736	cannabis	_	
185-4	30737-30740	use	_	
185-5	30741-30747	during	_	
185-6	30748-30753	early	_	
185-7	30754-30765	adolescence	_	
185-8	30766-30769	may	_	
185-9	30770-30772	be	_	
185-10	30773-30774	a	_	
185-11	30775-30783	stronger	_	
185-12	30784-30793	indicator	_	
185-13	30794-30796	of	_	
185-14	30797-30806	substance	_	
185-15	30807-30810	use	_	
185-16	30811-30819	severity	_	
185-17	30819-30820	.	_	

#Text=Nevertheless, given the high overlap in alcohol and cannabis initiation in our sample, the reported neurocognitive differences may support a model of general substance use risk.
186-1	30821-30833	Nevertheless	_	
186-2	30833-30834	,	_	
186-3	30835-30840	given	_	
186-4	30841-30844	the	_	
186-5	30845-30849	high	_	
186-6	30850-30857	overlap	_	
186-7	30858-30860	in	_	
186-8	30861-30868	alcohol	_	
186-9	30869-30872	and	_	
186-10	30873-30881	cannabis	_	
186-11	30882-30892	initiation	_	
186-12	30893-30895	in	_	
186-13	30896-30899	our	_	
186-14	30900-30906	sample	_	
186-15	30906-30907	,	_	
186-16	30908-30911	the	_	
186-17	30912-30920	reported	_	
186-18	30921-30935	neurocognitive	_	
186-19	30936-30947	differences	_	
186-20	30948-30951	may	_	
186-21	30952-30959	support	_	
186-22	30960-30961	a	_	
186-23	30962-30967	model	_	
186-24	30968-30970	of	_	
186-25	30971-30978	general	_	
186-26	30979-30988	substance	_	
186-27	30989-30992	use	_	
186-28	30993-30997	risk	_	
186-29	30997-30998	.	_	

#Text=Fully distinguishing substance-specific risk factors will require larger samples of subjects who initiate one but not both drugs.
187-1	30999-31004	Fully	_	
187-2	31005-31019	distinguishing	_	
187-3	31020-31038	substance-specific	_	
187-4	31039-31043	risk	_	
187-5	31044-31051	factors	_	
187-6	31052-31056	will	_	
187-7	31057-31064	require	_	
187-8	31065-31071	larger	_	
187-9	31072-31079	samples	_	
187-10	31080-31082	of	_	
187-11	31083-31091	subjects	_	
187-12	31092-31095	who	_	
187-13	31096-31104	initiate	_	
187-14	31105-31108	one	_	
187-15	31109-31112	but	_	
187-16	31113-31116	not	_	
187-17	31117-31121	both	_	
187-18	31122-31127	drugs	_	
187-19	31127-31128	.	_	

#Text=Future work may also examine latent dimensions of substance use to address the specificity and generality of brain-based predictors of cannabis use.
188-1	31129-31135	Future	_	
188-2	31136-31140	work	_	
188-3	31141-31144	may	_	
188-4	31145-31149	also	_	
188-5	31150-31157	examine	_	
188-6	31158-31164	latent	_	
188-7	31165-31175	dimensions	_	
188-8	31176-31178	of	_	
188-9	31179-31188	substance	_	
188-10	31189-31192	use	_	
188-11	31193-31195	to	_	
188-12	31196-31203	address	_	
188-13	31204-31207	the	_	
188-14	31208-31219	specificity	_	
188-15	31220-31223	and	_	
188-16	31224-31234	generality	_	
188-17	31235-31237	of	_	
188-18	31238-31249	brain-based	_	
188-19	31250-31260	predictors	_	
188-20	31261-31263	of	_	
188-21	31264-31272	cannabis	_	
188-22	31273-31276	use	_	
188-23	31276-31277	.	_	

#Text=Neurocognitive Development and Early Cannabis Initiation
#Text=The consistency of our results from baseline to follow-up and a lack of group differences in behavioral development do not support the idea that early cannabis initiation alone predicts cognitive dysfunction by 15 years of age.
189-1	31278-31292	Neurocognitive	_	
189-2	31293-31304	Development	_	
189-3	31305-31308	and	_	
189-4	31309-31314	Early	_	
189-5	31315-31323	Cannabis	_	
189-6	31324-31334	Initiation	_	
189-7	31335-31338	The	_	
189-8	31339-31350	consistency	_	
189-9	31351-31353	of	_	
189-10	31354-31357	our	_	
189-11	31358-31365	results	_	
189-12	31366-31370	from	_	
189-13	31371-31379	baseline	_	
189-14	31380-31382	to	_	
189-15	31383-31392	follow-up	_	
189-16	31393-31396	and	_	
189-17	31397-31398	a	_	
189-18	31399-31403	lack	_	
189-19	31404-31406	of	_	
189-20	31407-31412	group	_	
189-21	31413-31424	differences	_	
189-22	31425-31427	in	_	
189-23	31428-31438	behavioral	_	
189-24	31439-31450	development	_	
189-25	31451-31453	do	_	
189-26	31454-31457	not	_	
189-27	31458-31465	support	_	
189-28	31466-31469	the	_	
189-29	31470-31474	idea	_	
189-30	31475-31479	that	_	
189-31	31480-31485	early	_	
189-32	31486-31494	cannabis	_	
189-33	31495-31505	initiation	_	
189-34	31506-31511	alone	_	
189-35	31512-31520	predicts	_	
189-36	31521-31530	cognitive	_	
189-37	31531-31542	dysfunction	_	
189-38	31543-31545	by	_	
189-39	31546-31548	15	_	
189-40	31549-31554	years	_	
189-41	31555-31557	of	_	
189-42	31558-31561	age	_	
189-43	31561-31562	.	_	

#Text=In addition, the amount of reported cannabis use was not associated with behavioral performance.
190-1	31563-31565	In	_	
190-2	31566-31574	addition	_	
190-3	31574-31575	,	_	
190-4	31576-31579	the	_	
190-5	31580-31586	amount	_	
190-6	31587-31589	of	_	
190-7	31590-31598	reported	_	
190-8	31599-31607	cannabis	_	
190-9	31608-31611	use	_	
190-10	31612-31615	was	_	
190-11	31616-31619	not	_	
190-12	31620-31630	associated	_	
190-13	31631-31635	with	_	
190-14	31636-31646	behavioral	_	
190-15	31647-31658	performance	_	
190-16	31658-31659	.	_	

#Text=In contrast to behavior, brain activation differences were suggestive of possible outcomes of cannabis use.
191-1	31660-31662	In	_	
191-2	31663-31671	contrast	_	
191-3	31672-31674	to	_	
191-4	31675-31683	behavior	_	
191-5	31683-31684	,	_	
191-6	31685-31690	brain	_	
191-7	31691-31701	activation	_	
191-8	31702-31713	differences	_	
191-9	31714-31718	were	_	
191-10	31719-31729	suggestive	_	
191-11	31730-31732	of	_	
191-12	31733-31741	possible	_	
191-13	31742-31750	outcomes	_	
191-14	31751-31753	of	_	
191-15	31754-31762	cannabis	_	
191-16	31763-31766	use	_	
191-17	31766-31767	.	_	

#Text=A significant dose-response relationship was found in cuneus activity at follow-up, where greater deactivation was associated with greater cannabis use.
192-1	31768-31769	A	_	
192-2	31770-31781	significant	_	
192-3	31782-31795	dose-response	_	
192-4	31796-31808	relationship	_	
192-5	31809-31812	was	_	
192-6	31813-31818	found	_	
192-7	31819-31821	in	_	
192-8	31822-31828	cuneus	_	
192-9	31829-31837	activity	_	
192-10	31838-31840	at	_	
192-11	31841-31850	follow-up	_	
192-12	31850-31851	,	_	
192-13	31852-31857	where	_	
192-14	31858-31865	greater	_	
192-15	31866-31878	deactivation	_	
192-16	31879-31882	was	_	
192-17	31883-31893	associated	_	
192-18	31894-31898	with	_	
192-19	31899-31906	greater	_	
192-20	31907-31915	cannabis	_	
192-21	31916-31919	use	_	
192-22	31919-31920	.	_	

#Text=These results are consistent with work demonstrating differential cuneus activation between abstinent adolescent marijuana users and control subjects and adult daily marijuana users and control subjects.
193-1	31921-31926	These	_	
193-2	31927-31934	results	_	
193-3	31935-31938	are	_	
193-4	31939-31949	consistent	_	
193-5	31950-31954	with	_	
193-6	31955-31959	work	_	
193-7	31960-31973	demonstrating	_	
193-8	31974-31986	differential	_	
193-9	31987-31993	cuneus	_	
193-10	31994-32004	activation	_	
193-11	32005-32012	between	_	
193-12	32013-32022	abstinent	_	
193-13	32023-32033	adolescent	_	
193-14	32034-32043	marijuana	_	
193-15	32044-32049	users	_	
193-16	32050-32053	and	_	
193-17	32054-32061	control	_	
193-18	32062-32070	subjects	_	
193-19	32071-32074	and	_	
193-20	32075-32080	adult	_	
193-21	32081-32086	daily	_	
193-22	32087-32096	marijuana	_	
193-23	32097-32102	users	_	
193-24	32103-32106	and	_	
193-25	32107-32114	control	_	
193-26	32115-32123	subjects	_	
193-27	32123-32124	.	_	

#Text=Furthermore, a recent pharmacological fMRI study showed that cuneus activity is modulated by THC administration.
194-1	32125-32136	Furthermore	_	
194-2	32136-32137	,	_	
194-3	32138-32139	a	_	
194-4	32140-32146	recent	_	
194-5	32147-32162	pharmacological	_	
194-6	32163-32167	fMRI	_	
194-7	32168-32173	study	_	
194-8	32174-32180	showed	_	
194-9	32181-32185	that	_	
194-10	32186-32192	cuneus	_	
194-11	32193-32201	activity	_	
194-12	32202-32204	is	_	
194-13	32205-32214	modulated	_	
194-14	32215-32217	by	_	
194-15	32218-32221	THC	_	
194-16	32222-32236	administration	_	
194-17	32236-32237	.	_	

#Text=However, given differences in reporting deactivation, it is difficult to determine whether the direction of effects is consistent across studies.
195-1	32238-32245	However	_	
195-2	32245-32246	,	_	
195-3	32247-32252	given	_	
195-4	32253-32264	differences	_	
195-5	32265-32267	in	_	
195-6	32268-32277	reporting	_	
195-7	32278-32290	deactivation	_	
195-8	32290-32291	,	_	
195-9	32292-32294	it	_	
195-10	32295-32297	is	_	
195-11	32298-32307	difficult	_	
195-12	32308-32310	to	_	
195-13	32311-32320	determine	_	
195-14	32321-32328	whether	_	
195-15	32329-32332	the	_	
195-16	32333-32342	direction	_	
195-17	32343-32345	of	_	
195-18	32346-32353	effects	_	
195-19	32354-32356	is	_	
195-20	32357-32367	consistent	_	
195-21	32368-32374	across	_	
195-22	32375-32382	studies	_	
195-23	32382-32383	.	_	

#Text=Furthermore, in this study, cuneus activity was not associated with cognitive performance.
196-1	32384-32395	Furthermore	_	
196-2	32395-32396	,	_	
196-3	32397-32399	in	_	
196-4	32400-32404	this	_	
196-5	32405-32410	study	_	
196-6	32410-32411	,	_	
196-7	32412-32418	cuneus	_	
196-8	32419-32427	activity	_	
196-9	32428-32431	was	_	
196-10	32432-32435	not	_	
196-11	32436-32446	associated	_	
196-12	32447-32451	with	_	
196-13	32452-32461	cognitive	_	
196-14	32462-32473	performance	_	
196-15	32473-32474	.	_	

#Text=Accordingly, the functional impact of dose-dependent changes in cuneus activation remains unclear.
197-1	32475-32486	Accordingly	_	
197-2	32486-32487	,	_	
197-3	32488-32491	the	_	
197-4	32492-32502	functional	_	
197-5	32503-32509	impact	_	
197-6	32510-32512	of	_	
197-7	32513-32527	dose-dependent	_	
197-8	32528-32535	changes	_	
197-9	32536-32538	in	_	
197-10	32539-32545	cuneus	_	
197-11	32546-32556	activation	_	
197-12	32557-32564	remains	_	
197-13	32565-32572	unclear	_	
197-14	32572-32573	.	_	

#Text=Limitations
#Text=While the current study has a relatively large sample size for a neuroimaging study, it is small compared to epidemiological studies such as that by Miech et al..
198-1	32574-32585	Limitations	_	
198-2	32586-32591	While	_	
198-3	32592-32595	the	_	
198-4	32596-32603	current	_	
198-5	32604-32609	study	_	
198-6	32610-32613	has	_	
198-7	32614-32615	a	_	
198-8	32616-32626	relatively	_	
198-9	32627-32632	large	_	
198-10	32633-32639	sample	_	
198-11	32640-32644	size	_	
198-12	32645-32648	for	_	
198-13	32649-32650	a	_	
198-14	32651-32663	neuroimaging	_	
198-15	32664-32669	study	_	
198-16	32669-32670	,	_	
198-17	32671-32673	it	_	
198-18	32674-32676	is	_	
198-19	32677-32682	small	_	
198-20	32683-32691	compared	_	
198-21	32692-32694	to	_	
198-22	32695-32710	epidemiological	_	
198-23	32711-32718	studies	_	
198-24	32719-32723	such	_	
198-25	32724-32726	as	_	
198-26	32727-32731	that	_	
198-27	32732-32734	by	_	
198-28	32735-32740	Miech	_	
198-29	32741-32743	et	_	
198-30	32744-32746	al	_	
198-31	32746-32747	.	_	
198-32	32747-32748	.	_	

#Text=In addition, within our sample, cannabis use was low relative to other high-risk behavioral cohorts; comparing use with other neuroimaging samples is difficult, with the literature including a range of cannabis use severity.
199-1	32749-32751	In	_	
199-2	32752-32760	addition	_	
199-3	32760-32761	,	_	
199-4	32762-32768	within	_	
199-5	32769-32772	our	_	
199-6	32773-32779	sample	_	
199-7	32779-32780	,	_	
199-8	32781-32789	cannabis	_	
199-9	32790-32793	use	_	
199-10	32794-32797	was	_	
199-11	32798-32801	low	_	
199-12	32802-32810	relative	_	
199-13	32811-32813	to	_	
199-14	32814-32819	other	_	
199-15	32820-32829	high-risk	_	
199-16	32830-32840	behavioral	_	
199-17	32841-32848	cohorts	_	
199-18	32848-32849	;	_	
199-19	32850-32859	comparing	_	
199-20	32860-32863	use	_	
199-21	32864-32868	with	_	
199-22	32869-32874	other	_	
199-23	32875-32887	neuroimaging	_	
199-24	32888-32895	samples	_	
199-25	32896-32898	is	_	
199-26	32899-32908	difficult	_	
199-27	32908-32909	,	_	
199-28	32910-32914	with	_	
199-29	32915-32918	the	_	
199-30	32919-32929	literature	_	
199-31	32930-32939	including	_	
199-32	32940-32941	a	_	
199-33	32942-32947	range	_	
199-34	32948-32950	of	_	
199-35	32951-32959	cannabis	_	
199-36	32960-32963	use	_	
199-37	32964-32972	severity	_	
199-38	32972-32973	.	_	

#Text=We attempted to address this possible limitation by estimating continuous associations with cannabis dose using robust regression, although there was significant variability in reported cannabis dose and a small number of subjects with relatively higher cannabis use.
200-1	32974-32976	We	_	
200-2	32977-32986	attempted	_	
200-3	32987-32989	to	_	
200-4	32990-32997	address	_	
200-5	32998-33002	this	_	
200-6	33003-33011	possible	_	
200-7	33012-33022	limitation	_	
200-8	33023-33025	by	_	
200-9	33026-33036	estimating	_	
200-10	33037-33047	continuous	_	
200-11	33048-33060	associations	_	
200-12	33061-33065	with	_	
200-13	33066-33074	cannabis	_	
200-14	33075-33079	dose	_	
200-15	33080-33085	using	_	
200-16	33086-33092	robust	_	
200-17	33093-33103	regression	_	
200-18	33103-33104	,	_	
200-19	33105-33113	although	_	
200-20	33114-33119	there	_	
200-21	33120-33123	was	_	
200-22	33124-33135	significant	_	
200-23	33136-33147	variability	_	
200-24	33148-33150	in	_	
200-25	33151-33159	reported	_	
200-26	33160-33168	cannabis	_	
200-27	33169-33173	dose	_	
200-28	33174-33177	and	_	
200-29	33178-33179	a	_	
200-30	33180-33185	small	_	
200-31	33186-33192	number	_	
200-32	33193-33195	of	_	
200-33	33196-33204	subjects	_	
200-34	33205-33209	with	_	
200-35	33210-33220	relatively	_	
200-36	33221-33227	higher	_	
200-37	33228-33236	cannabis	_	
200-38	33237-33240	use	_	
200-39	33240-33241	.	_	

#Text=Accordingly, it is possible that greater evidence for cannabis effects would have been observed with a larger sample and greater cannabis exposure, particularly if exposure effects require a minimal threshold of use.
201-1	33242-33253	Accordingly	_	
201-2	33253-33254	,	_	
201-3	33255-33257	it	_	
201-4	33258-33260	is	_	
201-5	33261-33269	possible	_	
201-6	33270-33274	that	_	
201-7	33275-33282	greater	_	
201-8	33283-33291	evidence	_	
201-9	33292-33295	for	_	
201-10	33296-33304	cannabis	_	
201-11	33305-33312	effects	_	
201-12	33313-33318	would	_	
201-13	33319-33323	have	_	
201-14	33324-33328	been	_	
201-15	33329-33337	observed	_	
201-16	33338-33342	with	_	
201-17	33343-33344	a	_	
201-18	33345-33351	larger	_	
201-19	33352-33358	sample	_	
201-20	33359-33362	and	_	
201-21	33363-33370	greater	_	
201-22	33371-33379	cannabis	_	
201-23	33380-33388	exposure	_	
201-24	33388-33389	,	_	
201-25	33390-33402	particularly	_	
201-26	33403-33405	if	_	
201-27	33406-33414	exposure	_	
201-28	33415-33422	effects	_	
201-29	33423-33430	require	_	
201-30	33431-33432	a	_	
201-31	33433-33440	minimal	_	
201-32	33441-33450	threshold	_	
201-33	33451-33453	of	_	
201-34	33454-33457	use	_	
201-35	33457-33458	.	_	

#Text=It is also worth noting that adolescents may under- and overreport substance use.
202-1	33459-33461	It	_	
202-2	33462-33464	is	_	
202-3	33465-33469	also	_	
202-4	33470-33475	worth	_	
202-5	33476-33482	noting	_	
202-6	33483-33487	that	_	
202-7	33488-33499	adolescents	_	
202-8	33500-33503	may	_	
202-9	33504-33509	under	_	
202-10	33509-33510	-	_	
202-11	33511-33514	and	_	
202-12	33515-33525	overreport	_	
202-13	33526-33535	substance	_	
202-14	33536-33539	use	_	
202-15	33539-33540	.	_	

#Text=We attempted to address this limitation by including a THC urine screen.
203-1	33541-33543	We	_	
203-2	33544-33553	attempted	_	
203-3	33554-33556	to	_	
203-4	33557-33564	address	_	
203-5	33565-33569	this	_	
203-6	33570-33580	limitation	_	
203-7	33581-33583	by	_	
203-8	33584-33593	including	_	
203-9	33594-33595	a	_	
203-10	33596-33599	THC	_	
203-11	33600-33605	urine	_	
203-12	33606-33612	screen	_	
203-13	33612-33613	.	_	

#Text=However, future work may incorporate multi-informant substance use assessment and target more high-use populations.
204-1	33614-33621	However	_	
204-2	33621-33622	,	_	
204-3	33623-33629	future	_	
204-4	33630-33634	work	_	
204-5	33635-33638	may	_	
204-6	33639-33650	incorporate	_	
204-7	33651-33666	multi-informant	_	
204-8	33667-33676	substance	_	
204-9	33677-33680	use	_	
204-10	33681-33691	assessment	_	
204-11	33692-33695	and	_	
204-12	33696-33702	target	_	
204-13	33703-33707	more	_	
204-14	33708-33716	high-use	_	
204-15	33717-33728	populations	_	
204-16	33728-33729	.	_	

#Text=Another potential limitation is the relatively short time period between cannabis onset and follow-up.
205-1	33730-33737	Another	_	
205-2	33738-33747	potential	_	
205-3	33748-33758	limitation	_	
205-4	33759-33761	is	_	
205-5	33762-33765	the	_	
205-6	33766-33776	relatively	_	
205-7	33777-33782	short	_	
205-8	33783-33787	time	_	
205-9	33788-33794	period	_	
205-10	33795-33802	between	_	
205-11	33803-33811	cannabis	_	
205-12	33812-33817	onset	_	
205-13	33818-33821	and	_	
205-14	33822-33831	follow-up	_	
205-15	33831-33832	.	_	

#Text=It is possible that cannabis use effects emerge after longer periods of development.
206-1	33833-33835	It	_	
206-2	33836-33838	is	_	
206-3	33839-33847	possible	_	
206-4	33848-33852	that	_	
206-5	33853-33861	cannabis	_	
206-6	33862-33865	use	_	
206-7	33866-33873	effects	_	
206-8	33874-33880	emerge	_	
206-9	33881-33886	after	_	
206-10	33887-33893	longer	_	
206-11	33894-33901	periods	_	
206-12	33902-33904	of	_	
206-13	33905-33916	development	_	
206-14	33916-33917	.	_	

#Text=Alternatively, early cannabis onset effects may be driven by an early user’s tendency to accrue more cumulative use, which is associated with cognitive performance.
207-1	33918-33931	Alternatively	_	
207-2	33931-33932	,	_	
207-3	33933-33938	early	_	
207-4	33939-33947	cannabis	_	
207-5	33948-33953	onset	_	
207-6	33954-33961	effects	_	
207-7	33962-33965	may	_	
207-8	33966-33968	be	_	
207-9	33969-33975	driven	_	
207-10	33976-33978	by	_	
207-11	33979-33981	an	_	
207-12	33982-33987	early	_	
207-13	33988-33992	user	_	
207-14	33992-33993	’	_	
207-15	33993-33994	s	_	
207-16	33995-34003	tendency	_	
207-17	34004-34006	to	_	
207-18	34007-34013	accrue	_	
207-19	34014-34018	more	_	
207-20	34019-34029	cumulative	_	
207-21	34030-34033	use	_	
207-22	34033-34034	,	_	
207-23	34035-34040	which	_	
207-24	34041-34043	is	_	
207-25	34044-34054	associated	_	
207-26	34055-34059	with	_	
207-27	34060-34069	cognitive	_	
207-28	34070-34081	performance	_	
207-29	34081-34082	.	_	

#Text=Accordingly, full characterization of cannabis onset effects requires prospective neuroimaging samples that extend into adulthood (e.g., the National Institutes of Health Adolescent Brain and Cognitive Development study).
208-1	34083-34094	Accordingly	_	
208-2	34094-34095	,	_	
208-3	34096-34100	full	_	
208-4	34101-34117	characterization	_	
208-5	34118-34120	of	_	
208-6	34121-34129	cannabis	_	
208-7	34130-34135	onset	_	
208-8	34136-34143	effects	_	
208-9	34144-34152	requires	_	
208-10	34153-34164	prospective	_	
208-11	34165-34177	neuroimaging	_	
208-12	34178-34185	samples	_	
208-13	34186-34190	that	_	
208-14	34191-34197	extend	_	
208-15	34198-34202	into	_	
208-16	34203-34212	adulthood	_	
208-17	34213-34214	(	_	
208-18	34214-34217	e.g	_	
208-19	34217-34218	.	_	
208-20	34218-34219	,	_	
208-21	34220-34223	the	_	
208-22	34224-34232	National	_	
208-23	34233-34243	Institutes	_	
208-24	34244-34246	of	_	
208-25	34247-34253	Health	_	
208-26	34254-34264	Adolescent	_	
208-27	34265-34270	Brain	_	
208-28	34271-34274	and	_	
208-29	34275-34284	Cognitive	_	
208-30	34285-34296	Development	_	
208-31	34297-34302	study	_	
208-32	34302-34303	)	_	
208-33	34303-34304	.	_	

#Text=Finally, our voxelwise analysis only included voxels that were reliably activated across both groups in the WM task.
209-1	34305-34312	Finally	_	
209-2	34312-34313	,	_	
209-3	34314-34317	our	_	
209-4	34318-34327	voxelwise	_	
209-5	34328-34336	analysis	_	
209-6	34337-34341	only	_	
209-7	34342-34350	included	_	
209-8	34351-34357	voxels	_	
209-9	34358-34362	that	_	
209-10	34363-34367	were	_	
209-11	34368-34376	reliably	_	
209-12	34377-34386	activated	_	
209-13	34387-34393	across	_	
209-14	34394-34398	both	_	
209-15	34399-34405	groups	_	
209-16	34406-34408	in	_	
209-17	34409-34412	the	_	
209-18	34413-34415	WM	_	
209-19	34416-34420	task	_	
209-20	34420-34421	.	_	

#Text=However, it is possible that some voxels were moderately active during the WM task in one group but not the other.
210-1	34422-34429	However	_	
210-2	34429-34430	,	_	
210-3	34431-34433	it	_	
210-4	34434-34436	is	_	
210-5	34437-34445	possible	_	
210-6	34446-34450	that	_	
210-7	34451-34455	some	_	
210-8	34456-34462	voxels	_	
210-9	34463-34467	were	_	
210-10	34468-34478	moderately	_	
210-11	34479-34485	active	_	
210-12	34486-34492	during	_	
210-13	34493-34496	the	_	
210-14	34497-34499	WM	_	
210-15	34500-34504	task	_	
210-16	34505-34507	in	_	
210-17	34508-34511	one	_	
210-18	34512-34517	group	_	
210-19	34518-34521	but	_	
210-20	34522-34525	not	_	
210-21	34526-34529	the	_	
210-22	34530-34535	other	_	
210-23	34535-34536	.	_	

#Text=Future work may use multiple tasks to assess cognitive functions drawing on a wider array of brain regions reliably activated across groups.
211-1	34537-34543	Future	_	
211-2	34544-34548	work	_	
211-3	34549-34552	may	_	
211-4	34553-34556	use	_	
211-5	34557-34565	multiple	_	
211-6	34566-34571	tasks	_	
211-7	34572-34574	to	_	
211-8	34575-34581	assess	_	
211-9	34582-34591	cognitive	_	
211-10	34592-34601	functions	_	
211-11	34602-34609	drawing	_	
211-12	34610-34612	on	_	
211-13	34613-34614	a	_	
211-14	34615-34620	wider	_	
211-15	34621-34626	array	_	
211-16	34627-34629	of	_	
211-17	34630-34635	brain	_	
211-18	34636-34643	regions	_	
211-19	34644-34652	reliably	_	
211-20	34653-34662	activated	_	
211-21	34663-34669	across	_	
211-22	34670-34676	groups	_	
211-23	34676-34677	.	_	

#Text=Conclusions
#Text=We provide evidence for preexisting neurocognitive differences in early onset cannabis users, in whom brain activation differences and cognitive performance measures previously associated with cannabis use are present before initiation.
212-1	34678-34689	Conclusions	_	
212-2	34690-34692	We	_	
212-3	34693-34700	provide	_	
212-4	34701-34709	evidence	_	
212-5	34710-34713	for	_	
212-6	34714-34725	preexisting	_	
212-7	34726-34740	neurocognitive	_	
212-8	34741-34752	differences	_	
212-9	34753-34755	in	_	
212-10	34756-34761	early	_	
212-11	34762-34767	onset	_	
212-12	34768-34776	cannabis	_	
212-13	34777-34782	users	_	
212-14	34782-34783	,	_	
212-15	34784-34786	in	_	
212-16	34787-34791	whom	_	
212-17	34792-34797	brain	_	
212-18	34798-34808	activation	_	
212-19	34809-34820	differences	_	
212-20	34821-34824	and	_	
212-21	34825-34834	cognitive	_	
212-22	34835-34846	performance	_	
212-23	34847-34855	measures	_	
212-24	34856-34866	previously	_	
212-25	34867-34877	associated	_	
212-26	34878-34882	with	_	
212-27	34883-34891	cannabis	_	
212-28	34892-34895	use	_	
212-29	34896-34899	are	_	
212-30	34900-34907	present	_	
212-31	34908-34914	before	_	
212-32	34915-34925	initiation	_	
212-33	34925-34926	.	_	

#Text=Negative outcomes of early cannabis initiation on behavior by 15 years of age were not supported, but a dose-response relationship was observed in cuneus activation.
213-1	34927-34935	Negative	_	
213-2	34936-34944	outcomes	_	
213-3	34945-34947	of	_	
213-4	34948-34953	early	_	
213-5	34954-34962	cannabis	_	
213-6	34963-34973	initiation	_	
213-7	34974-34976	on	_	
213-8	34977-34985	behavior	_	
213-9	34986-34988	by	_	
213-10	34989-34991	15	_	
213-11	34992-34997	years	_	
213-12	34998-35000	of	_	
213-13	35001-35004	age	_	
213-14	35005-35009	were	_	
213-15	35010-35013	not	_	
213-16	35014-35023	supported	_	
213-17	35023-35024	,	_	
213-18	35025-35028	but	_	
213-19	35029-35030	a	_	
213-20	35031-35044	dose-response	_	
213-21	35045-35057	relationship	_	
213-22	35058-35061	was	_	
213-23	35062-35070	observed	_	
213-24	35071-35073	in	_	
213-25	35074-35080	cuneus	_	
213-26	35081-35091	activation	_	
213-27	35091-35092	.	_	

#Text=Supplementary Material
#Text=Supplementary material cited in this article is available online at https://doi.org/10.1016/j.bpsc.2018.05.004.
214-1	35093-35106	Supplementary	_	
214-2	35107-35115	Material	_	
214-3	35116-35129	Supplementary	_	
214-4	35130-35138	material	_	
214-5	35139-35144	cited	_	
214-6	35145-35147	in	_	
214-7	35148-35152	this	_	
214-8	35153-35160	article	_	
214-9	35161-35163	is	_	
214-10	35164-35173	available	_	
214-11	35174-35180	online	_	
214-12	35181-35183	at	_	
214-13	35184-35189	https	_	
214-14	35189-35190	:	_	
214-15	35190-35191	/	_	
214-16	35191-35192	/	_	
214-17	35192-35199	doi.org	_	
214-18	35199-35200	/	_	
214-19	35200-35207	10.1016	_	
214-20	35207-35208	/	_	
214-21	35208-35214	j.bpsc	_	
214-22	35214-35226	.2018.05.004	_	
214-23	35226-35227	.	_	

#Text=REFERENCES
#Text=Development of cannabinoid 1 receptor protein and messenger RNA in monkey dorsolateral prefrontal cortex
#Text=Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system
#Text=Dynamic mapping of human cortical development during childhood through early adulthood
#Text=What has fMRI told us about the development of cognitive control through adolescence?
215-1	35228-35238	REFERENCES	_	
215-2	35239-35250	Development	_	
215-3	35251-35253	of	_	
215-4	35254-35265	cannabinoid	_	
215-5	35266-35267	1	_	
215-6	35268-35276	receptor	_	
215-7	35277-35284	protein	_	
215-8	35285-35288	and	_	
215-9	35289-35298	messenger	_	
215-10	35299-35302	RNA	_	
215-11	35303-35305	in	_	
215-12	35306-35312	monkey	_	
215-13	35313-35325	dorsolateral	_	
215-14	35326-35336	prefrontal	_	
215-15	35337-35343	cortex	_	
215-16	35344-35363	Immunohistochemical	_	
215-17	35364-35376	distribution	_	
215-18	35377-35379	of	_	
215-19	35380-35391	cannabinoid	_	
215-20	35392-35395	CB1	_	
215-21	35396-35405	receptors	_	
215-22	35406-35408	in	_	
215-23	35409-35412	the	_	
215-24	35413-35416	rat	_	
215-25	35417-35424	central	_	
215-26	35425-35432	nervous	_	
215-27	35433-35439	system	_	
215-28	35440-35447	Dynamic	_	
215-29	35448-35455	mapping	_	
215-30	35456-35458	of	_	
215-31	35459-35464	human	_	
215-32	35465-35473	cortical	_	
215-33	35474-35485	development	_	
215-34	35486-35492	during	_	
215-35	35493-35502	childhood	_	
215-36	35503-35510	through	_	
215-37	35511-35516	early	_	
215-38	35517-35526	adulthood	_	
215-39	35527-35531	What	_	
215-40	35532-35535	has	_	
215-41	35536-35540	fMRI	_	
215-42	35541-35545	told	_	
215-43	35546-35548	us	_	
215-44	35549-35554	about	_	
215-45	35555-35558	the	_	
215-46	35559-35570	development	_	
215-47	35571-35573	of	_	
215-48	35574-35583	cognitive	_	
215-49	35584-35591	control	_	
215-50	35592-35599	through	_	
215-51	35600-35611	adolescence	_	
215-52	35611-35612	?	_	

#Text=An integrative model of the maturation of cognitive control
#Text=Early-onset cannabis use and cognitive deficits: What is the nature of the association?
216-1	35613-35615	An	_	
216-2	35616-35627	integrative	_	
216-3	35628-35633	model	_	
216-4	35634-35636	of	_	
216-5	35637-35640	the	_	
216-6	35641-35651	maturation	_	
216-7	35652-35654	of	_	
216-8	35655-35664	cognitive	_	
216-9	35665-35672	control	_	
216-10	35673-35684	Early-onset	_	
216-11	35685-35693	cannabis	_	
216-12	35694-35697	use	_	
216-13	35698-35701	and	_	
216-14	35702-35711	cognitive	_	
216-15	35712-35720	deficits	_	
216-16	35720-35721	:	_	
216-17	35722-35726	What	_	
216-18	35727-35729	is	_	
216-19	35730-35733	the	_	
216-20	35734-35740	nature	_	
216-21	35741-35743	of	_	
216-22	35744-35747	the	_	
216-23	35748-35759	association	_	
216-24	35759-35760	?	_	

#Text=The impact of early-onset cannabis use on functional brain correlates of working memory
#Text=Specific attentional dysfunction in adults following early start of cannabis use
#Text=Neuropsychological deficits associated with cannabis use in young adults
#Text=Cannabis use before age 15 and subsequent executive functioning
#Text=Abstinent adolescent marijuana users show altered fMRI response during spatial working memory
#Text=Functional brain organization of working memory in adolescents varies in relation to family income and academic achievement
#Text=Data-driven phenotypic categorization for neurobiological analyses: Beyond DSM-5 labels
#Text=Neural correlates of rewarded response inhibition in youth at risk for problematic alcohol use
#Text=Impact of adolescent marijuana use on intelligence: Results from two longitudinal twin studies
#Text=Adolescent cannabis use and brain systems supporting adult working memory encoding, maintenance, and retrieval
#Text=The Mini-International Neuropsychiatric Interview (MINI): The development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10
#Text=Prenatal marijuana exposure contributes to the prediction of marijuana use at age 14
#Text=
#Text=
#Text=
#Text=Statistical improvements in functional magnetic resonance imaging analyses produced by censoring high-motion data points
#Text=Applications of multivariate modeling to neuroimaging group analysis: A comprehensive alternative to univariate general linear model
#Text=
#Text=Marijuana use is associated with a reorganized visual-attention network and cerebellar hypoactivation
#Text=Prefrontal activity during working memory is modulated by the interaction of variation in CB1 and COX2 coding genes and correlates with frequency of cannabis use
#Text=Origins and consequences of age at first drink.
217-1	35761-35764	The	_	
217-2	35765-35771	impact	_	
217-3	35772-35774	of	_	
217-4	35775-35786	early-onset	_	
217-5	35787-35795	cannabis	_	
217-6	35796-35799	use	_	
217-7	35800-35802	on	_	
217-8	35803-35813	functional	_	
217-9	35814-35819	brain	_	
217-10	35820-35830	correlates	_	
217-11	35831-35833	of	_	
217-12	35834-35841	working	_	
217-13	35842-35848	memory	_	
217-14	35849-35857	Specific	_	
217-15	35858-35869	attentional	_	
217-16	35870-35881	dysfunction	_	
217-17	35882-35884	in	_	
217-18	35885-35891	adults	_	
217-19	35892-35901	following	_	
217-20	35902-35907	early	_	
217-21	35908-35913	start	_	
217-22	35914-35916	of	_	
217-23	35917-35925	cannabis	_	
217-24	35926-35929	use	_	
217-25	35930-35948	Neuropsychological	_	
217-26	35949-35957	deficits	_	
217-27	35958-35968	associated	_	
217-28	35969-35973	with	_	
217-29	35974-35982	cannabis	_	
217-30	35983-35986	use	_	
217-31	35987-35989	in	_	
217-32	35990-35995	young	_	
217-33	35996-36002	adults	_	
217-34	36003-36011	Cannabis	_	
217-35	36012-36015	use	_	
217-36	36016-36022	before	_	
217-37	36023-36026	age	_	
217-38	36027-36029	15	_	
217-39	36030-36033	and	_	
217-40	36034-36044	subsequent	_	
217-41	36045-36054	executive	_	
217-42	36055-36066	functioning	_	
217-43	36067-36076	Abstinent	_	
217-44	36077-36087	adolescent	_	
217-45	36088-36097	marijuana	_	
217-46	36098-36103	users	_	
217-47	36104-36108	show	_	
217-48	36109-36116	altered	_	
217-49	36117-36121	fMRI	_	
217-50	36122-36130	response	_	
217-51	36131-36137	during	_	
217-52	36138-36145	spatial	_	
217-53	36146-36153	working	_	
217-54	36154-36160	memory	_	
217-55	36161-36171	Functional	_	
217-56	36172-36177	brain	_	
217-57	36178-36190	organization	_	
217-58	36191-36193	of	_	
217-59	36194-36201	working	_	
217-60	36202-36208	memory	_	
217-61	36209-36211	in	_	
217-62	36212-36223	adolescents	_	
217-63	36224-36230	varies	_	
217-64	36231-36233	in	_	
217-65	36234-36242	relation	_	
217-66	36243-36245	to	_	
217-67	36246-36252	family	_	
217-68	36253-36259	income	_	
217-69	36260-36263	and	_	
217-70	36264-36272	academic	_	
217-71	36273-36284	achievement	_	
217-72	36285-36296	Data-driven	_	
217-73	36297-36307	phenotypic	_	
217-74	36308-36322	categorization	_	
217-75	36323-36326	for	_	
217-76	36327-36342	neurobiological	_	
217-77	36343-36351	analyses	_	
217-78	36351-36352	:	_	
217-79	36353-36359	Beyond	_	
217-80	36360-36363	DSM	_	
217-81	36363-36364	-	_	
217-82	36364-36365	5	_	
217-83	36366-36372	labels	_	
217-84	36373-36379	Neural	_	
217-85	36380-36390	correlates	_	
217-86	36391-36393	of	_	
217-87	36394-36402	rewarded	_	
217-88	36403-36411	response	_	
217-89	36412-36422	inhibition	_	
217-90	36423-36425	in	_	
217-91	36426-36431	youth	_	
217-92	36432-36434	at	_	
217-93	36435-36439	risk	_	
217-94	36440-36443	for	_	
217-95	36444-36455	problematic	_	
217-96	36456-36463	alcohol	_	
217-97	36464-36467	use	_	
217-98	36468-36474	Impact	_	
217-99	36475-36477	of	_	
217-100	36478-36488	adolescent	_	
217-101	36489-36498	marijuana	_	
217-102	36499-36502	use	_	
217-103	36503-36505	on	_	
217-104	36506-36518	intelligence	_	
217-105	36518-36519	:	_	
217-106	36520-36527	Results	_	
217-107	36528-36532	from	_	
217-108	36533-36536	two	_	
217-109	36537-36549	longitudinal	_	
217-110	36550-36554	twin	_	
217-111	36555-36562	studies	_	
217-112	36563-36573	Adolescent	_	
217-113	36574-36582	cannabis	_	
217-114	36583-36586	use	_	
217-115	36587-36590	and	_	
217-116	36591-36596	brain	_	
217-117	36597-36604	systems	_	
217-118	36605-36615	supporting	_	
217-119	36616-36621	adult	_	
217-120	36622-36629	working	_	
217-121	36630-36636	memory	_	
217-122	36637-36645	encoding	_	
217-123	36645-36646	,	_	
217-124	36647-36658	maintenance	_	
217-125	36658-36659	,	_	
217-126	36660-36663	and	_	
217-127	36664-36673	retrieval	_	
217-128	36674-36677	The	_	
217-129	36678-36696	Mini-International	_	
217-130	36697-36713	Neuropsychiatric	_	
217-131	36714-36723	Interview	_	
217-132	36724-36725	(	_	
217-133	36725-36729	MINI	_	
217-134	36729-36730	)	_	
217-135	36730-36731	:	_	
217-136	36732-36735	The	_	
217-137	36736-36747	development	_	
217-138	36748-36751	and	_	
217-139	36752-36762	validation	_	
217-140	36763-36765	of	_	
217-141	36766-36767	a	_	
217-142	36768-36778	structured	_	
217-143	36779-36789	diagnostic	_	
217-144	36790-36801	psychiatric	_	
217-145	36802-36811	interview	_	
217-146	36812-36815	for	_	
217-147	36816-36822	DSM-IV	_	
217-148	36823-36826	and	_	
217-149	36827-36830	ICD	_	
217-150	36830-36831	-	_	
217-151	36831-36833	10	_	
217-152	36834-36842	Prenatal	_	
217-153	36843-36852	marijuana	_	
217-154	36853-36861	exposure	_	
217-155	36862-36873	contributes	_	
217-156	36874-36876	to	_	
217-157	36877-36880	the	_	
217-158	36881-36891	prediction	_	
217-159	36892-36894	of	_	
217-160	36895-36904	marijuana	_	
217-161	36905-36908	use	_	
217-162	36909-36911	at	_	
217-163	36912-36915	age	_	
217-164	36916-36918	14	_	
217-165	36922-36933	Statistical	_	
217-166	36934-36946	improvements	_	
217-167	36947-36949	in	_	
217-168	36950-36960	functional	_	
217-169	36961-36969	magnetic	_	
217-170	36970-36979	resonance	_	
217-171	36980-36987	imaging	_	
217-172	36988-36996	analyses	_	
217-173	36997-37005	produced	_	
217-174	37006-37008	by	_	
217-175	37009-37018	censoring	_	
217-176	37019-37030	high-motion	_	
217-177	37031-37035	data	_	
217-178	37036-37042	points	_	
217-179	37043-37055	Applications	_	
217-180	37056-37058	of	_	
217-181	37059-37071	multivariate	_	
217-182	37072-37080	modeling	_	
217-183	37081-37083	to	_	
217-184	37084-37096	neuroimaging	_	
217-185	37097-37102	group	_	
217-186	37103-37111	analysis	_	
217-187	37111-37112	:	_	
217-188	37113-37114	A	_	
217-189	37115-37128	comprehensive	_	
217-190	37129-37140	alternative	_	
217-191	37141-37143	to	_	
217-192	37144-37154	univariate	_	
217-193	37155-37162	general	_	
217-194	37163-37169	linear	_	
217-195	37170-37175	model	_	
217-196	37177-37186	Marijuana	_	
217-197	37187-37190	use	_	
217-198	37191-37193	is	_	
217-199	37194-37204	associated	_	
217-200	37205-37209	with	_	
217-201	37210-37211	a	_	
217-202	37212-37223	reorganized	_	
217-203	37224-37240	visual-attention	_	
217-204	37241-37248	network	_	
217-205	37249-37252	and	_	
217-206	37253-37263	cerebellar	_	
217-207	37264-37278	hypoactivation	_	
217-208	37279-37289	Prefrontal	_	
217-209	37290-37298	activity	_	
217-210	37299-37305	during	_	
217-211	37306-37313	working	_	
217-212	37314-37320	memory	_	
217-213	37321-37323	is	_	
217-214	37324-37333	modulated	_	
217-215	37334-37336	by	_	
217-216	37337-37340	the	_	
217-217	37341-37352	interaction	_	
217-218	37353-37355	of	_	
217-219	37356-37365	variation	_	
217-220	37366-37368	in	_	
217-221	37369-37372	CB1	_	
217-222	37373-37376	and	_	
217-223	37377-37381	COX2	_	
217-224	37382-37388	coding	_	
217-225	37389-37394	genes	_	
217-226	37395-37398	and	_	
217-227	37399-37409	correlates	_	
217-228	37410-37414	with	_	
217-229	37415-37424	frequency	_	
217-230	37425-37427	of	_	
217-231	37428-37436	cannabis	_	
217-232	37437-37440	use	_	
217-233	37441-37448	Origins	_	
217-234	37449-37452	and	_	
217-235	37453-37465	consequences	_	
217-236	37466-37468	of	_	
217-237	37469-37472	age	_	
217-238	37473-37475	at	_	
217-239	37476-37481	first	_	
217-240	37482-37487	drink	_	
217-241	37487-37488	.	_	

#Text=II.
218-1	37489-37491	II	_	
218-2	37491-37492	.	_	

#Text=Familial risk and heritability
#Text=Neurobehavioral disinhibition in childhood predicts early age at onset of substance use disorder
#Text=Protracted development of executive and mnemonic brain systems underlying working memory in adolescence: A longitudinal fMRI study
#Text=Risk and protective factors for alcohol and other drug problems in adolescence and early adulthood: Implications for substance abuse prevention
#Text=Inhibition during early adolescence predicts alcohol and marijuana use by late adolescence
#Text=
#Text=fMRI study of neural sensitization to hedonic stimuli in long-term, daily cannabis users
#Text=Effects of D9-tetrahydrocannabinol administration on human encoding and recall memory function: A pharmacological fMRI study
#Text=
#Text=The influence of marijuana use on neurocognitive functioning in adolescents
#Text=Validity of adolescent self-report of substance use
#Text=Persistent cannabis users show neuropsychological decline from childhood to midlife
#Text=Cognitive functioning of long-term heavy cannabis users seeking treatment
#Text=(A) Working memory (WM) task.
219-1	37493-37501	Familial	_	
219-2	37502-37506	risk	_	
219-3	37507-37510	and	_	
219-4	37511-37523	heritability	_	
219-5	37524-37539	Neurobehavioral	_	
219-6	37540-37553	disinhibition	_	
219-7	37554-37556	in	_	
219-8	37557-37566	childhood	_	
219-9	37567-37575	predicts	_	
219-10	37576-37581	early	_	
219-11	37582-37585	age	_	
219-12	37586-37588	at	_	
219-13	37589-37594	onset	_	
219-14	37595-37597	of	_	
219-15	37598-37607	substance	_	
219-16	37608-37611	use	_	
219-17	37612-37620	disorder	_	
219-18	37621-37631	Protracted	_	
219-19	37632-37643	development	_	
219-20	37644-37646	of	_	
219-21	37647-37656	executive	_	
219-22	37657-37660	and	_	
219-23	37661-37669	mnemonic	_	
219-24	37670-37675	brain	_	
219-25	37676-37683	systems	_	
219-26	37684-37694	underlying	_	
219-27	37695-37702	working	_	
219-28	37703-37709	memory	_	
219-29	37710-37712	in	_	
219-30	37713-37724	adolescence	_	
219-31	37724-37725	:	_	
219-32	37726-37727	A	_	
219-33	37728-37740	longitudinal	_	
219-34	37741-37745	fMRI	_	
219-35	37746-37751	study	_	
219-36	37752-37756	Risk	_	
219-37	37757-37760	and	_	
219-38	37761-37771	protective	_	
219-39	37772-37779	factors	_	
219-40	37780-37783	for	_	
219-41	37784-37791	alcohol	_	
219-42	37792-37795	and	_	
219-43	37796-37801	other	_	
219-44	37802-37806	drug	_	
219-45	37807-37815	problems	_	
219-46	37816-37818	in	_	
219-47	37819-37830	adolescence	_	
219-48	37831-37834	and	_	
219-49	37835-37840	early	_	
219-50	37841-37850	adulthood	_	
219-51	37850-37851	:	_	
219-52	37852-37864	Implications	_	
219-53	37865-37868	for	_	
219-54	37869-37878	substance	_	
219-55	37879-37884	abuse	_	
219-56	37885-37895	prevention	_	
219-57	37896-37906	Inhibition	_	
219-58	37907-37913	during	_	
219-59	37914-37919	early	_	
219-60	37920-37931	adolescence	_	
219-61	37932-37940	predicts	_	
219-62	37941-37948	alcohol	_	
219-63	37949-37952	and	_	
219-64	37953-37962	marijuana	_	
219-65	37963-37966	use	_	
219-66	37967-37969	by	_	
219-67	37970-37974	late	_	
219-68	37975-37986	adolescence	_	
219-69	37988-37992	fMRI	_	
219-70	37993-37998	study	_	
219-71	37999-38001	of	_	
219-72	38002-38008	neural	_	
219-73	38009-38022	sensitization	_	
219-74	38023-38025	to	_	
219-75	38026-38033	hedonic	_	
219-76	38034-38041	stimuli	_	
219-77	38042-38044	in	_	
219-78	38045-38054	long-term	_	
219-79	38054-38055	,	_	
219-80	38056-38061	daily	_	
219-81	38062-38070	cannabis	_	
219-82	38071-38076	users	_	
219-83	38077-38084	Effects	_	
219-84	38085-38087	of	_	
219-85	38088-38090	D9	_	
219-86	38090-38091	-	_	
219-87	38091-38111	tetrahydrocannabinol	_	
219-88	38112-38126	administration	_	
219-89	38127-38129	on	_	
219-90	38130-38135	human	_	
219-91	38136-38144	encoding	_	
219-92	38145-38148	and	_	
219-93	38149-38155	recall	_	
219-94	38156-38162	memory	_	
219-95	38163-38171	function	_	
219-96	38171-38172	:	_	
219-97	38173-38174	A	_	
219-98	38175-38190	pharmacological	_	
219-99	38191-38195	fMRI	_	
219-100	38196-38201	study	_	
219-101	38203-38206	The	_	
219-102	38207-38216	influence	_	
219-103	38217-38219	of	_	
219-104	38220-38229	marijuana	_	
219-105	38230-38233	use	_	
219-106	38234-38236	on	_	
219-107	38237-38251	neurocognitive	_	
219-108	38252-38263	functioning	_	
219-109	38264-38266	in	_	
219-110	38267-38278	adolescents	_	
219-111	38279-38287	Validity	_	
219-112	38288-38290	of	_	
219-113	38291-38301	adolescent	_	
219-114	38302-38313	self-report	_	
219-115	38314-38316	of	_	
219-116	38317-38326	substance	_	
219-117	38327-38330	use	_	
219-118	38331-38341	Persistent	_	
219-119	38342-38350	cannabis	_	
219-120	38351-38356	users	_	
219-121	38357-38361	show	_	
219-122	38362-38380	neuropsychological	_	
219-123	38381-38388	decline	_	
219-124	38389-38393	from	_	
219-125	38394-38403	childhood	_	
219-126	38404-38406	to	_	
219-127	38407-38414	midlife	_	
219-128	38415-38424	Cognitive	_	
219-129	38425-38436	functioning	_	
219-130	38437-38439	of	_	
219-131	38440-38449	long-term	_	
219-132	38450-38455	heavy	_	
219-133	38456-38464	cannabis	_	
219-134	38465-38470	users	_	
219-135	38471-38478	seeking	_	
219-136	38479-38488	treatment	_	
219-137	38489-38490	(	_	
219-138	38490-38491	A	_	
219-139	38491-38492	)	_	
219-140	38493-38500	Working	_	
219-141	38501-38507	memory	_	
219-142	38508-38509	(	_	
219-143	38509-38511	WM	_	
219-144	38511-38512	)	_	
219-145	38513-38517	task	_	
219-146	38517-38518	.	_	

#Text=Three cues (yellow circles) were presented sequentially (300-ms presentation, 200-ms interstimulus interval) in one of eight possible locations (2 row × 4 column grid).
220-1	38519-38524	Three	_	
220-2	38525-38529	cues	_	
220-3	38530-38531	(	_	
220-4	38531-38537	yellow	_	
220-5	38538-38545	circles	_	
220-6	38545-38546	)	_	
220-7	38547-38551	were	_	
220-8	38552-38561	presented	_	
220-9	38562-38574	sequentially	_	
220-10	38575-38576	(	_	
220-11	38576-38579	300	_	
220-12	38579-38580	-	_	
220-13	38580-38582	ms	_	
220-14	38583-38595	presentation	_	
220-15	38595-38596	,	_	
220-16	38597-38600	200	_	
220-17	38600-38601	-	_	
220-18	38601-38603	ms	_	
220-19	38604-38617	interstimulus	_	
220-20	38618-38626	interval	_	
220-21	38626-38627	)	_	
220-22	38628-38630	in	_	
220-23	38631-38634	one	_	
220-24	38635-38637	of	_	
220-25	38638-38643	eight	_	
220-26	38644-38652	possible	_	
220-27	38653-38662	locations	_	
220-28	38663-38664	(	_	
220-29	38664-38665	2	_	
220-30	38666-38669	row	_	
220-31	38670-38671	×	_	
220-32	38672-38673	4	_	
220-33	38674-38680	column	_	
220-34	38681-38685	grid	_	
220-35	38685-38686	)	_	
220-36	38686-38687	.	_	

#Text=Cues appeared in either the same location three times (set size 1) or in three different locations (set size 3) followed by a delay period (1500 or 6000 ms), where participants viewed a red fixation cross.
221-1	38688-38692	Cues	_	
221-2	38693-38701	appeared	_	
221-3	38702-38704	in	_	
221-4	38705-38711	either	_	
221-5	38712-38715	the	_	
221-6	38716-38720	same	_	
221-7	38721-38729	location	_	
221-8	38730-38735	three	_	
221-9	38736-38741	times	_	
221-10	38742-38743	(	_	
221-11	38743-38746	set	_	
221-12	38747-38751	size	_	
221-13	38752-38753	1	_	
221-14	38753-38754	)	_	
221-15	38755-38757	or	_	
221-16	38758-38760	in	_	
221-17	38761-38766	three	_	
221-18	38767-38776	different	_	
221-19	38777-38786	locations	_	
221-20	38787-38788	(	_	
221-21	38788-38791	set	_	
221-22	38792-38796	size	_	
221-23	38797-38798	3	_	
221-24	38798-38799	)	_	
221-25	38800-38808	followed	_	
221-26	38809-38811	by	_	
221-27	38812-38813	a	_	
221-28	38814-38819	delay	_	
221-29	38820-38826	period	_	
221-30	38827-38828	(	_	
221-31	38828-38832	1500	_	
221-32	38833-38835	or	_	
221-33	38836-38840	6000	_	
221-34	38841-38843	ms	_	
221-35	38843-38844	)	_	
221-36	38844-38845	,	_	
221-37	38846-38851	where	_	
221-38	38852-38864	participants	_	
221-39	38865-38871	viewed	_	
221-40	38872-38873	a	_	
221-41	38874-38877	red	_	
221-42	38878-38886	fixation	_	
221-43	38887-38892	cross	_	
221-44	38892-38893	.	_	

#Text=Subsequently, a frame appeared showing four probes (yellow circles) located among the eight possible locations, indicating a required response as to whether one of the probes had occurred in any of the previous cue locations.
222-1	38894-38906	Subsequently	_	
222-2	38906-38907	,	_	
222-3	38908-38909	a	_	
222-4	38910-38915	frame	_	
222-5	38916-38924	appeared	_	
222-6	38925-38932	showing	_	
222-7	38933-38937	four	_	
222-8	38938-38944	probes	_	
222-9	38945-38946	(	_	
222-10	38946-38952	yellow	_	
222-11	38953-38960	circles	_	
222-12	38960-38961	)	_	
222-13	38962-38969	located	_	
222-14	38970-38975	among	_	
222-15	38976-38979	the	_	
222-16	38980-38985	eight	_	
222-17	38986-38994	possible	_	
222-18	38995-39004	locations	_	
222-19	39004-39005	,	_	
222-20	39006-39016	indicating	_	
222-21	39017-39018	a	_	
222-22	39019-39027	required	_	
222-23	39028-39036	response	_	
222-24	39037-39039	as	_	
222-25	39040-39042	to	_	
222-26	39043-39050	whether	_	
222-27	39051-39054	one	_	
222-28	39055-39057	of	_	
222-29	39058-39061	the	_	
222-30	39062-39068	probes	_	
222-31	39069-39072	had	_	
222-32	39073-39081	occurred	_	
222-33	39082-39084	in	_	
222-34	39085-39088	any	_	
222-35	39089-39091	of	_	
222-36	39092-39095	the	_	
222-37	39096-39104	previous	_	
222-38	39105-39108	cue	_	
222-39	39109-39118	locations	_	
222-40	39118-39119	.	_	

#Text=Half of all trials were match trials, where one of the probes occupied a previously cued location, and half of all trials were nonmatch trials.
223-1	39120-39124	Half	_	
223-2	39125-39127	of	_	
223-3	39128-39131	all	_	
223-4	39132-39138	trials	_	
223-5	39139-39143	were	_	
223-6	39144-39149	match	_	
223-7	39150-39156	trials	_	
223-8	39156-39157	,	_	
223-9	39158-39163	where	_	
223-10	39164-39167	one	_	
223-11	39168-39170	of	_	
223-12	39171-39174	the	_	
223-13	39175-39181	probes	_	
223-14	39182-39190	occupied	_	
223-15	39191-39192	a	_	
223-16	39193-39203	previously	_	
223-17	39204-39208	cued	_	
223-18	39209-39217	location	_	
223-19	39217-39218	,	_	
223-20	39219-39222	and	_	
223-21	39223-39227	half	_	
223-22	39228-39230	of	_	
223-23	39231-39234	all	_	
223-24	39235-39241	trials	_	
223-25	39242-39246	were	_	
223-26	39247-39255	nonmatch	_	
223-27	39256-39262	trials	_	
223-28	39262-39263	.	_	

#Text=[Adapted with permission from.]
224-1	39264-39265	[	_	
224-2	39265-39272	Adapted	_	
224-3	39273-39277	with	_	
224-4	39278-39288	permission	_	
224-5	39289-39293	from	_	
224-6	39293-39294	.	_	
224-7	39294-39295	]	_	

#Text=(B) Scanner WM task performance.
225-1	39296-39297	(	_	
225-2	39297-39298	B	_	
225-3	39298-39299	)	_	
225-4	39300-39307	Scanner	_	
225-5	39308-39310	WM	_	
225-6	39311-39315	task	_	
225-7	39316-39327	performance	_	
225-8	39327-39328	.	_	

#Text=(Top panel) WM accuracy.
226-1	39329-39330	(	_	
226-2	39330-39333	Top	_	
226-3	39334-39339	panel	_	
226-4	39339-39340	)	_	
226-5	39341-39343	WM	_	
226-6	39344-39352	accuracy	_	
226-7	39352-39353	.	_	

#Text=(Bottom panel) Reaction time.
227-1	39354-39355	(	_	
227-2	39355-39361	Bottom	_	
227-3	39362-39367	panel	_	
227-4	39367-39368	)	_	
227-5	39369-39377	Reaction	_	
227-6	39378-39382	time	_	
227-7	39382-39383	.	_	

#Text=Full sample (N = 85; nonusers = 63, users = 22); RIO sample (N = 81; nonusers = 63, users = 18); longitudinal sample (n = 67; nonusers = 53, users = 15).
228-1	39384-39388	Full	_	
228-2	39389-39395	sample	_	
228-3	39396-39397	(	_	
228-4	39397-39398	N	_	
228-5	39399-39400	=	_	
228-6	39401-39403	85	_	
228-7	39403-39404	;	_	
228-8	39405-39413	nonusers	_	
228-9	39414-39415	=	_	
228-10	39416-39418	63	_	
228-11	39418-39419	,	_	
228-12	39420-39425	users	_	
228-13	39426-39427	=	_	
228-14	39428-39430	22	_	
228-15	39430-39431	)	_	
228-16	39431-39432	;	_	
228-17	39433-39436	RIO	_	
228-18	39437-39443	sample	_	
228-19	39444-39445	(	_	
228-20	39445-39446	N	_	
228-21	39447-39448	=	_	
228-22	39449-39451	81	_	
228-23	39451-39452	;	_	
228-24	39453-39461	nonusers	_	
228-25	39462-39463	=	_	
228-26	39464-39466	63	_	
228-27	39466-39467	,	_	
228-28	39468-39473	users	_	
228-29	39474-39475	=	_	
228-30	39476-39478	18	_	
228-31	39478-39479	)	_	
228-32	39479-39480	;	_	
228-33	39481-39493	longitudinal	_	
228-34	39494-39500	sample	_	
228-35	39501-39502	(	_	
228-36	39502-39503	n	_	
228-37	39504-39505	=	_	
228-38	39506-39508	67	_	
228-39	39508-39509	;	_	
228-40	39510-39518	nonusers	_	
228-41	39519-39520	=	_	
228-42	39521-39523	53	_	
228-43	39523-39524	,	_	
228-44	39525-39530	users	_	
228-45	39531-39532	=	_	
228-46	39533-39535	15	_	
228-47	39535-39536	)	_	
228-48	39536-39537	.	_	

#Text=+p < .10, *p < .05.
229-1	39538-39539	+	_	
229-2	39539-39540	p	_	
229-3	39541-39542	<	_	
229-4	39543-39546	.10	_	
229-5	39546-39547	,	_	
229-6	39548-39549	*	_	
229-7	39549-39550	p	_	
229-8	39551-39552	<	_	
229-9	39553-39556	.05	_	
229-10	39556-39557	.	_	

#Text=ITI, intertrial interval; RIO, removing subjects with inconsistent cannabis onset report.
230-1	39558-39561	ITI	_	
230-2	39561-39562	,	_	
230-3	39563-39573	intertrial	_	
230-4	39574-39582	interval	_	
230-5	39582-39583	;	_	
230-6	39584-39587	RIO	_	
230-7	39587-39588	,	_	
230-8	39589-39597	removing	_	
230-9	39598-39606	subjects	_	
230-10	39607-39611	with	_	
230-11	39612-39624	inconsistent	_	
230-12	39625-39633	cannabis	_	
230-13	39634-39639	onset	_	
230-14	39640-39646	report	_	
230-15	39646-39647	.	_	

#Text=Group functional magnetic resonance imaging differences at baseline.
231-1	39648-39653	Group	_	
231-2	39654-39664	functional	_	
231-3	39665-39673	magnetic	_	
231-4	39674-39683	resonance	_	
231-5	39684-39691	imaging	_	
231-6	39692-39703	differences	_	
231-7	39704-39706	at	_	
231-8	39707-39715	baseline	_	
231-9	39715-39716	.	_	

#Text=(Top panel) At baseline, participants who would initiate cannabis use by 15 years of age had reduced activation in visual association regions.
232-1	39717-39718	(	_	
232-2	39718-39721	Top	_	
232-3	39722-39727	panel	_	
232-4	39727-39728	)	_	
232-5	39729-39731	At	_	
232-6	39732-39740	baseline	_	
232-7	39740-39741	,	_	
232-8	39742-39754	participants	_	
232-9	39755-39758	who	_	
232-10	39759-39764	would	_	
232-11	39765-39773	initiate	_	
232-12	39774-39782	cannabis	_	
232-13	39783-39786	use	_	
232-14	39787-39789	by	_	
232-15	39790-39792	15	_	
232-16	39793-39798	years	_	
232-17	39799-39801	of	_	
232-18	39802-39805	age	_	
232-19	39806-39809	had	_	
232-20	39810-39817	reduced	_	
232-21	39818-39828	activation	_	
232-22	39829-39831	in	_	
232-23	39832-39838	visual	_	
232-24	39839-39850	association	_	
232-25	39851-39858	regions	_	
232-26	39858-39859	.	_	

#Text=Example hemodynamic response function time course (R lingual gyrus A) and bar plots of blood oxygen level–dependent (BOLD) dot products (L lingual gyrus, L lateral occipital gyrus A).
233-1	39860-39867	Example	_	
233-2	39868-39879	hemodynamic	_	
233-3	39880-39888	response	_	
233-4	39889-39897	function	_	
233-5	39898-39902	time	_	
233-6	39903-39909	course	_	
233-7	39910-39911	(	_	
233-8	39911-39912	R	_	
233-9	39913-39920	lingual	_	
233-10	39921-39926	gyrus	_	
233-11	39927-39928	A	_	
233-12	39928-39929	)	_	
233-13	39930-39933	and	_	
233-14	39934-39937	bar	_	
233-15	39938-39943	plots	_	
233-16	39944-39946	of	_	
233-17	39947-39952	blood	_	
233-18	39953-39959	oxygen	_	
233-19	39960-39975	level–dependent	_	
233-20	39976-39977	(	_	
233-21	39977-39981	BOLD	_	
233-22	39981-39982	)	_	
233-23	39983-39986	dot	_	
233-24	39987-39995	products	_	
233-25	39996-39997	(	_	
233-26	39997-39998	L	_	
233-27	39999-40006	lingual	_	
233-28	40007-40012	gyrus	_	
233-29	40012-40013	,	_	
233-30	40014-40015	L	_	
233-31	40016-40023	lateral	_	
233-32	40024-40033	occipital	_	
233-33	40034-40039	gyrus	_	
233-34	40040-40041	A	_	
233-35	40041-40042	)	_	
233-36	40042-40043	.	_	

#Text=(Bottom panel) At baseline, participants who initiated cannabis by 15 years of age had increased activation in frontoparietal regions.
234-1	40044-40045	(	_	
234-2	40045-40051	Bottom	_	
234-3	40052-40057	panel	_	
234-4	40057-40058	)	_	
234-5	40059-40061	At	_	
234-6	40062-40070	baseline	_	
234-7	40070-40071	,	_	
234-8	40072-40084	participants	_	
234-9	40085-40088	who	_	
234-10	40089-40098	initiated	_	
234-11	40099-40107	cannabis	_	
234-12	40108-40110	by	_	
234-13	40111-40113	15	_	
234-14	40114-40119	years	_	
234-15	40120-40122	of	_	
234-16	40123-40126	age	_	
234-17	40127-40130	had	_	
234-18	40131-40140	increased	_	
234-19	40141-40151	activation	_	
234-20	40152-40154	in	_	
234-21	40155-40169	frontoparietal	_	
234-22	40170-40177	regions	_	
234-23	40177-40178	.	_	

#Text=Example hemodynamic response function time course (L inferior parietal lobule [IPL]) and bar plots of BOLD dot products (L middle frontal gyrus [MFG] and presupplementary motor area [pre-SMA]).
235-1	40179-40186	Example	_	
235-2	40187-40198	hemodynamic	_	
235-3	40199-40207	response	_	
235-4	40208-40216	function	_	
235-5	40217-40221	time	_	
235-6	40222-40228	course	_	
235-7	40229-40230	(	_	
235-8	40230-40231	L	_	
235-9	40232-40240	inferior	_	
235-10	40241-40249	parietal	_	
235-11	40250-40256	lobule	_	
235-12	40257-40258	[	_	
235-13	40258-40261	IPL	_	
235-14	40261-40262	]	_	
235-15	40262-40263	)	_	
235-16	40264-40267	and	_	
235-17	40268-40271	bar	_	
235-18	40272-40277	plots	_	
235-19	40278-40280	of	_	
235-20	40281-40285	BOLD	_	
235-21	40286-40289	dot	_	
235-22	40290-40298	products	_	
235-23	40299-40300	(	_	
235-24	40300-40301	L	_	
235-25	40302-40308	middle	_	
235-26	40309-40316	frontal	_	
235-27	40317-40322	gyrus	_	
235-28	40323-40324	[	_	
235-29	40324-40327	MFG	_	
235-30	40327-40328	]	_	
235-31	40329-40332	and	_	
235-32	40333-40349	presupplementary	_	
235-33	40350-40355	motor	_	
235-34	40356-40360	area	_	
235-35	40361-40362	[	_	
235-36	40362-40369	pre-SMA	_	
235-37	40369-40370	]	_	
235-38	40370-40371	)	_	
235-39	40371-40372	.	_	

#Text=All clusters p < .05 (cluster size correction; 11 contiguous voxels) with a single voxel threshold of p = .0013 (q < .05).
236-1	40373-40376	All	_	
236-2	40377-40385	clusters	_	
236-3	40386-40387	p	_	
236-4	40388-40389	<	_	
236-5	40390-40393	.05	_	
236-6	40394-40395	(	_	
236-7	40395-40402	cluster	_	
236-8	40403-40407	size	_	
236-9	40408-40418	correction	_	
236-10	40418-40419	;	_	
236-11	40420-40422	11	_	
236-12	40423-40433	contiguous	_	
236-13	40434-40440	voxels	_	
236-14	40440-40441	)	_	
236-15	40442-40446	with	_	
236-16	40447-40448	a	_	
236-17	40449-40455	single	_	
236-18	40456-40461	voxel	_	
236-19	40462-40471	threshold	_	
236-20	40472-40474	of	_	
236-21	40475-40476	p	_	
236-22	40477-40478	=	_	
236-23	40479-40484	.0013	_	
236-24	40485-40486	(	_	
236-25	40486-40487	q	_	
236-26	40488-40489	<	_	
236-27	40490-40493	.05	_	
236-28	40493-40494	)	_	
236-29	40494-40495	.	_	

#Text=Statistical maps displayed over Montreal Neurological Institute-152 template in neurological view.
237-1	40496-40507	Statistical	_	
237-2	40508-40512	maps	_	
237-3	40513-40522	displayed	_	
237-4	40523-40527	over	_	
237-5	40528-40536	Montreal	_	
237-6	40537-40549	Neurological	_	
237-7	40550-40559	Institute	_	
237-8	40559-40560	-	_	
237-9	40560-40563	152	_	
237-10	40564-40572	template	_	
237-11	40573-40575	in	_	
237-12	40576-40588	neurological	_	
237-13	40589-40593	view	_	
237-14	40593-40594	.	_	

#Text=A.U., arbitrary units; L, left; R, right.
238-1	40595-40598	A.U	_	
238-2	40598-40599	.	_	
238-3	40599-40600	,	_	
238-4	40601-40610	arbitrary	_	
238-5	40611-40616	units	_	
238-6	40616-40617	;	_	
238-7	40618-40619	L	_	
238-8	40619-40620	,	_	
238-9	40621-40625	left	_	
238-10	40625-40626	;	_	
238-11	40627-40628	R	_	
238-12	40628-40629	,	_	
238-13	40630-40635	right	_	
238-14	40635-40636	.	_	

#Text=Group functional magnetic resonance imaging differences at follow-up and group by visit interaction.
239-1	40637-40642	Group	_	
239-2	40643-40653	functional	_	
239-3	40654-40662	magnetic	_	
239-4	40663-40672	resonance	_	
239-5	40673-40680	imaging	_	
239-6	40681-40692	differences	_	
239-7	40693-40695	at	_	
239-8	40696-40705	follow-up	_	
239-9	40706-40709	and	_	
239-10	40710-40715	group	_	
239-11	40716-40718	by	_	
239-12	40719-40724	visit	_	
239-13	40725-40736	interaction	_	
239-14	40736-40737	.	_	

#Text=(Top panel) At follow-up, cannabis users had reduced activation in the right cuneus.
240-1	40738-40739	(	_	
240-2	40739-40742	Top	_	
240-3	40743-40748	panel	_	
240-4	40748-40749	)	_	
240-5	40750-40752	At	_	
240-6	40753-40762	follow-up	_	
240-7	40762-40763	,	_	
240-8	40764-40772	cannabis	_	
240-9	40773-40778	users	_	
240-10	40779-40782	had	_	
240-11	40783-40790	reduced	_	
240-12	40791-40801	activation	_	
240-13	40802-40804	in	_	
240-14	40805-40808	the	_	
240-15	40809-40814	right	_	
240-16	40815-40821	cuneus	_	
240-17	40821-40822	.	_	

#Text=Hemodynamic response function time courses and bar plots of blood oxygen level–dependent (BOLD) dot products (R cuneus A, R cuneus B).
241-1	40823-40834	Hemodynamic	_	
241-2	40835-40843	response	_	
241-3	40844-40852	function	_	
241-4	40853-40857	time	_	
241-5	40858-40865	courses	_	
241-6	40866-40869	and	_	
241-7	40870-40873	bar	_	
241-8	40874-40879	plots	_	
241-9	40880-40882	of	_	
241-10	40883-40888	blood	_	
241-11	40889-40895	oxygen	_	
241-12	40896-40911	level–dependent	_	
241-13	40912-40913	(	_	
241-14	40913-40917	BOLD	_	
241-15	40917-40918	)	_	
241-16	40919-40922	dot	_	
241-17	40923-40931	products	_	
241-18	40932-40933	(	_	
241-19	40933-40934	R	_	
241-20	40935-40941	cuneus	_	
241-21	40942-40943	A	_	
241-22	40943-40944	,	_	
241-23	40945-40946	R	_	
241-24	40947-40953	cuneus	_	
241-25	40954-40955	B	_	
241-26	40955-40956	)	_	
241-27	40956-40957	.	_	

#Text=(Bottom panel) A significant group by visit interaction was observed for the posterior cingulate, where larger group differences were observed at baseline compared to follow-up.
242-1	40958-40959	(	_	
242-2	40959-40965	Bottom	_	
242-3	40966-40971	panel	_	
242-4	40971-40972	)	_	
242-5	40973-40974	A	_	
242-6	40975-40986	significant	_	
242-7	40987-40992	group	_	
242-8	40993-40995	by	_	
242-9	40996-41001	visit	_	
242-10	41002-41013	interaction	_	
242-11	41014-41017	was	_	
242-12	41018-41026	observed	_	
242-13	41027-41030	for	_	
242-14	41031-41034	the	_	
242-15	41035-41044	posterior	_	
242-16	41045-41054	cingulate	_	
242-17	41054-41055	,	_	
242-18	41056-41061	where	_	
242-19	41062-41068	larger	_	
242-20	41069-41074	group	_	
242-21	41075-41086	differences	_	
242-22	41087-41091	were	_	
242-23	41092-41100	observed	_	
242-24	41101-41103	at	_	
242-25	41104-41112	baseline	_	
242-26	41113-41121	compared	_	
242-27	41122-41124	to	_	
242-28	41125-41134	follow-up	_	
242-29	41134-41135	.	_	

#Text=Hemodynamic response function time courses and bar plots of BOLD dot products.
243-1	41136-41147	Hemodynamic	_	
243-2	41148-41156	response	_	
243-3	41157-41165	function	_	
243-4	41166-41170	time	_	
243-5	41171-41178	courses	_	
243-6	41179-41182	and	_	
243-7	41183-41186	bar	_	
243-8	41187-41192	plots	_	
243-9	41193-41195	of	_	
243-10	41196-41200	BOLD	_	
243-11	41201-41204	dot	_	
243-12	41205-41213	products	_	
243-13	41213-41214	.	_	

#Text=All clusters p < .05 corrected (cluster size correction; 11 contiguous voxels, faces touching) with a single voxel threshold of p = .0007 (q < .05) for follow-up and p = .002 (q < .05) for group by visit interaction.
244-1	41215-41218	All	_	
244-2	41219-41227	clusters	_	
244-3	41228-41229	p	_	
244-4	41230-41231	<	_	
244-5	41232-41235	.05	_	
244-6	41236-41245	corrected	_	
244-7	41246-41247	(	_	
244-8	41247-41254	cluster	_	
244-9	41255-41259	size	_	
244-10	41260-41270	correction	_	
244-11	41270-41271	;	_	
244-12	41272-41274	11	_	
244-13	41275-41285	contiguous	_	
244-14	41286-41292	voxels	_	
244-15	41292-41293	,	_	
244-16	41294-41299	faces	_	
244-17	41300-41308	touching	_	
244-18	41308-41309	)	_	
244-19	41310-41314	with	_	
244-20	41315-41316	a	_	
244-21	41317-41323	single	_	
244-22	41324-41329	voxel	_	
244-23	41330-41339	threshold	_	
244-24	41340-41342	of	_	
244-25	41343-41344	p	_	
244-26	41345-41346	=	_	
244-27	41347-41352	.0007	_	
244-28	41353-41354	(	_	
244-29	41354-41355	q	_	
244-30	41356-41357	<	_	
244-31	41358-41361	.05	_	
244-32	41361-41362	)	_	
244-33	41363-41366	for	_	
244-34	41367-41376	follow-up	_	
244-35	41377-41380	and	_	
244-36	41381-41382	p	_	
244-37	41383-41384	=	_	
244-38	41385-41389	.002	_	
244-39	41390-41391	(	_	
244-40	41391-41392	q	_	
244-41	41393-41394	<	_	
244-42	41395-41398	.05	_	
244-43	41398-41399	)	_	
244-44	41400-41403	for	_	
244-45	41404-41409	group	_	
244-46	41410-41412	by	_	
244-47	41413-41418	visit	_	
244-48	41419-41430	interaction	_	
244-49	41430-41431	.	_	

#Text=Statistical maps displayed over Montreal Neurological Institute-152 template in neurological view.
245-1	41432-41443	Statistical	_	
245-2	41444-41448	maps	_	
245-3	41449-41458	displayed	_	
245-4	41459-41463	over	_	
245-5	41464-41472	Montreal	_	
245-6	41473-41485	Neurological	_	
245-7	41486-41495	Institute	_	
245-8	41495-41496	-	_	
245-9	41496-41499	152	_	
245-10	41500-41508	template	_	
245-11	41509-41511	in	_	
245-12	41512-41524	neurological	_	
245-13	41525-41529	view	_	
245-14	41529-41530	.	_	

#Text=Note; BOLD dot products represent participant expression of mean hemodynamic response function.
246-1	41531-41535	Note	_	
246-2	41535-41536	;	_	
246-3	41537-41541	BOLD	_	
246-4	41542-41545	dot	_	
246-5	41546-41554	products	_	
246-6	41555-41564	represent	_	
246-7	41565-41576	participant	_	
246-8	41577-41587	expression	_	
246-9	41588-41590	of	_	
246-10	41591-41595	mean	_	
246-11	41596-41607	hemodynamic	_	
246-12	41608-41616	response	_	
246-13	41617-41625	function	_	
246-14	41625-41626	.	_	

#Text=Accordingly, greater deactivation leads to a positive dot product.
247-1	41627-41638	Accordingly	_	
247-2	41638-41639	,	_	
247-3	41640-41647	greater	_	
247-4	41648-41660	deactivation	_	
247-5	41661-41666	leads	_	
247-6	41667-41669	to	_	
247-7	41670-41671	a	_	
247-8	41672-41680	positive	_	
247-9	41681-41684	dot	_	
247-10	41685-41692	product	_	
247-11	41692-41693	.	_	

#Text=A.U., arbitrary units; R, right.
248-1	41694-41697	A.U	_	
248-2	41697-41698	.	_	
248-3	41698-41699	,	_	
248-4	41700-41709	arbitrary	_	
248-5	41710-41715	units	_	
248-6	41715-41716	;	_	
248-7	41717-41718	R	_	
248-8	41718-41719	,	_	
248-9	41720-41725	right	_	
248-10	41725-41726	.	_	

#Text=Functional magnetic resonance imaging dose-response associations in the longitudinal neuroimaging sample (n = 65; nonusers = 52, users = 13).
249-1	41727-41737	Functional	_	
249-2	41738-41746	magnetic	_	
249-3	41747-41756	resonance	_	
249-4	41757-41764	imaging	_	
249-5	41765-41778	dose-response	_	
249-6	41779-41791	associations	_	
249-7	41792-41794	in	_	
249-8	41795-41798	the	_	
249-9	41799-41811	longitudinal	_	
249-10	41812-41824	neuroimaging	_	
249-11	41825-41831	sample	_	
249-12	41832-41833	(	_	
249-13	41833-41834	n	_	
249-14	41835-41836	=	_	
249-15	41837-41839	65	_	
249-16	41839-41840	;	_	
249-17	41841-41849	nonusers	_	
249-18	41850-41851	=	_	
249-19	41852-41854	52	_	
249-20	41854-41855	,	_	
249-21	41856-41861	users	_	
249-22	41862-41863	=	_	
249-23	41864-41866	13	_	
249-24	41866-41867	)	_	
249-25	41867-41868	.	_	

#Text=(Top left panel) Cuneus (B) hemodynamic response function time courses with user group median split by dose (low-dose user: n = 6; high-dose user: n = 7).
250-1	41869-41870	(	_	
250-2	41870-41873	Top	_	
250-3	41874-41878	left	_	
250-4	41879-41884	panel	_	
250-5	41884-41885	)	_	
250-6	41886-41892	Cuneus	_	
250-7	41893-41894	(	_	
250-8	41894-41895	B	_	
250-9	41895-41896	)	_	
250-10	41897-41908	hemodynamic	_	
250-11	41909-41917	response	_	
250-12	41918-41926	function	_	
250-13	41927-41931	time	_	
250-14	41932-41939	courses	_	
250-15	41940-41944	with	_	
250-16	41945-41949	user	_	
250-17	41950-41955	group	_	
250-18	41956-41962	median	_	
250-19	41963-41968	split	_	
250-20	41969-41971	by	_	
250-21	41972-41976	dose	_	
250-22	41977-41978	(	_	
250-23	41978-41986	low-dose	_	
250-24	41987-41991	user	_	
250-25	41991-41992	:	_	
250-26	41993-41994	n	_	
250-27	41995-41996	=	_	
250-28	41997-41998	6	_	
250-29	41998-41999	;	_	
250-30	42000-42009	high-dose	_	
250-31	42010-42014	user	_	
250-32	42014-42015	:	_	
250-33	42016-42017	n	_	
250-34	42018-42019	=	_	
250-35	42020-42021	7	_	
250-36	42021-42022	)	_	
250-37	42022-42023	.	_	

#Text=(Top right panel) Scatter plots of blood oxygen level–dependent (BOLD) dot products and total cannabis use (log joints per day [jpd]) in cuneus B.
251-1	42024-42025	(	_	
251-2	42025-42028	Top	_	
251-3	42029-42034	right	_	
251-4	42035-42040	panel	_	
251-5	42040-42041	)	_	
251-6	42042-42049	Scatter	_	
251-7	42050-42055	plots	_	
251-8	42056-42058	of	_	
251-9	42059-42064	blood	_	
251-10	42065-42071	oxygen	_	
251-11	42072-42087	level–dependent	_	
251-12	42088-42089	(	_	
251-13	42089-42093	BOLD	_	
251-14	42093-42094	)	_	
251-15	42095-42098	dot	_	
251-16	42099-42107	products	_	
251-17	42108-42111	and	_	
251-18	42112-42117	total	_	
251-19	42118-42126	cannabis	_	
251-20	42127-42130	use	_	
251-21	42131-42132	(	_	
251-22	42132-42135	log	_	
251-23	42136-42142	joints	_	
251-24	42143-42146	per	_	
251-25	42147-42150	day	_	
251-26	42151-42152	[	_	
251-27	42152-42155	jpd	_	
251-28	42155-42156	]	_	
251-29	42156-42157	)	_	
251-30	42158-42160	in	_	
251-31	42161-42167	cuneus	_	
251-32	42168-42169	B	_	
251-33	42169-42170	.	_	

#Text=(Bottom left panel) Cuneus aggregate (A, B, and C) hemodynamic response function time courses with user group median split by dose.
252-1	42171-42172	(	_	
252-2	42172-42178	Bottom	_	
252-3	42179-42183	left	_	
252-4	42184-42189	panel	_	
252-5	42189-42190	)	_	
252-6	42191-42197	Cuneus	_	
252-7	42198-42207	aggregate	_	
252-8	42208-42209	(	_	
252-9	42209-42210	A	_	
252-10	42210-42211	,	_	
252-11	42212-42213	B	_	
252-12	42213-42214	,	_	
252-13	42215-42218	and	_	
252-14	42219-42220	C	_	
252-15	42220-42221	)	_	
252-16	42222-42233	hemodynamic	_	
252-17	42234-42242	response	_	
252-18	42243-42251	function	_	
252-19	42252-42256	time	_	
252-20	42257-42264	courses	_	
252-21	42265-42269	with	_	
252-22	42270-42274	user	_	
252-23	42275-42280	group	_	
252-24	42281-42287	median	_	
252-25	42288-42293	split	_	
252-26	42294-42296	by	_	
252-27	42297-42301	dose	_	
252-28	42301-42302	.	_	

#Text=(Bottom right panel) Scatter plots of BOLD dot products and total cannabis use (log jpd) in cuneus aggregate.
253-1	42303-42304	(	_	
253-2	42304-42310	Bottom	_	
253-3	42311-42316	right	_	
253-4	42317-42322	panel	_	
253-5	42322-42323	)	_	
253-6	42324-42331	Scatter	_	
253-7	42332-42337	plots	_	
253-8	42338-42340	of	_	
253-9	42341-42345	BOLD	_	
253-10	42346-42349	dot	_	
253-11	42350-42358	products	_	
253-12	42359-42362	and	_	
253-13	42363-42368	total	_	
253-14	42369-42377	cannabis	_	
253-15	42378-42381	use	_	
253-16	42382-42383	(	_	
253-17	42383-42386	log	_	
253-18	42387-42390	jpd	_	
253-19	42390-42391	)	_	
253-20	42392-42394	in	_	
253-21	42395-42401	cuneus	_	
253-22	42402-42411	aggregate	_	
253-23	42411-42412	.	_	

#Text=Statistical maps displayed over Montreal Neurological Institute-152 template in neurological view.
254-1	42413-42424	Statistical	_	
254-2	42425-42429	maps	_	
254-3	42430-42439	displayed	_	
254-4	42440-42444	over	_	
254-5	42445-42453	Montreal	_	
254-6	42454-42466	Neurological	_	
254-7	42467-42476	Institute	_	
254-8	42476-42477	-	_	
254-9	42477-42480	152	_	
254-10	42481-42489	template	_	
254-11	42490-42492	in	_	
254-12	42493-42505	neurological	_	
254-13	42506-42510	view	_	
254-14	42510-42511	.	_	

#Text=Clusters are displayed in red to denote that mean activation was calculated.
255-1	42512-42520	Clusters	_	
255-2	42521-42524	are	_	
255-3	42525-42534	displayed	_	
255-4	42535-42537	in	_	
255-5	42538-42541	red	_	
255-6	42542-42544	to	_	
255-7	42545-42551	denote	_	
255-8	42552-42556	that	_	
255-9	42557-42561	mean	_	
255-10	42562-42572	activation	_	
255-11	42573-42576	was	_	
255-12	42577-42587	calculated	_	
255-13	42587-42588	.	_	

#Text=BOLD dot products represent participant expression of mean hemodynamic response function; accordingly, greater deactivation leads to a positive dot product.
256-1	42589-42593	BOLD	_	
256-2	42594-42597	dot	_	
256-3	42598-42606	products	_	
256-4	42607-42616	represent	_	
256-5	42617-42628	participant	_	
256-6	42629-42639	expression	_	
256-7	42640-42642	of	_	
256-8	42643-42647	mean	_	
256-9	42648-42659	hemodynamic	_	
256-10	42660-42668	response	_	
256-11	42669-42677	function	_	
256-12	42677-42678	;	_	
256-13	42679-42690	accordingly	_	
256-14	42690-42691	,	_	
256-15	42692-42699	greater	_	
256-16	42700-42712	deactivation	_	
256-17	42713-42718	leads	_	
256-18	42719-42721	to	_	
256-19	42722-42723	a	_	
256-20	42724-42732	positive	_	
256-21	42733-42736	dot	_	
256-22	42737-42744	product	_	
256-23	42744-42745	.	_	

#Text=A.U., arbitrary units.
257-1	42746-42749	A.U	_	
257-2	42749-42750	.	_	
257-3	42750-42751	,	_	
257-4	42752-42761	arbitrary	_	
257-5	42762-42767	units	_	
257-6	42767-42768	.	_	

#Text=Effect sizes from cognitive battery.
258-1	42769-42775	Effect	_	
258-2	42776-42781	sizes	_	
258-3	42782-42786	from	_	
258-4	42787-42796	cognitive	_	
258-5	42797-42804	battery	_	
258-6	42804-42805	.	_	

#Text=Cohen’s d and their 95% confidence intervals are presented for the Wechsler Intelligence Scale for Children (WISC-IV) and the Cambridge Neuropsychological Test Automated Battery (CANTAB).
259-1	42806-42811	Cohen	_	
259-2	42811-42812	’	_	
259-3	42812-42813	s	_	
259-4	42814-42815	d	_	
259-5	42816-42819	and	_	
259-6	42820-42825	their	_	
259-7	42826-42829	95%	_	
259-8	42830-42840	confidence	_	
259-9	42841-42850	intervals	_	
259-10	42851-42854	are	_	
259-11	42855-42864	presented	_	
259-12	42865-42868	for	_	
259-13	42869-42872	the	_	
259-14	42873-42881	Wechsler	_	
259-15	42882-42894	Intelligence	_	
259-16	42895-42900	Scale	_	
259-17	42901-42904	for	_	
259-18	42905-42913	Children	_	
259-19	42914-42915	(	_	
259-20	42915-42922	WISC-IV	_	
259-21	42922-42923	)	_	
259-22	42924-42927	and	_	
259-23	42928-42931	the	_	
259-24	42932-42941	Cambridge	_	
259-25	42942-42960	Neuropsychological	_	
259-26	42961-42965	Test	_	
259-27	42966-42975	Automated	_	
259-28	42976-42983	Battery	_	
259-29	42984-42985	(	_	
259-30	42985-42991	CANTAB	_	
259-31	42991-42992	)	_	
259-32	42992-42993	.	_	

#Text=*p < .05 (false discovery rate–corrected); Ep < .05 while excluding 4 participants with inconsistent cannabis onset.
260-1	42994-42995	*	_	
260-2	42995-42996	p	_	
260-3	42997-42998	<	_	
260-4	42999-43002	.05	_	
260-5	43003-43004	(	_	
260-6	43004-43009	false	_	
260-7	43010-43019	discovery	_	
260-8	43020-43034	rate–corrected	_	
260-9	43034-43035	)	_	
260-10	43035-43036	;	_	
260-11	43037-43039	Ep	_	
260-12	43040-43041	<	_	
260-13	43042-43045	.05	_	
260-14	43046-43051	while	_	
260-15	43052-43061	excluding	_	
260-16	43062-43063	4	_	
260-17	43064-43076	participants	_	
260-18	43077-43081	with	_	
260-19	43082-43094	inconsistent	_	
260-20	43095-43103	cannabis	_	
260-21	43104-43109	onset	_	
260-22	43109-43110	.	_	

#Text=FSIQ, Full-scale IQ; IED, Intra-Extra Dimensional Set Shift; OTS, One Touch Stockings of Cambridge; PER, Perceptual Reasoning; PRO, Processing Speed; SSP, Spatial Span; SWM, Spatial Working Memory; VER, Verbal Reasoning; WM, Working Memory.
261-1	43111-43115	FSIQ	_	
261-2	43115-43116	,	_	
261-3	43117-43127	Full-scale	_	
261-4	43128-43130	IQ	_	
261-5	43130-43131	;	_	
261-6	43132-43135	IED	_	
261-7	43135-43136	,	_	
261-8	43137-43148	Intra-Extra	_	
261-9	43149-43160	Dimensional	_	
261-10	43161-43164	Set	_	
261-11	43165-43170	Shift	_	
261-12	43170-43171	;	_	
261-13	43172-43175	OTS	_	
261-14	43175-43176	,	_	
261-15	43177-43180	One	_	
261-16	43181-43186	Touch	_	
261-17	43187-43196	Stockings	_	
261-18	43197-43199	of	_	
261-19	43200-43209	Cambridge	_	
261-20	43209-43210	;	_	
261-21	43211-43214	PER	_	
261-22	43214-43215	,	_	
261-23	43216-43226	Perceptual	_	
261-24	43227-43236	Reasoning	_	
261-25	43236-43237	;	_	
261-26	43238-43241	PRO	_	
261-27	43241-43242	,	_	
261-28	43243-43253	Processing	_	
261-29	43254-43259	Speed	_	
261-30	43259-43260	;	_	
261-31	43261-43264	SSP	_	
261-32	43264-43265	,	_	
261-33	43266-43273	Spatial	_	
261-34	43274-43278	Span	_	
261-35	43278-43279	;	_	
261-36	43280-43283	SWM	_	
261-37	43283-43284	,	_	
261-38	43285-43292	Spatial	_	
261-39	43293-43300	Working	_	
261-40	43301-43307	Memory	_	
261-41	43307-43308	;	_	
261-42	43309-43312	VER	_	
261-43	43312-43313	,	_	
261-44	43314-43320	Verbal	_	
261-45	43321-43330	Reasoning	_	
261-46	43330-43331	;	_	
261-47	43332-43334	WM	_	
261-48	43334-43335	,	_	
261-49	43336-43343	Working	_	
261-50	43344-43350	Memory	_	
261-51	43350-43351	.	_	

#Text=Sample Sizes
#Text=\tBaseline(12 Years of Age)\tFollow-up(15 Years of Age)\t \tNonusers\tPreusers\tNonusers\tUsers\t \tSubstance Use and Cognitive Battery\t63\t22\t63\t22\t \tfMRI Session\t \t WM behavioral data\t63\t22\t52\t15\t \t fMRI data\t63\t21\t51\t15\t \t
#Text=fMRI, functional magnetic resonance imaging; WM, working memory.
262-1	43352-43358	Sample	_	
262-2	43359-43364	Sizes	_	
262-3	43366-43374	Baseline	_	
262-4	43374-43375	(	_	
262-5	43375-43377	12	_	
262-6	43378-43383	Years	_	
262-7	43384-43386	of	_	
262-8	43387-43390	Age	_	
262-9	43390-43391	)	_	
262-10	43392-43401	Follow-up	_	
262-11	43401-43402	(	_	
262-12	43402-43404	15	_	
262-13	43405-43410	Years	_	
262-14	43411-43413	of	_	
262-15	43414-43417	Age	_	
262-16	43417-43418	)	_	
262-17	43421-43429	Nonusers	_	
262-18	43430-43438	Preusers	_	
262-19	43439-43447	Nonusers	_	
262-20	43448-43453	Users	_	
262-21	43456-43465	Substance	_	
262-22	43466-43469	Use	_	
262-23	43470-43473	and	_	
262-24	43474-43483	Cognitive	_	
262-25	43484-43491	Battery	_	
262-26	43492-43494	63	_	
262-27	43495-43497	22	_	
262-28	43498-43500	63	_	
262-29	43501-43503	22	_	
262-30	43506-43510	fMRI	_	
262-31	43511-43518	Session	_	
262-32	43522-43524	WM	_	
262-33	43525-43535	behavioral	_	
262-34	43536-43540	data	_	
262-35	43541-43543	63	_	
262-36	43544-43546	22	_	
262-37	43547-43549	52	_	
262-38	43550-43552	15	_	
262-39	43556-43560	fMRI	_	
262-40	43561-43565	data	_	
262-41	43566-43568	63	_	
262-42	43569-43571	21	_	
262-43	43572-43574	51	_	
262-44	43575-43577	15	_	
262-45	43581-43585	fMRI	_	
262-46	43585-43586	,	_	
262-47	43587-43597	functional	_	
262-48	43598-43606	magnetic	_	
262-49	43607-43616	resonance	_	
262-50	43617-43624	imaging	_	
262-51	43624-43625	;	_	
262-52	43626-43628	WM	_	
262-53	43628-43629	,	_	
262-54	43630-43637	working	_	
262-55	43638-43644	memory	_	
262-56	43644-43645	.	_	

#Text=Sample Characteristics
#Text=Variable\tNonusers\tUsers\tNonusers vs.
263-1	43646-43652	Sample	_	
263-2	43653-43668	Characteristics	_	
263-3	43669-43677	Variable	_	
263-4	43678-43686	Nonusers	_	
263-5	43687-43692	Users	_	
263-6	43693-43701	Nonusers	_	
263-7	43702-43704	vs	_	
263-8	43704-43705	.	_	

#Text=Users\t \tAge at fMRI Session, Years\t \t Baseline\t12.77 (0.361)\t12.67 (0.322)\tt40.80 = 1.16\t \t Follow-up\t15.65 (0.373)\t15.58 (0.345)\tt24.21 = 0.64\t \tGender, n\t\t\tχ21 = 0.19\t \t Male\t29\t12\t\t \t Female\t34\t10\t\t \tWISC-IV Full Scale IQa\t103.79 (11.09)\t98.45 (13.40)\tt31.63 = 1.68\t \tCBCL Externalizing Baseline t Score\t48.27 (9.41)\t51.32 (7.97)\tt43.00 = −1.47\t \tCBCL Externalizing Follow-up t Score\t45.38 (9.53)\t52.68 (10.42)\tt34.06 = −2.89b\t \tFamily Income, Dollars per Montha\t7001.63 (11,381.40)\t2996.36 (3043.25)\tt78.77 = 2.53c\t \tMaternal Education, Years\t14.17 (2.18)\t13.40 (1.94)\tt40.87 = 1.54\t \tSES Composite, z Family Income + z Maternal Education\t0.196 (1.85)\t−0.560 (1.17)\tt58.68 = 2.22c\t \tRace\t\t\tχ21 = 4.79c\t \t Caucasian\t39\t7\t\t \t Non-Caucasian\t24\t15\t\t \tCannabis Age of Onset, Yearsd\t-\t13.67e (1.33)\t\t \tPeak Cannabis Use, Maximum No. of Joints per Day (13- to 15-year-olds)d\t-\t0.076 (0.161)\t\t \tTotal Cannabis Use, Sum Joints per Day (13- to 15-year-olds)d\t-\t0.078f (0.161)\t\t \tAny Alcohol Use (13- to 15-year-olds)\t8\t12\tχ21 = 13.63b\t \tPeak Alcohol Use, Maximum No. of Drinks per Day (13- to 15-year-olds)\t0.038 (0.055)\t0.075 (0.101)\tt22.08 = −1.07\t \tTotal Alcohol Use, Sum Drinks per Day (13- to 15-year-olds)\t0.040 (0.054)\t0.081 (0.101)\tt22.06 = −1.17\t \tOther Illicit Drug Use, Any Use (13- to 15-year-olds)\t0\t3\tχ21 = 5.35c\t \t
#Text=Values are presented as mean (SD) or n.
#Text=t values determined using Welch’s unequal variance t test. χ2 values determined using Yates’s χ2 test.
264-1	43706-43711	Users	_	
264-2	43714-43717	Age	_	
264-3	43718-43720	at	_	
264-4	43721-43725	fMRI	_	
264-5	43726-43733	Session	_	
264-6	43733-43734	,	_	
264-7	43735-43740	Years	_	
264-8	43744-43752	Baseline	_	
264-9	43753-43758	12.77	_	
264-10	43759-43760	(	_	
264-11	43760-43765	0.361	_	
264-12	43765-43766	)	_	
264-13	43767-43772	12.67	_	
264-14	43773-43774	(	_	
264-15	43774-43779	0.322	_	
264-16	43779-43780	)	_	
264-17	43781-43787	t40.80	_	
264-18	43788-43789	=	_	
264-19	43790-43794	1.16	_	
264-20	43798-43807	Follow-up	_	
264-21	43808-43813	15.65	_	
264-22	43814-43815	(	_	
264-23	43815-43820	0.373	_	
264-24	43820-43821	)	_	
264-25	43822-43827	15.58	_	
264-26	43828-43829	(	_	
264-27	43829-43834	0.345	_	
264-28	43834-43835	)	_	
264-29	43836-43842	t24.21	_	
264-30	43843-43844	=	_	
264-31	43845-43849	0.64	_	
264-32	43852-43858	Gender	_	
264-33	43858-43859	,	_	
264-34	43860-43861	n	_	
264-35	43864-43867	χ21	_	
264-36	43868-43869	=	_	
264-37	43870-43874	0.19	_	
264-38	43878-43882	Male	_	
264-39	43883-43885	29	_	
264-40	43886-43888	12	_	
264-41	43893-43899	Female	_	
264-42	43900-43902	34	_	
264-43	43903-43905	10	_	
264-44	43909-43916	WISC-IV	_	
264-45	43917-43921	Full	_	
264-46	43922-43927	Scale	_	
264-47	43928-43931	IQa	_	
264-48	43932-43938	103.79	_	
264-49	43939-43940	(	_	
264-50	43940-43945	11.09	_	
264-51	43945-43946	)	_	
264-52	43947-43952	98.45	_	
264-53	43953-43954	(	_	
264-54	43954-43959	13.40	_	
264-55	43959-43960	)	_	
264-56	43961-43967	t31.63	_	
264-57	43968-43969	=	_	
264-58	43970-43974	1.68	_	
264-59	43977-43981	CBCL	_	
264-60	43982-43995	Externalizing	_	
264-61	43996-44004	Baseline	_	
264-62	44005-44006	t	_	
264-63	44007-44012	Score	_	
264-64	44013-44018	48.27	_	
264-65	44019-44020	(	_	
264-66	44020-44024	9.41	_	
264-67	44024-44025	)	_	
264-68	44026-44031	51.32	_	
264-69	44032-44033	(	_	
264-70	44033-44037	7.97	_	
264-71	44037-44038	)	_	
264-72	44039-44045	t43.00	_	
264-73	44046-44047	=	_	
264-74	44048-44049	−	_	
264-75	44049-44053	1.47	_	
264-76	44056-44060	CBCL	_	
264-77	44061-44074	Externalizing	_	
264-78	44075-44084	Follow-up	_	
264-79	44085-44086	t	_	
264-80	44087-44092	Score	_	
264-81	44093-44098	45.38	_	
264-82	44099-44100	(	_	
264-83	44100-44104	9.53	_	
264-84	44104-44105	)	_	
264-85	44106-44111	52.68	_	
264-86	44112-44113	(	_	
264-87	44113-44118	10.42	_	
264-88	44118-44119	)	_	
264-89	44120-44126	t34.06	_	
264-90	44127-44128	=	_	
264-91	44129-44130	−	_	
264-92	44130-44135	2.89b	_	
264-93	44138-44144	Family	_	
264-94	44145-44151	Income	_	
264-95	44151-44152	,	_	
264-96	44153-44160	Dollars	_	
264-97	44161-44164	per	_	
264-98	44165-44171	Montha	_	
264-99	44172-44179	7001.63	_	
264-100	44180-44181	(	_	
264-101	44181-44190	11,381.40	_	
264-102	44190-44191	)	_	
264-103	44192-44199	2996.36	_	
264-104	44200-44201	(	_	
264-105	44201-44208	3043.25	_	
264-106	44208-44209	)	_	
264-107	44210-44216	t78.77	_	
264-108	44217-44218	=	_	
264-109	44219-44224	2.53c	_	
264-110	44227-44235	Maternal	_	
264-111	44236-44245	Education	_	
264-112	44245-44246	,	_	
264-113	44247-44252	Years	_	
264-114	44253-44258	14.17	_	
264-115	44259-44260	(	_	
264-116	44260-44264	2.18	_	
264-117	44264-44265	)	_	
264-118	44266-44271	13.40	_	
264-119	44272-44273	(	_	
264-120	44273-44277	1.94	_	
264-121	44277-44278	)	_	
264-122	44279-44285	t40.87	_	
264-123	44286-44287	=	_	
264-124	44288-44292	1.54	_	
264-125	44295-44298	SES	_	
264-126	44299-44308	Composite	_	
264-127	44308-44309	,	_	
264-128	44310-44311	z	_	
264-129	44312-44318	Family	_	
264-130	44319-44325	Income	_	
264-131	44326-44327	+	_	
264-132	44328-44329	z	_	
264-133	44330-44338	Maternal	_	
264-134	44339-44348	Education	_	
264-135	44349-44354	0.196	_	
264-136	44355-44356	(	_	
264-137	44356-44360	1.85	_	
264-138	44360-44361	)	_	
264-139	44362-44363	−	_	
264-140	44363-44368	0.560	_	
264-141	44369-44370	(	_	
264-142	44370-44374	1.17	_	
264-143	44374-44375	)	_	
264-144	44376-44382	t58.68	_	
264-145	44383-44384	=	_	
264-146	44385-44390	2.22c	_	
264-147	44393-44397	Race	_	
264-148	44400-44403	χ21	_	
264-149	44404-44405	=	_	
264-150	44406-44411	4.79c	_	
264-151	44415-44424	Caucasian	_	
264-152	44425-44427	39	_	
264-153	44428-44429	7	_	
264-154	44434-44447	Non-Caucasian	_	
264-155	44448-44450	24	_	
264-156	44451-44453	15	_	
264-157	44457-44465	Cannabis	_	
264-158	44466-44469	Age	_	
264-159	44470-44472	of	_	
264-160	44473-44478	Onset	_	
264-161	44478-44479	,	_	
264-162	44480-44486	Yearsd	_	
264-163	44487-44488	-	_	
264-164	44489-44495	13.67e	_	
264-165	44496-44497	(	_	
264-166	44497-44501	1.33	_	
264-167	44501-44502	)	_	
264-168	44506-44510	Peak	_	
264-169	44511-44519	Cannabis	_	
264-170	44520-44523	Use	_	
264-171	44523-44524	,	_	
264-172	44525-44532	Maximum	_	
264-173	44533-44535	No	_	
264-174	44535-44536	.	_	
264-175	44537-44539	of	_	
264-176	44540-44546	Joints	_	
264-177	44547-44550	per	_	
264-178	44551-44554	Day	_	
264-179	44555-44556	(	_	
264-180	44556-44558	13	_	
264-181	44558-44559	-	_	
264-182	44560-44562	to	_	
264-183	44563-44565	15	_	
264-184	44565-44566	-	_	
264-185	44566-44575	year-olds	_	
264-186	44575-44576	)	_	
264-187	44576-44577	d	_	
264-188	44578-44579	-	_	
264-189	44580-44585	0.076	_	
264-190	44586-44587	(	_	
264-191	44587-44592	0.161	_	
264-192	44592-44593	)	_	
264-193	44597-44602	Total	_	
264-194	44603-44611	Cannabis	_	
264-195	44612-44615	Use	_	
264-196	44615-44616	,	_	
264-197	44617-44620	Sum	_	
264-198	44621-44627	Joints	_	
264-199	44628-44631	per	_	
264-200	44632-44635	Day	_	
264-201	44636-44637	(	_	
264-202	44637-44639	13	_	
264-203	44639-44640	-	_	
264-204	44641-44643	to	_	
264-205	44644-44646	15	_	
264-206	44646-44647	-	_	
264-207	44647-44656	year-olds	_	
264-208	44656-44657	)	_	
264-209	44657-44658	d	_	
264-210	44659-44660	-	_	
264-211	44661-44667	0.078f	_	
264-212	44668-44669	(	_	
264-213	44669-44674	0.161	_	
264-214	44674-44675	)	_	
264-215	44679-44682	Any	_	
264-216	44683-44690	Alcohol	_	
264-217	44691-44694	Use	_	
264-218	44695-44696	(	_	
264-219	44696-44698	13	_	
264-220	44698-44699	-	_	
264-221	44700-44702	to	_	
264-222	44703-44705	15	_	
264-223	44705-44706	-	_	
264-224	44706-44715	year-olds	_	
264-225	44715-44716	)	_	
264-226	44717-44718	8	_	
264-227	44719-44721	12	_	
264-228	44722-44725	χ21	_	
264-229	44726-44727	=	_	
264-230	44728-44734	13.63b	_	
264-231	44737-44741	Peak	_	
264-232	44742-44749	Alcohol	_	
264-233	44750-44753	Use	_	
264-234	44753-44754	,	_	
264-235	44755-44762	Maximum	_	
264-236	44763-44765	No	_	
264-237	44765-44766	.	_	
264-238	44767-44769	of	_	
264-239	44770-44776	Drinks	_	
264-240	44777-44780	per	_	
264-241	44781-44784	Day	_	
264-242	44785-44786	(	_	
264-243	44786-44788	13	_	
264-244	44788-44789	-	_	
264-245	44790-44792	to	_	
264-246	44793-44795	15	_	
264-247	44795-44796	-	_	
264-248	44796-44805	year-olds	_	
264-249	44805-44806	)	_	
264-250	44807-44812	0.038	_	
264-251	44813-44814	(	_	
264-252	44814-44819	0.055	_	
264-253	44819-44820	)	_	
264-254	44821-44826	0.075	_	
264-255	44827-44828	(	_	
264-256	44828-44833	0.101	_	
264-257	44833-44834	)	_	
264-258	44835-44841	t22.08	_	
264-259	44842-44843	=	_	
264-260	44844-44845	−	_	
264-261	44845-44849	1.07	_	
264-262	44852-44857	Total	_	
264-263	44858-44865	Alcohol	_	
264-264	44866-44869	Use	_	
264-265	44869-44870	,	_	
264-266	44871-44874	Sum	_	
264-267	44875-44881	Drinks	_	
264-268	44882-44885	per	_	
264-269	44886-44889	Day	_	
264-270	44890-44891	(	_	
264-271	44891-44893	13	_	
264-272	44893-44894	-	_	
264-273	44895-44897	to	_	
264-274	44898-44900	15	_	
264-275	44900-44901	-	_	
264-276	44901-44910	year-olds	_	
264-277	44910-44911	)	_	
264-278	44912-44917	0.040	_	
264-279	44918-44919	(	_	
264-280	44919-44924	0.054	_	
264-281	44924-44925	)	_	
264-282	44926-44931	0.081	_	
264-283	44932-44933	(	_	
264-284	44933-44938	0.101	_	
264-285	44938-44939	)	_	
264-286	44940-44946	t22.06	_	
264-287	44947-44948	=	_	
264-288	44949-44950	−	_	
264-289	44950-44954	1.17	_	
264-290	44957-44962	Other	_	
264-291	44963-44970	Illicit	_	
264-292	44971-44975	Drug	_	
264-293	44976-44979	Use	_	
264-294	44979-44980	,	_	
264-295	44981-44984	Any	_	
264-296	44985-44988	Use	_	
264-297	44989-44990	(	_	
264-298	44990-44992	13	_	
264-299	44992-44993	-	_	
264-300	44994-44996	to	_	
264-301	44997-44999	15	_	
264-302	44999-45000	-	_	
264-303	45000-45009	year-olds	_	
264-304	45009-45010	)	_	
264-305	45011-45012	0	_	
264-306	45013-45014	3	_	
264-307	45015-45018	χ21	_	
264-308	45019-45020	=	_	
264-309	45021-45026	5.35c	_	
264-310	45030-45036	Values	_	
264-311	45037-45040	are	_	
264-312	45041-45050	presented	_	
264-313	45051-45053	as	_	
264-314	45054-45058	mean	_	
264-315	45059-45060	(	_	
264-316	45060-45062	SD	_	
264-317	45062-45063	)	_	
264-318	45064-45066	or	_	
264-319	45067-45068	n	_	
264-320	45068-45069	.	_	
264-321	45070-45071	t	_	
264-322	45072-45078	values	_	
264-323	45079-45089	determined	_	
264-324	45090-45095	using	_	
264-325	45096-45101	Welch	_	
264-326	45101-45102	’	_	
264-327	45102-45103	s	_	
264-328	45104-45111	unequal	_	
264-329	45112-45120	variance	_	
264-330	45121-45122	t	_	
264-331	45123-45127	test	_	
264-332	45127-45128	.	_	
264-333	45129-45131	χ2	_	
264-334	45132-45138	values	_	
264-335	45139-45149	determined	_	
264-336	45150-45155	using	_	
264-337	45156-45161	Yates	_	
264-338	45161-45162	’	_	
264-339	45162-45163	s	_	
264-340	45164-45166	χ2	_	
264-341	45167-45171	test	_	
264-342	45171-45172	.	_	

#Text=Peak and total alcohol use were calculated only in participants with reported alcohol use.
265-1	45173-45177	Peak	_	
265-2	45178-45181	and	_	
265-3	45182-45187	total	_	
265-4	45188-45195	alcohol	_	
265-5	45196-45199	use	_	
265-6	45200-45204	were	_	
265-7	45205-45215	calculated	_	
265-8	45216-45220	only	_	
265-9	45221-45223	in	_	
265-10	45224-45236	participants	_	
265-11	45237-45241	with	_	
265-12	45242-45250	reported	_	
265-13	45251-45258	alcohol	_	
265-14	45259-45262	use	_	
265-15	45262-45263	.	_	

#Text=CBCL, Child Behavior Checklist; fMRI, functional magnetic resonance imaging; SES, socioeconomic status; WISC, Wechsler’s Intelligence Scale for Children.
266-1	45264-45268	CBCL	_	
266-2	45268-45269	,	_	
266-3	45270-45275	Child	_	
266-4	45276-45284	Behavior	_	
266-5	45285-45294	Checklist	_	
266-6	45294-45295	;	_	
266-7	45296-45300	fMRI	_	
266-8	45300-45301	,	_	
266-9	45302-45312	functional	_	
266-10	45313-45321	magnetic	_	
266-11	45322-45331	resonance	_	
266-12	45332-45339	imaging	_	
266-13	45339-45340	;	_	
266-14	45341-45344	SES	_	
266-15	45344-45345	,	_	
266-16	45346-45359	socioeconomic	_	
266-17	45360-45366	status	_	
266-18	45366-45367	;	_	
266-19	45368-45372	WISC	_	
266-20	45372-45373	,	_	
266-21	45374-45382	Wechsler	_	
266-22	45382-45383	’	_	
266-23	45383-45384	s	_	
266-24	45385-45397	Intelligence	_	
266-25	45398-45403	Scale	_	
266-26	45404-45407	for	_	
266-27	45408-45416	Children	_	
266-28	45416-45417	.	_	

#Text=Measures from the baseline visit.
#Text=p < .01.
#Text=p < .05.
267-1	45418-45426	Measures	_	
267-2	45427-45431	from	_	
267-3	45432-45435	the	_	
267-4	45436-45444	baseline	_	
267-5	45445-45450	visit	_	
267-6	45450-45451	.	_	
267-7	45452-45453	p	_	
267-8	45454-45455	<	_	
267-9	45456-45459	.01	_	
267-10	45459-45460	.	_	
267-11	45461-45462	p	_	
267-12	45463-45464	<	_	
267-13	45465-45468	.05	_	
267-14	45468-45469	.	_	

#Text=Cannabis users with reported dose (n = 21); 1 participant was classified as a user based on a failed urine screen but did not report cannabis use.
268-1	45470-45478	Cannabis	_	
268-2	45479-45484	users	_	
268-3	45485-45489	with	_	
268-4	45490-45498	reported	_	
268-5	45499-45503	dose	_	
268-6	45504-45505	(	_	
268-7	45505-45506	n	_	
268-8	45507-45508	=	_	
268-9	45509-45511	21	_	
268-10	45511-45512	)	_	
268-11	45512-45513	;	_	
268-12	45514-45515	1	_	
268-13	45516-45527	participant	_	
268-14	45528-45531	was	_	
268-15	45532-45542	classified	_	
268-16	45543-45545	as	_	
268-17	45546-45547	a	_	
268-18	45548-45552	user	_	
268-19	45553-45558	based	_	
268-20	45559-45561	on	_	
268-21	45562-45563	a	_	
268-22	45564-45570	failed	_	
268-23	45571-45576	urine	_	
268-24	45577-45583	screen	_	
268-25	45584-45587	but	_	
268-26	45588-45591	did	_	
268-27	45592-45595	not	_	
268-28	45596-45602	report	_	
268-29	45603-45611	cannabis	_	
268-30	45612-45615	use	_	
268-31	45615-45616	.	_	

#Text=Cannabis age of onset from the full user sample with reported onset (n = 21); cannabis age of onset when removing the 4 participants with inconsistent cannabis onset report was 14.20 years (SD 0.887 years).
269-1	45617-45625	Cannabis	_	
269-2	45626-45629	age	_	
269-3	45630-45632	of	_	
269-4	45633-45638	onset	_	
269-5	45639-45643	from	_	
269-6	45644-45647	the	_	
269-7	45648-45652	full	_	
269-8	45653-45657	user	_	
269-9	45658-45664	sample	_	
269-10	45665-45669	with	_	
269-11	45670-45678	reported	_	
269-12	45679-45684	onset	_	
269-13	45685-45686	(	_	
269-14	45686-45687	n	_	
269-15	45688-45689	=	_	
269-16	45690-45692	21	_	
269-17	45692-45693	)	_	
269-18	45693-45694	;	_	
269-19	45695-45703	cannabis	_	
269-20	45704-45707	age	_	
269-21	45708-45710	of	_	
269-22	45711-45716	onset	_	
269-23	45717-45721	when	_	
269-24	45722-45730	removing	_	
269-25	45731-45734	the	_	
269-26	45735-45736	4	_	
269-27	45737-45749	participants	_	
269-28	45750-45754	with	_	
269-29	45755-45767	inconsistent	_	
269-30	45768-45776	cannabis	_	
269-31	45777-45782	onset	_	
269-32	45783-45789	report	_	
269-33	45790-45793	was	_	
269-34	45794-45799	14.20	_	
269-35	45800-45805	years	_	
269-36	45806-45807	(	_	
269-37	45807-45809	SD	_	
269-38	45810-45815	0.887	_	
269-39	45816-45821	years	_	
269-40	45821-45822	)	_	
269-41	45822-45823	.	_	

#Text=Total cannabis use range was 0.005 to 0.6 joints per day.
#Text=fMRI Time Series Activation Interactions for Cannabis Group at Baseline, at Follow-up, and Between Visits
#Text=Region\tBA\tNo. of Voxels\tF Value (Peak)\tMNI-152 Coordinates at Peak\t \tX\tY\tZ\t \tBaseline\t \t R lingual gyrus (A)\t18\t57\t5.79\t−1.5\t79.5\t1.5\t \t L lingual gyrus\t18\t35\t6.33\t10.5\t79.5\t−7.5\t \t L precuneus\t19\t18\t4.75\t28.5\t76.5\t37.5\t \t L MFG\t6\t17\t5.11\t28.5\t−10.5\t64.5\t \t L IPL\t40\t15\t4.22\t40.5\t55.5\t52.5\t \t R MFG\t6\t15\t4.10\t−13.5\t−7.5\t70.5\t \t Paracentral lobule/cingulate gyrus\t31/7\t14\t4.65\t−10.5\t34.5\t49.5\t \t Pre-SMA\t8\t14\t5.60\t−1.5\t−19.5\t55.5\t \t R lingual gyrus (B)\t18\t13\t4.28\t−34.5\t67.5\t−7.5\t \t L lateral occipital gyrus (A)\t19\t12\t3.68\t52.5\t76.5\t7.5\t \t L lateral occipital gyrus (B)\t19\t12\t5.37\t40.5\t88.5\t7.5\t \tFollow-up\t \t R cuneus (A)\t19\t16\t4.67\t−7.5\t88.5\t31.5\t \t R cuneus (B)\t23\t12\t4.88\t−4.5\t73.5\t7.5\t \t R cuneus (C)\t19\t11\t4.32\t−19.5\t91.5\t28.5\t \tVisit by Group\t \t Posterior cingulatea\t31\t11\t4.93\t1.5\t58.5\t25.5\t \t
#Text=F value cluster peak test statistic for group by time step (TR) interaction (baseline F14,1148; follow-up F14,896; visit by group F14,882).
270-1	45824-45829	Total	_	
270-2	45830-45838	cannabis	_	
270-3	45839-45842	use	_	
270-4	45843-45848	range	_	
270-5	45849-45852	was	_	
270-6	45853-45858	0.005	_	
270-7	45859-45861	to	_	
270-8	45862-45865	0.6	_	
270-9	45866-45872	joints	_	
270-10	45873-45876	per	_	
270-11	45877-45880	day	_	
270-12	45880-45881	.	_	
270-13	45882-45886	fMRI	_	
270-14	45887-45891	Time	_	
270-15	45892-45898	Series	_	
270-16	45899-45909	Activation	_	
270-17	45910-45922	Interactions	_	
270-18	45923-45926	for	_	
270-19	45927-45935	Cannabis	_	
270-20	45936-45941	Group	_	
270-21	45942-45944	at	_	
270-22	45945-45953	Baseline	_	
270-23	45953-45954	,	_	
270-24	45955-45957	at	_	
270-25	45958-45967	Follow-up	_	
270-26	45967-45968	,	_	
270-27	45969-45972	and	_	
270-28	45973-45980	Between	_	
270-29	45981-45987	Visits	_	
270-30	45988-45994	Region	_	
270-31	45995-45997	BA	_	
270-32	45998-46000	No	_	
270-33	46000-46001	.	_	
270-34	46002-46004	of	_	
270-35	46005-46011	Voxels	_	
270-36	46012-46013	F	_	
270-37	46014-46019	Value	_	
270-38	46020-46021	(	_	
270-39	46021-46025	Peak	_	
270-40	46025-46026	)	_	
270-41	46027-46030	MNI	_	
270-42	46030-46031	-	_	
270-43	46031-46034	152	_	
270-44	46035-46046	Coordinates	_	
270-45	46047-46049	at	_	
270-46	46050-46054	Peak	_	
270-47	46057-46058	X	_	
270-48	46059-46060	Y	_	
270-49	46061-46062	Z	_	
270-50	46065-46073	Baseline	_	
270-51	46077-46078	R	_	
270-52	46079-46086	lingual	_	
270-53	46087-46092	gyrus	_	
270-54	46093-46094	(	_	
270-55	46094-46095	A	_	
270-56	46095-46096	)	_	
270-57	46097-46099	18	_	
270-58	46100-46102	57	_	
270-59	46103-46107	5.79	_	
270-60	46108-46109	−	_	
270-61	46109-46112	1.5	_	
270-62	46113-46117	79.5	_	
270-63	46118-46121	1.5	_	
270-64	46125-46126	L	_	
270-65	46127-46134	lingual	_	
270-66	46135-46140	gyrus	_	
270-67	46141-46143	18	_	
270-68	46144-46146	35	_	
270-69	46147-46151	6.33	_	
270-70	46152-46156	10.5	_	
270-71	46157-46161	79.5	_	
270-72	46162-46163	−	_	
270-73	46163-46166	7.5	_	
270-74	46170-46171	L	_	
270-75	46172-46181	precuneus	_	
270-76	46182-46184	19	_	
270-77	46185-46187	18	_	
270-78	46188-46192	4.75	_	
270-79	46193-46197	28.5	_	
270-80	46198-46202	76.5	_	
270-81	46203-46207	37.5	_	
270-82	46211-46212	L	_	
270-83	46213-46216	MFG	_	
270-84	46217-46218	6	_	
270-85	46219-46221	17	_	
270-86	46222-46226	5.11	_	
270-87	46227-46231	28.5	_	
270-88	46232-46233	−	_	
270-89	46233-46237	10.5	_	
270-90	46238-46242	64.5	_	
270-91	46246-46247	L	_	
270-92	46248-46251	IPL	_	
270-93	46252-46254	40	_	
270-94	46255-46257	15	_	
270-95	46258-46262	4.22	_	
270-96	46263-46267	40.5	_	
270-97	46268-46272	55.5	_	
270-98	46273-46277	52.5	_	
270-99	46281-46282	R	_	
270-100	46283-46286	MFG	_	
270-101	46287-46288	6	_	
270-102	46289-46291	15	_	
270-103	46292-46296	4.10	_	
270-104	46297-46298	−	_	
270-105	46298-46302	13.5	_	
270-106	46303-46304	−	_	
270-107	46304-46307	7.5	_	
270-108	46308-46312	70.5	_	
270-109	46316-46327	Paracentral	_	
270-110	46328-46334	lobule	_	
270-111	46334-46335	/	_	
270-112	46335-46344	cingulate	_	
270-113	46345-46350	gyrus	_	
270-114	46351-46353	31	_	
270-115	46353-46354	/	_	
270-116	46354-46355	7	_	
270-117	46356-46358	14	_	
270-118	46359-46363	4.65	_	
270-119	46364-46365	−	_	
270-120	46365-46369	10.5	_	
270-121	46370-46374	34.5	_	
270-122	46375-46379	49.5	_	
270-123	46383-46390	Pre-SMA	_	
270-124	46391-46392	8	_	
270-125	46393-46395	14	_	
270-126	46396-46400	5.60	_	
270-127	46401-46402	−	_	
270-128	46402-46405	1.5	_	
270-129	46406-46407	−	_	
270-130	46407-46411	19.5	_	
270-131	46412-46416	55.5	_	
270-132	46420-46421	R	_	
270-133	46422-46429	lingual	_	
270-134	46430-46435	gyrus	_	
270-135	46436-46437	(	_	
270-136	46437-46438	B	_	
270-137	46438-46439	)	_	
270-138	46440-46442	18	_	
270-139	46443-46445	13	_	
270-140	46446-46450	4.28	_	
270-141	46451-46452	−	_	
270-142	46452-46456	34.5	_	
270-143	46457-46461	67.5	_	
270-144	46462-46463	−	_	
270-145	46463-46466	7.5	_	
270-146	46470-46471	L	_	
270-147	46472-46479	lateral	_	
270-148	46480-46489	occipital	_	
270-149	46490-46495	gyrus	_	
270-150	46496-46497	(	_	
270-151	46497-46498	A	_	
270-152	46498-46499	)	_	
270-153	46500-46502	19	_	
270-154	46503-46505	12	_	
270-155	46506-46510	3.68	_	
270-156	46511-46515	52.5	_	
270-157	46516-46520	76.5	_	
270-158	46521-46524	7.5	_	
270-159	46528-46529	L	_	
270-160	46530-46537	lateral	_	
270-161	46538-46547	occipital	_	
270-162	46548-46553	gyrus	_	
270-163	46554-46555	(	_	
270-164	46555-46556	B	_	
270-165	46556-46557	)	_	
270-166	46558-46560	19	_	
270-167	46561-46563	12	_	
270-168	46564-46568	5.37	_	
270-169	46569-46573	40.5	_	
270-170	46574-46578	88.5	_	
270-171	46579-46582	7.5	_	
270-172	46585-46594	Follow-up	_	
270-173	46598-46599	R	_	
270-174	46600-46606	cuneus	_	
270-175	46607-46608	(	_	
270-176	46608-46609	A	_	
270-177	46609-46610	)	_	
270-178	46611-46613	19	_	
270-179	46614-46616	16	_	
270-180	46617-46621	4.67	_	
270-181	46622-46623	−	_	
270-182	46623-46626	7.5	_	
270-183	46627-46631	88.5	_	
270-184	46632-46636	31.5	_	
270-185	46640-46641	R	_	
270-186	46642-46648	cuneus	_	
270-187	46649-46650	(	_	
270-188	46650-46651	B	_	
270-189	46651-46652	)	_	
270-190	46653-46655	23	_	
270-191	46656-46658	12	_	
270-192	46659-46663	4.88	_	
270-193	46664-46665	−	_	
270-194	46665-46668	4.5	_	
270-195	46669-46673	73.5	_	
270-196	46674-46677	7.5	_	
270-197	46681-46682	R	_	
270-198	46683-46689	cuneus	_	
270-199	46690-46691	(	_	
270-200	46691-46692	C	_	
270-201	46692-46693	)	_	
270-202	46694-46696	19	_	
270-203	46697-46699	11	_	
270-204	46700-46704	4.32	_	
270-205	46705-46706	−	_	
270-206	46706-46710	19.5	_	
270-207	46711-46715	91.5	_	
270-208	46716-46720	28.5	_	
270-209	46723-46728	Visit	_	
270-210	46729-46731	by	_	
270-211	46732-46737	Group	_	
270-212	46741-46750	Posterior	_	
270-213	46751-46761	cingulatea	_	
270-214	46762-46764	31	_	
270-215	46765-46767	11	_	
270-216	46768-46772	4.93	_	
270-217	46773-46776	1.5	_	
270-218	46777-46781	58.5	_	
270-219	46782-46786	25.5	_	
270-220	46790-46791	F	_	
270-221	46792-46797	value	_	
270-222	46798-46805	cluster	_	
270-223	46806-46810	peak	_	
270-224	46811-46815	test	_	
270-225	46816-46825	statistic	_	
270-226	46826-46829	for	_	
270-227	46830-46835	group	_	
270-228	46836-46838	by	_	
270-229	46839-46843	time	_	
270-230	46844-46848	step	_	
270-231	46849-46850	(	_	
270-232	46850-46852	TR	_	
270-233	46852-46853	)	_	
270-234	46854-46865	interaction	_	
270-235	46866-46867	(	_	
270-236	46867-46875	baseline	_	
270-237	46876-46884	F14,1148	_	
270-238	46884-46885	;	_	
270-239	46886-46895	follow-up	_	
270-240	46896-46903	F14,896	_	
270-241	46903-46904	;	_	
270-242	46905-46910	visit	_	
270-243	46911-46913	by	_	
270-244	46914-46919	group	_	
270-245	46920-46927	F14,882	_	
270-246	46927-46928	)	_	
270-247	46928-46929	.	_	

#Text=(A), (B), and (C) designations are used to distinguish clusters within the same region.
271-1	46930-46931	(	_	
271-2	46931-46932	A	_	
271-3	46932-46933	)	_	
271-4	46933-46934	,	_	
271-5	46935-46936	(	_	
271-6	46936-46937	B	_	
271-7	46937-46938	)	_	
271-8	46938-46939	,	_	
271-9	46940-46943	and	_	
271-10	46944-46945	(	_	
271-11	46945-46946	C	_	
271-12	46946-46947	)	_	
271-13	46948-46960	designations	_	
271-14	46961-46964	are	_	
271-15	46965-46969	used	_	
271-16	46970-46972	to	_	
271-17	46973-46984	distinguish	_	
271-18	46985-46993	clusters	_	
271-19	46994-47000	within	_	
271-20	47001-47004	the	_	
271-21	47005-47009	same	_	
271-22	47010-47016	region	_	
271-23	47016-47017	.	_	

#Text=Region and BA taken from a consensus among AFNI atlases (MNI and TT_Daemon).
272-1	47018-47024	Region	_	
272-2	47025-47028	and	_	
272-3	47029-47031	BA	_	
272-4	47032-47037	taken	_	
272-5	47038-47042	from	_	
272-6	47043-47044	a	_	
272-7	47045-47054	consensus	_	
272-8	47055-47060	among	_	
272-9	47061-47065	AFNI	_	
272-10	47066-47073	atlases	_	
272-11	47074-47075	(	_	
272-12	47075-47078	MNI	_	
272-13	47079-47082	and	_	
272-14	47083-47092	TT_Daemon	_	
272-15	47092-47093	)	_	
272-16	47093-47094	.	_	

#Text=BA, Brodmann area; fMRI, functional magnetic resonance imaging; IPL, inferior parietal lobule; L, left; MFG, middle frontal gyrus; MNI, Montreal Neurological Institute; R, right; SMA, supplementary motor area.
273-1	47095-47097	BA	_	
273-2	47097-47098	,	_	
273-3	47099-47107	Brodmann	_	
273-4	47108-47112	area	_	
273-5	47112-47113	;	_	
273-6	47114-47118	fMRI	_	
273-7	47118-47119	,	_	
273-8	47120-47130	functional	_	
273-9	47131-47139	magnetic	_	
273-10	47140-47149	resonance	_	
273-11	47150-47157	imaging	_	
273-12	47157-47158	;	_	
273-13	47159-47162	IPL	_	
273-14	47162-47163	,	_	
273-15	47164-47172	inferior	_	
273-16	47173-47181	parietal	_	
273-17	47182-47188	lobule	_	
273-18	47188-47189	;	_	
273-19	47190-47191	L	_	
273-20	47191-47192	,	_	
273-21	47193-47197	left	_	
273-22	47197-47198	;	_	
273-23	47199-47202	MFG	_	
273-24	47202-47203	,	_	
273-25	47204-47210	middle	_	
273-26	47211-47218	frontal	_	
273-27	47219-47224	gyrus	_	
273-28	47224-47225	;	_	
273-29	47226-47229	MNI	_	
273-30	47229-47230	,	_	
273-31	47231-47239	Montreal	_	
273-32	47240-47252	Neurological	_	
273-33	47253-47262	Institute	_	
273-34	47262-47263	;	_	
273-35	47264-47265	R	_	
273-36	47265-47266	,	_	
273-37	47267-47272	right	_	
273-38	47272-47273	;	_	
273-39	47274-47277	SMA	_	
273-40	47277-47278	,	_	
273-41	47279-47292	supplementary	_	
273-42	47293-47298	motor	_	
273-43	47299-47303	area	_	
273-44	47303-47304	.	_	

#Text=Estimates based on the longitudinal sample only.
274-1	47305-47314	Estimates	_	
274-2	47315-47320	based	_	
274-3	47321-47323	on	_	
274-4	47324-47327	the	_	
274-5	47328-47340	longitudinal	_	
274-6	47341-47347	sample	_	
274-7	47348-47352	only	_	
274-8	47352-47353	.	_	

#Text=Standardized (β) Brain-Behavior and Covariate Relationships With BOLD Activation From Clusters With Cannabis Group Differences
#Text=\tCannabis(Nonuser vs.
275-1	47354-47366	Standardized	_	
275-2	47367-47368	(	_	
275-3	47368-47369	β	_	
275-4	47369-47370	)	_	
275-5	47371-47385	Brain-Behavior	_	
275-6	47386-47389	and	_	
275-7	47390-47399	Covariate	_	
275-8	47400-47413	Relationships	_	
275-9	47414-47418	With	_	
275-10	47419-47423	BOLD	_	
275-11	47424-47434	Activation	_	
275-12	47435-47439	From	_	
275-13	47440-47448	Clusters	_	
275-14	47449-47453	With	_	
275-15	47454-47462	Cannabis	_	
275-16	47463-47468	Group	_	
275-17	47469-47480	Differences	_	
275-18	47482-47490	Cannabis	_	
275-19	47490-47491	(	_	
275-20	47491-47498	Nonuser	_	
275-21	47499-47501	vs	_	
275-22	47501-47502	.	_	

#Text=User), d\tWMAccuracy, β\tSES, β\tEXT, β\tCannabisDose, β\tAlcohol(Nonuser vs.
276-1	47503-47507	User	_	
276-2	47507-47508	)	_	
276-3	47508-47509	,	_	
276-4	47510-47511	d	_	
276-5	47512-47522	WMAccuracy	_	
276-6	47522-47523	,	_	
276-7	47524-47525	β	_	
276-8	47526-47529	SES	_	
276-9	47529-47530	,	_	
276-10	47531-47532	β	_	
276-11	47533-47536	EXT	_	
276-12	47536-47537	,	_	
276-13	47538-47539	β	_	
276-14	47540-47552	CannabisDose	_	
276-15	47552-47553	,	_	
276-16	47554-47555	β	_	
276-17	47556-47563	Alcohol	_	
276-18	47563-47564	(	_	
276-19	47564-47571	Nonuser	_	
276-20	47572-47574	vs	_	
276-21	47574-47575	.	_	

#Text=User), d\t \tBaseline\t \t R lingual gyrus (A)\t0.871\t.258a\t.164\t.184\t.004\t−0.407\t \t L lingual gyrus\t0.778\t.215a\t.044\t.062\t.141\t−0.322\t \t L precuneus\t−0.723\t.129\t.108\t.076\t.165\t−0.046\t \t L MFG\t−0.905\t−.056\t−.092\t.005\t.160\t0.035\t \t L IPL\t−0.598\t.011\t−.045\t.131\t−.005\t0.004\t \t R MFG\t−1.168\t−.092\t−.076\t.016\t.065\t0.435\t \t Cingulate\t0.016\t−.229a\t−.098\t.188\t−.213\t0.149\t \t Pre-SMA\t−0.899\t−.097\t−.172\t−.252\t.175\t0.479\t \t R lingual gyrus (B)\t0.883\t.246a\t.120\t−.027\t−.351\t0.130\t \t L lateral occipital gyrus/BA 19 (A)\t0.847\t.340b\t.093\t.079\t−.360\t−0.162\t \t L lateral occipital gyrus/BA 18 (B)\t0.841\t.289a\t.150\t.146\t−.355\t−0.089\t \tFollow-up\t \t R cuneus (A)\t−1.358\t−.131\t.019\t.031\t.419\t−0.427\t \t R cuneus (B)\t−0.938\t−.077\t.197\t.062\t.647b\t−0.360\t \t R cuneus (C)\t−0.961\t.007\t.007\t.131\t.424\t−0.027\t \t R cuneus aggregate (A, B, and C)c\t−1.656\t−.024\t.091\t.124\t.673b\t−0.330\t \tVisit by Group\t \t Posterior cingulatec\t \t Baseline\t−0.514\t−.040\t−.189\t−.002\t.274\t0.437\t \t Follow-up\t−0.034\t−.058\t.013\t.095\t−.317\t0.083\t \t
#Text=Cannabis nonuser vs. user Cohen’s d values from BOLD dot product; no significance is displayed because group differences were used to define clusters at the voxelwise level. β values used a standardized regression coefficient (m-estimation).
277-1	47576-47580	User	_	
277-2	47580-47581	)	_	
277-3	47581-47582	,	_	
277-4	47583-47584	d	_	
277-5	47587-47595	Baseline	_	
277-6	47599-47600	R	_	
277-7	47601-47608	lingual	_	
277-8	47609-47614	gyrus	_	
277-9	47615-47616	(	_	
277-10	47616-47617	A	_	
277-11	47617-47618	)	_	
277-12	47619-47624	0.871	_	
277-13	47625-47630	.258a	_	
277-14	47631-47635	.164	_	
277-15	47636-47640	.184	_	
277-16	47641-47645	.004	_	
277-17	47646-47647	−	_	
277-18	47647-47652	0.407	_	
277-19	47656-47657	L	_	
277-20	47658-47665	lingual	_	
277-21	47666-47671	gyrus	_	
277-22	47672-47677	0.778	_	
277-23	47678-47683	.215a	_	
277-24	47684-47688	.044	_	
277-25	47689-47693	.062	_	
277-26	47694-47698	.141	_	
277-27	47699-47700	−	_	
277-28	47700-47705	0.322	_	
277-29	47709-47710	L	_	
277-30	47711-47720	precuneus	_	
277-31	47721-47722	−	_	
277-32	47722-47727	0.723	_	
277-33	47728-47732	.129	_	
277-34	47733-47737	.108	_	
277-35	47738-47742	.076	_	
277-36	47743-47747	.165	_	
277-37	47748-47749	−	_	
277-38	47749-47754	0.046	_	
277-39	47758-47759	L	_	
277-40	47760-47763	MFG	_	
277-41	47764-47765	−	_	
277-42	47765-47770	0.905	_	
277-43	47771-47772	−	_	
277-44	47772-47776	.056	_	
277-45	47777-47778	−	_	
277-46	47778-47782	.092	_	
277-47	47783-47787	.005	_	
277-48	47788-47792	.160	_	
277-49	47793-47798	0.035	_	
277-50	47802-47803	L	_	
277-51	47804-47807	IPL	_	
277-52	47808-47809	−	_	
277-53	47809-47814	0.598	_	
277-54	47815-47819	.011	_	
277-55	47820-47821	−	_	
277-56	47821-47825	.045	_	
277-57	47826-47830	.131	_	
277-58	47831-47832	−	_	
277-59	47832-47836	.005	_	
277-60	47837-47842	0.004	_	
277-61	47846-47847	R	_	
277-62	47848-47851	MFG	_	
277-63	47852-47853	−	_	
277-64	47853-47858	1.168	_	
277-65	47859-47860	−	_	
277-66	47860-47864	.092	_	
277-67	47865-47866	−	_	
277-68	47866-47870	.076	_	
277-69	47871-47875	.016	_	
277-70	47876-47880	.065	_	
277-71	47881-47886	0.435	_	
277-72	47890-47899	Cingulate	_	
277-73	47900-47905	0.016	_	
277-74	47906-47907	−	_	
277-75	47907-47912	.229a	_	
277-76	47913-47914	−	_	
277-77	47914-47918	.098	_	
277-78	47919-47923	.188	_	
277-79	47924-47925	−	_	
277-80	47925-47929	.213	_	
277-81	47930-47935	0.149	_	
277-82	47939-47946	Pre-SMA	_	
277-83	47947-47948	−	_	
277-84	47948-47953	0.899	_	
277-85	47954-47955	−	_	
277-86	47955-47959	.097	_	
277-87	47960-47961	−	_	
277-88	47961-47965	.172	_	
277-89	47966-47967	−	_	
277-90	47967-47971	.252	_	
277-91	47972-47976	.175	_	
277-92	47977-47982	0.479	_	
277-93	47986-47987	R	_	
277-94	47988-47995	lingual	_	
277-95	47996-48001	gyrus	_	
277-96	48002-48003	(	_	
277-97	48003-48004	B	_	
277-98	48004-48005	)	_	
277-99	48006-48011	0.883	_	
277-100	48012-48017	.246a	_	
277-101	48018-48022	.120	_	
277-102	48023-48024	−	_	
277-103	48024-48028	.027	_	
277-104	48029-48030	−	_	
277-105	48030-48034	.351	_	
277-106	48035-48040	0.130	_	
277-107	48044-48045	L	_	
277-108	48046-48053	lateral	_	
277-109	48054-48063	occipital	_	
277-110	48064-48069	gyrus	_	
277-111	48069-48070	/	_	
277-112	48070-48072	BA	_	
277-113	48073-48075	19	_	
277-114	48076-48077	(	_	
277-115	48077-48078	A	_	
277-116	48078-48079	)	_	
277-117	48080-48085	0.847	_	
277-118	48086-48091	.340b	_	
277-119	48092-48096	.093	_	
277-120	48097-48101	.079	_	
277-121	48102-48103	−	_	
277-122	48103-48107	.360	_	
277-123	48108-48109	−	_	
277-124	48109-48114	0.162	_	
277-125	48118-48119	L	_	
277-126	48120-48127	lateral	_	
277-127	48128-48137	occipital	_	
277-128	48138-48143	gyrus	_	
277-129	48143-48144	/	_	
277-130	48144-48146	BA	_	
277-131	48147-48149	18	_	
277-132	48150-48151	(	_	
277-133	48151-48152	B	_	
277-134	48152-48153	)	_	
277-135	48154-48159	0.841	_	
277-136	48160-48165	.289a	_	
277-137	48166-48170	.150	_	
277-138	48171-48175	.146	_	
277-139	48176-48177	−	_	
277-140	48177-48181	.355	_	
277-141	48182-48183	−	_	
277-142	48183-48188	0.089	_	
277-143	48191-48200	Follow-up	_	
277-144	48204-48205	R	_	
277-145	48206-48212	cuneus	_	
277-146	48213-48214	(	_	
277-147	48214-48215	A	_	
277-148	48215-48216	)	_	
277-149	48217-48218	−	_	
277-150	48218-48223	1.358	_	
277-151	48224-48225	−	_	
277-152	48225-48229	.131	_	
277-153	48230-48234	.019	_	
277-154	48235-48239	.031	_	
277-155	48240-48244	.419	_	
277-156	48245-48246	−	_	
277-157	48246-48251	0.427	_	
277-158	48255-48256	R	_	
277-159	48257-48263	cuneus	_	
277-160	48264-48265	(	_	
277-161	48265-48266	B	_	
277-162	48266-48267	)	_	
277-163	48268-48269	−	_	
277-164	48269-48274	0.938	_	
277-165	48275-48276	−	_	
277-166	48276-48280	.077	_	
277-167	48281-48285	.197	_	
277-168	48286-48290	.062	_	
277-169	48291-48296	.647b	_	
277-170	48297-48298	−	_	
277-171	48298-48303	0.360	_	
277-172	48307-48308	R	_	
277-173	48309-48315	cuneus	_	
277-174	48316-48317	(	_	
277-175	48317-48318	C	_	
277-176	48318-48319	)	_	
277-177	48320-48321	−	_	
277-178	48321-48326	0.961	_	
277-179	48327-48331	.007	_	
277-180	48332-48336	.007	_	
277-181	48337-48341	.131	_	
277-182	48342-48346	.424	_	
277-183	48347-48348	−	_	
277-184	48348-48353	0.027	_	
277-185	48357-48358	R	_	
277-186	48359-48365	cuneus	_	
277-187	48366-48375	aggregate	_	
277-188	48376-48377	(	_	
277-189	48377-48378	A	_	
277-190	48378-48379	,	_	
277-191	48380-48381	B	_	
277-192	48381-48382	,	_	
277-193	48383-48386	and	_	
277-194	48387-48388	C	_	
277-195	48388-48389	)	_	
277-196	48389-48390	c	_	
277-197	48391-48392	−	_	
277-198	48392-48397	1.656	_	
277-199	48398-48399	−	_	
277-200	48399-48403	.024	_	
277-201	48404-48408	.091	_	
277-202	48409-48413	.124	_	
277-203	48414-48419	.673b	_	
277-204	48420-48421	−	_	
277-205	48421-48426	0.330	_	
277-206	48429-48434	Visit	_	
277-207	48435-48437	by	_	
277-208	48438-48443	Group	_	
277-209	48447-48456	Posterior	_	
277-210	48457-48467	cingulatec	_	
277-211	48471-48479	Baseline	_	
277-212	48480-48481	−	_	
277-213	48481-48486	0.514	_	
277-214	48487-48488	−	_	
277-215	48488-48492	.040	_	
277-216	48493-48494	−	_	
277-217	48494-48498	.189	_	
277-218	48499-48500	−	_	
277-219	48500-48504	.002	_	
277-220	48505-48509	.274	_	
277-221	48510-48515	0.437	_	
277-222	48519-48528	Follow-up	_	
277-223	48529-48530	−	_	
277-224	48530-48535	0.034	_	
277-225	48536-48537	−	_	
277-226	48537-48541	.058	_	
277-227	48542-48546	.013	_	
277-228	48547-48551	.095	_	
277-229	48552-48553	−	_	
277-230	48553-48557	.317	_	
277-231	48558-48563	0.083	_	
277-232	48567-48575	Cannabis	_	
277-233	48576-48583	nonuser	_	
277-234	48584-48586	vs	_	
277-235	48586-48587	.	_	
277-236	48588-48592	user	_	
277-237	48593-48598	Cohen	_	
277-238	48598-48599	’	_	
277-239	48599-48600	s	_	
277-240	48601-48602	d	_	
277-241	48603-48609	values	_	
277-242	48610-48614	from	_	
277-243	48615-48619	BOLD	_	
277-244	48620-48623	dot	_	
277-245	48624-48631	product	_	
277-246	48631-48632	;	_	
277-247	48633-48635	no	_	
277-248	48636-48648	significance	_	
277-249	48649-48651	is	_	
277-250	48652-48661	displayed	_	
277-251	48662-48669	because	_	
277-252	48670-48675	group	_	
277-253	48676-48687	differences	_	
277-254	48688-48692	were	_	
277-255	48693-48697	used	_	
277-256	48698-48700	to	_	
277-257	48701-48707	define	_	
277-258	48708-48716	clusters	_	
277-259	48717-48719	at	_	
277-260	48720-48723	the	_	
277-261	48724-48733	voxelwise	_	
277-262	48734-48739	level	_	
277-263	48739-48740	.	_	
277-264	48741-48742	β	_	
277-265	48743-48749	values	_	
277-266	48750-48754	used	_	
277-267	48755-48756	a	_	
277-268	48757-48769	standardized	_	
277-269	48770-48780	regression	_	
277-270	48781-48792	coefficient	_	
277-271	48793-48794	(	_	
277-272	48794-48806	m-estimation	_	
277-273	48806-48807	)	_	
277-274	48807-48808	.	_	

#Text=WM accuracy, SES, and EXT models used the full neuroimaging sample (baseline n = 84; follow-up n = 66) and included usage group (baseline nonusers = 63, users = 21; follow-up nonusers = 51, users = 15) as a covariate.
278-1	48809-48811	WM	_	
278-2	48812-48820	accuracy	_	
278-3	48820-48821	,	_	
278-4	48822-48825	SES	_	
278-5	48825-48826	,	_	
278-6	48827-48830	and	_	
278-7	48831-48834	EXT	_	
278-8	48835-48841	models	_	
278-9	48842-48846	used	_	
278-10	48847-48850	the	_	
278-11	48851-48855	full	_	
278-12	48856-48868	neuroimaging	_	
278-13	48869-48875	sample	_	
278-14	48876-48877	(	_	
278-15	48877-48885	baseline	_	
278-16	48886-48887	n	_	
278-17	48888-48889	=	_	
278-18	48890-48892	84	_	
278-19	48892-48893	;	_	
278-20	48894-48903	follow-up	_	
278-21	48904-48905	n	_	
278-22	48906-48907	=	_	
278-23	48908-48910	66	_	
278-24	48910-48911	)	_	
278-25	48912-48915	and	_	
278-26	48916-48924	included	_	
278-27	48925-48930	usage	_	
278-28	48931-48936	group	_	
278-29	48937-48938	(	_	
278-30	48938-48946	baseline	_	
278-31	48947-48955	nonusers	_	
278-32	48956-48957	=	_	
278-33	48958-48960	63	_	
278-34	48960-48961	,	_	
278-35	48962-48967	users	_	
278-36	48968-48969	=	_	
278-37	48970-48972	21	_	
278-38	48972-48973	;	_	
278-39	48974-48983	follow-up	_	
278-40	48984-48992	nonusers	_	
278-41	48993-48994	=	_	
278-42	48995-48997	51	_	
278-43	48997-48998	,	_	
278-44	48999-49004	users	_	
278-45	49005-49006	=	_	
278-46	49007-49009	15	_	
278-47	49009-49010	)	_	
278-48	49011-49013	as	_	
278-49	49014-49015	a	_	
278-50	49016-49025	covariate	_	
278-51	49025-49026	.	_	

#Text=Cannabis dose β (total joints per day between baseline and follow-up) effects were examined in users with reported cannabis use and frequency (baseline n = 20; follow-up n = 14).
279-1	49027-49035	Cannabis	_	
279-2	49036-49040	dose	_	
279-3	49041-49042	β	_	
279-4	49043-49044	(	_	
279-5	49044-49049	total	_	
279-6	49050-49056	joints	_	
279-7	49057-49060	per	_	
279-8	49061-49064	day	_	
279-9	49065-49072	between	_	
279-10	49073-49081	baseline	_	
279-11	49082-49085	and	_	
279-12	49086-49095	follow-up	_	
279-13	49095-49096	)	_	
279-14	49097-49104	effects	_	
279-15	49105-49109	were	_	
279-16	49110-49118	examined	_	
279-17	49119-49121	in	_	
279-18	49122-49127	users	_	
279-19	49128-49132	with	_	
279-20	49133-49141	reported	_	
279-21	49142-49150	cannabis	_	
279-22	49151-49154	use	_	
279-23	49155-49158	and	_	
279-24	49159-49168	frequency	_	
279-25	49169-49170	(	_	
279-26	49170-49178	baseline	_	
279-27	49179-49180	n	_	
279-28	49181-49182	=	_	
279-29	49183-49185	20	_	
279-30	49185-49186	;	_	
279-31	49187-49196	follow-up	_	
279-32	49197-49198	n	_	
279-33	49199-49200	=	_	
279-34	49201-49203	14	_	
279-35	49203-49204	)	_	
279-36	49204-49205	.	_	

#Text=Alcohol nonuser (n = 65) vs. user (n = 20) Cohen’s d values adjusted for cannabis usage group.
280-1	49206-49213	Alcohol	_	
280-2	49214-49221	nonuser	_	
280-3	49222-49223	(	_	
280-4	49223-49224	n	_	
280-5	49225-49226	=	_	
280-6	49227-49229	65	_	
280-7	49229-49230	)	_	
280-8	49231-49233	vs	_	
280-9	49233-49234	.	_	
280-10	49235-49239	user	_	
280-11	49240-49241	(	_	
280-12	49241-49242	n	_	
280-13	49243-49244	=	_	
280-14	49245-49247	20	_	
280-15	49247-49248	)	_	
280-16	49249-49254	Cohen	_	
280-17	49254-49255	’	_	
280-18	49255-49256	s	_	
280-19	49257-49258	d	_	
280-20	49259-49265	values	_	
280-21	49266-49274	adjusted	_	
280-22	49275-49278	for	_	
280-23	49279-49287	cannabis	_	
280-24	49288-49293	usage	_	
280-25	49294-49299	group	_	
280-26	49299-49300	.	_	

#Text=BA, Brodmann area; BOLD, blood oxygen level–dependent; EXT, corrected externalizing scale t scores; IPL, inferior parietal lobule; L, left; MFG, middle frontal gyrus; R, right; SES, socioeconomic status; SMA, supplementary motor area; WM, working memory.
#Text=p <.10 (corrected).
#Text=p <.05 (corrected).
281-1	49301-49303	BA	_	
281-2	49303-49304	,	_	
281-3	49305-49313	Brodmann	_	
281-4	49314-49318	area	_	
281-5	49318-49319	;	_	
281-6	49320-49324	BOLD	_	
281-7	49324-49325	,	_	
281-8	49326-49331	blood	_	
281-9	49332-49338	oxygen	_	
281-10	49339-49354	level–dependent	_	
281-11	49354-49355	;	_	
281-12	49356-49359	EXT	_	
281-13	49359-49360	,	_	
281-14	49361-49370	corrected	_	
281-15	49371-49384	externalizing	_	
281-16	49385-49390	scale	_	
281-17	49391-49392	t	_	
281-18	49393-49399	scores	_	
281-19	49399-49400	;	_	
281-20	49401-49404	IPL	_	
281-21	49404-49405	,	_	
281-22	49406-49414	inferior	_	
281-23	49415-49423	parietal	_	
281-24	49424-49430	lobule	_	
281-25	49430-49431	;	_	
281-26	49432-49433	L	_	
281-27	49433-49434	,	_	
281-28	49435-49439	left	_	
281-29	49439-49440	;	_	
281-30	49441-49444	MFG	_	
281-31	49444-49445	,	_	
281-32	49446-49452	middle	_	
281-33	49453-49460	frontal	_	
281-34	49461-49466	gyrus	_	
281-35	49466-49467	;	_	
281-36	49468-49469	R	_	
281-37	49469-49470	,	_	
281-38	49471-49476	right	_	
281-39	49476-49477	;	_	
281-40	49478-49481	SES	_	
281-41	49481-49482	,	_	
281-42	49483-49496	socioeconomic	_	
281-43	49497-49503	status	_	
281-44	49503-49504	;	_	
281-45	49505-49508	SMA	_	
281-46	49508-49509	,	_	
281-47	49510-49523	supplementary	_	
281-48	49524-49529	motor	_	
281-49	49530-49534	area	_	
281-50	49534-49535	;	_	
281-51	49536-49538	WM	_	
281-52	49538-49539	,	_	
281-53	49540-49547	working	_	
281-54	49548-49554	memory	_	
281-55	49554-49555	.	_	
281-56	49556-49557	p	_	
281-57	49558-49559	<	_	
281-58	49559-49562	.10	_	
281-59	49563-49564	(	_	
281-60	49564-49573	corrected	_	
281-61	49573-49574	)	_	
281-62	49574-49575	.	_	
281-63	49576-49577	p	_	
281-64	49578-49579	<	_	
281-65	49579-49582	.05	_	
281-66	49583-49584	(	_	
281-67	49584-49593	corrected	_	
281-68	49593-49594	)	_	
281-69	49594-49595	.	_	

#Text=Estimates based on the longitudinal neuroimaging sample only (n = 65; nonusers = 52, users = 13).
282-1	49596-49605	Estimates	_	
282-2	49606-49611	based	_	
282-3	49612-49614	on	_	
282-4	49615-49618	the	_	
282-5	49619-49631	longitudinal	_	
282-6	49632-49644	neuroimaging	_	
282-7	49645-49651	sample	_	
282-8	49652-49656	only	_	
282-9	49657-49658	(	_	
282-10	49658-49659	n	_	
282-11	49660-49661	=	_	
282-12	49662-49664	65	_	
282-13	49664-49665	;	_	
282-14	49666-49674	nonusers	_	
282-15	49675-49676	=	_	
282-16	49677-49679	52	_	
282-17	49679-49680	,	_	
282-18	49681-49686	users	_	
282-19	49687-49688	=	_	
282-20	49689-49691	13	_	
282-21	49691-49692	)	_	
282-22	49692-49693	.	_	
